Multi-Institutional Randomized Phase II Trial of Gefitir With Advanced Non–Small-Cell Lung Cancer

Journal of Clinical Oncology 21, 2237-2246 DOI: 10.1200/jco.2003.10.038

Citation Report

#	Article	IF	CITATIONS
1	ecancermedicalscience. Ecancermedicalscience, 2010, 4, 178.	1.1	15
2	Amplified genes as therapeutic targets in cancer. Targets, 2003, 2, 147-153.	0.3	1
3	Management of Lung Cancer in Older Adults. Ca-A Cancer Journal for Clinicians, 2003, 53, 325-341.	329.8	92
4	Antitumor Activity and Tolerability of Gefitinib in Patients with Non–Small-Cell Lung Cancer Treated in an Expanded Access Program. Clinical Lung Cancer, 2003, 5, 182-186.	2.6	4
5	The Impact of Gefitinib on Epidermal Growth Factor Receptor Signaling Pathways in Cancer. Clinical Lung Cancer, 2003, 5, S5-S10.	2.6	2
6	Biologically Targeted Treatment of Non–Small-Cell Lung Cancer: Focus on Epidermal Growth Factor Receptor. Clinical Lung Cancer, 2003, 5, S11-S17.	2.6	10
7	Molecular Targeted Agents in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 5, S22-S28.	2.6	11
8	Resection of multifocal non–small cell lung cancer when the bronchioloalveolar subtype is involved. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 1597-1601.	0.8	71
10	ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. British Journal of Cancer, 2003, 89, 246-247.	6.4	44
11	Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. British Journal of Cancer, 2003, 89, S9-S14.	6.4	33
12	Lessons from the â€~Iressa' Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. British Journal of Cancer, 2003, 89, S19-S23.	6.4	22
13	Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene, 2003, 22, 6629-6638.	5.9	96
14	Pharmacogenomics: road to anticancer therapeutics nirvana?. Oncogene, 2003, 22, 6621-6628.	5.9	53
15	Clinical benefit in NSCLC: the evidence for gefitinib (â€~Iressa', ZD1839). European Journal of Cancer, Supplement, 2003, 1, 17-22.	2.2	2
16	Successful treatment of persistent bronchorrhea by gefitinib in a case with Recurrent Bronchioloalveolar Carcinoma: a case report. World Journal of Surgical Oncology, 2003, 1, 8.	1.9	22
17	Adjuvant Systemic Therapies in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2003, 5, S29-S35.	2.6	1
18	Primary and Secondary Prevention of Non–Small-Cell Lung Cancer: The SPORE Trials of Lung Cancer Prevention. Clinical Lung Cancer, 2003, 5, S36-S40.	2.6	12
19	Symptoms and quality of life: important patient outcomes?. European Journal of Cancer, Supplement, 2003, 1, 23-28.	2.2	0

ATION RED

	Сітатіо	CITATION REPORT	
#	Article	IF	CITATION
20	ErbB-targeted therapeutic approaches in human cancer. Experimental Cell Research, 2003, 284, 122-130.	2.6	206
21	Getting to grips with gefitinib. Lancet Oncology, The, 2003, 4, 719-720.	10.7	2
22	Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal of Cancer, Supplement, 2003, 1, 9-15.	2.2	5
23	Hurry Up and Wait: Is Accelerated Approval of New Cancer Drugs in the Best Interests of Cancer Patients?. Journal of Clinical Oncology, 2003, 21, 3718-3720.	1.6	12
24	Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2003, 290, 2149.	7.4	2,360
25	Gefitinib (ZD1839, Iressa®): a selective epidermal growth factor receptor-tyrosine kinase inhibitor. Journal of Oncology Pharmacy Practice, 2003, 9, 151-160.	0.9	4
26	Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer. Annals of Pharmacotherapy, 2003, 37, 1644-1653.	1.9	13
27	Smallâ€Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2003, 8, 576-586.	3.7	66
28	Activation of Tyrosine Kinases in Cancer. Oncologist, 2003, 8, 531-538.	3.7	166
29	Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes and Development, 2003, 17, 2998-3010.	5.9	149
30	Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. British Journal of Cancer, 2003, 89, 1827-1829.	6.4	67
31	Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. British Journal of Cancer, 2003, 89, S15-S18.	6.4	38
33	Extensive experience of disease control with gefitinib and the role of prognostic markers. British Journal of Cancer, 2003, 89, S3-S8.	6.4	47
35	Molecular mechanisms underlying the interaction between ZD1839 (†Iressa') and cisplatin/5-fluorouracil. British Journal of Cancer, 2003, 89, 585-592.	6.4	78
36	Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?. Journal of Clinical Oncology, 2003, 21, 2227-2229.	1.6	49
37	Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 2003, 21, 3798-3807.	1.6	1,333
38	Is There a Role for Epidermal Growth Factor Receptor Inhibitors in Breast Cancer Prevention?. Journal of the National Cancer Institute, 2003, 95, 1813-1815.	6.3	8
39	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opinion on Emerging Drugs, 2003, 8, 501-514.	2.4	27

#	Article	IF	CITATIONS
40	Pulmonary Toxicity due to Chemotherapy How is the Risk and Benefit from ZD1839 Treatment against Non-Small Cell Lung Cancer?. Internal Medicine, 2003, 42, 926-927.	0.7	4
41	Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience from a Single Institution. Cancer Control, 2003, 10, 388-395.	1.8	35
42	Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. American Journal of Health-System Pharmacy, 2003, 60, S16-S21.	1.0	1
43	ErbB-targeted therapeutic approaches in human cancer. , 2003, , 127-135.		0
44	Bortezomib Gefitinib. Hospital Pharmacy, 2003, 38, 733-736.	1.0	0
46	Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. American Journal of Health-System Pharmacy, 2004, 61, 889-898.	1.0	9
48	Receptor Tyrosine Kinases and Inhibitors in Lung Cancer. Scientific World Journal, The, 2004, 4, 589-604.	2.1	42
50	Clinical Development Issues. , 2004, , 287-306.		1
51	Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Therapy. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 17-27.	2.1	12
52	Inhibition of Epidermal Growth Factor Receptor and Symptom Improvement in Advanced Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 29-32.	2.1	0
53	Gefitinib (Iressa®): a novel treatment for non-small cell lung cancer. Expert Review of Anticancer Therapy, 2004, 4, 5-17.	2.4	46
54	Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. Expert Review of Anticancer Therapy, 2004, 4, 569-583.	2.4	6
55	Signaling multiplex of the epidermal growth factor receptor. Expert Review of Anticancer Therapy, 2004, 4, 1145-1156.	2.4	2
56	The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nature Clinical Practice Oncology, 2004, 1, 2-3.	4.3	17
57	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Annals of Oncology, 2004, 15, 1042-1047.	1.2	322
58	Safety, Pharmacokinetics, and Activity of ABX-ECF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology, 2004, 22, 3003-3015.	1.6	334
59	HER1/EGFR Targeting: Refining the Strategy. Oncologist, 2004, 9, 58-67.	3.7	101
60	Complications of Therapy in Cancer Patients. Journal of Clinical Oncology, 2004, 22, 4646-4648.	1.6	60

#	Article	IF	CITATIONS
61	Gefitinib: A new agent in palliative care. American Journal of Hospice and Palliative Medicine, 2004, 21, 222-227.	1.4	5
62	TTF-1, Cytokeratin 7, 34βE12, and CD56/NCAM Immunostaining in the Subclassification of Large Cell Carcinomas of the Lung. American Journal of Clinical Pathology, 2004, 122, 884-893.	0.7	96
63	Lung Cancer in US Women. JAMA - Journal of the American Medical Association, 2004, 291, 1763.	7.4	220
64	Antitumor Activity of Gefitinib in Malignant Rhabdoid Tumor Cells In vitro and In vivo. Clinical Cancer Research, 2004, 10, 5940-5948.	7.0	42
65	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer Is Rare. Journal of Clinical Oncology, 2004, 22, 4966-4970.	1.6	31
66	Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung. Clinical Cancer Research, 2004, 10, 7311-7317.	7.0	66
67	Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme. Clinical Cancer Research, 2004, 10, 3216-3224.	7.0	151
68	Twenty-five years of treating advanced NSCLC: what have we achieved?. Annals of Oncology, 2004, 15, iv81-iv83.	1.2	13
69	Development of the Novel Biologically Targeted Anticancer Agent Gefitinib. Clinical Cancer Research, 2004, 10, 4607-4613.	7.0	60
70	Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 136-143.	7.0	143
71	Phase II Trial of Gefitinib in Recurrent Glioblastoma. Journal of Clinical Oncology, 2004, 22, 133-142.	1.6	677
72	Combining the Anti-EGFR Agent Gefitinib With Chemotherapy in Non–Small-Cell Lung Cancer: How Do We Go From INTACT to Impact?. Journal of Clinical Oncology, 2004, 22, 759-761.	1.6	70
73	Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Annals of Oncology, 2004, 15, 786-792.	1.2	51
74	Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer. Journal of Oncology Pharmacy Practice, 2004, 10, 169-175.	0.9	0
75	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2004, 96, 1133-1141.	6.3	367
76	Pharmacological background of EGFR targeting. Annals of Oncology, 2004, 15, 1007-1012.	1.2	88
77	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer. Clinical Cancer Research, 2004, 10, 8613-8619.	7.0	17
78	High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan. Clinical Cancer Research, 2004, 10, 8195-8203.	7.0	500

#	Article	IF	Citations
79	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 6006-6012.	7.0	40
80	Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4383-4388.	7.0	74
81	Quality of life issues in non-small cell lung cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 215-226.	1.4	3
82	Molecularly Targeted Therapy: Have the Floodgates Opened?. Oncologist, 2004, 9, 357-360.	3.7	48
84	Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments Endocrine-Related Cancer, 2004, 11, 51-68.	3.1	31
85	Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 4725-4729.	1.6	84
86	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Human Molecular Genetics, 2004, 13, 3029-3043.	2.9	156
87	Brain Metastasis Responding to Gefitinib Alone. Oncology, 2004, 67, 174-178.	1.9	34
88	Second-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Chemotherapy, 2004, 16, 104-107.	1.5	12
89	Mutations in the EGFR: The Importance of Genotyping. Cancer Biology and Therapy, 2004, 3, 434-435.	3.4	7
90	Activity of a specific inhibitor, gefitinib (Iressaâ,,¢, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Annals of Oncology, 2004, 15, 33-37.	1.2	34
91	Imatinib: Paradigm or Anomaly?. Cell Cycle, 2004, 3, 831-833.	2.6	14
92	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. Personalized Medicine, 2004, 1, 27-34.	1.5	5
93	Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. Journal of Clinical Oncology, 2004, 22, 785-794.	1.6	1,669
94	Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECIST. Journal of Clinical Oncology, 2004, 22, 4442-4445.	1.6	218
95	A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 7812-7819.	7.0	108
96	Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer. Clinical Cancer Research, 2004, 10, 4874-4884.	7.0	78
97	Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice. Journal of the National Cancer Institute, 2004, 96, 990-997.	6.3	211

	CITATION	Report	
#	Article	IF	CITATIONS
98	Targeting the epidermal growth factor receptor. British Journal of Cancer, 2004, 91, 418-424.	6.4	151
99	EGF receptor gene mutations are common in lung cancers from "never smokers―and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13306-13311.	7.1	4,106
100	Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (â€Iressa', ZD1839) in non-small-cell lung cancer. British Journal of Cancer, 2004, 91, 208-212.	6.4	204
101	Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. British Journal of Cancer, 2004, 91, S1-S2.	6.4	20
102	Lung Cancer: A Cost and Outcome Study Based on Physician Practice Patterns. Disease Management: DM, 2004, 7, 112-123.	1.0	16
104	Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica, 2004, 34, 901-915.	1.1	45
105	In vitrometabolism of gefitinib in human liver microsomes. Xenobiotica, 2004, 34, 983-1000.	1.1	58
106	Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology, 2004, 15, 419-426.	1.2	140
107	Targeting Targeted Therapy. New England Journal of Medicine, 2004, 350, 2191-2193.	27.0	134
108	Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. Journal of the National Cancer Institute, 2004, 96, 715-715.	6.3	6
109	New Directions in Oncology Nursing Care: Focus on Gefitinib in Patients With Lung Cancer. Clinical Journal of Oncology Nursing, 2004, 8, 385-392.	0.6	3
110	Predicting Sensitivity of Non-Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt?. Journal of the National Cancer Institute, 2004, 96, 1117-1119.	6.3	36
111	Gefitinib, a novel, orally administered agent for the treatment of cancer. Journal of Clinical Pharmacy and Therapeutics, 2004, 29, 95-103.	1.5	60
112	Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. British Journal of Dermatology, 2004, 151, 238-241.	1.5	176
113	An image worth a thousand lives?. Nature Biotechnology, 2004, 22, 677-678.	17.5	4
114	Selecting the right patient for tumor therapy. Nature Medicine, 2004, 10, 577-578.	30.7	23
115	Gefitinib — a novel targeted approach to treating cancer. Nature Reviews Cancer, 2004, 4, 956-965.	28.4	340
116	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer, 2004, 90, 82-86.	6.4	52

#	Article	IF	CITATIONS
117	Gefitinib (â€~Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. British Journal of Cancer, 2004, 90, 566-572.	6.4	75
118	Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients. British Journal of Cancer, 2004, 90, 1563-1571.	6.4	19
119	Epidermal growth factor receptor tyrosine kinase inhibitors. British Journal of Cancer, 2004, 90, 2250-2255.	6.4	103
120	Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. British Journal of Cancer, 2004, 91, S11-S17.	6.4	27
121	Laminin-5 offsets the efficacy of gefitinib (â€~Iressa') in hepatocellular carcinoma cells. British Journal of Cancer, 2004, 91, 1964-1969.	6.4	50
122	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. British Journal of Cancer, 2004, 91, 1996-2004.	6.4	158
123	†Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC). Seminars in Cancer Biology, 2004, 14, 33-40.	9.6	64
124	Mutations in the Epidermal Growth Factor Receptor Tyrosine Kinase May Predict Response to Gefitinib in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 5, 331-332.	2.6	Ο
125	2004 Highlights From: 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana June 2004. Clinical Lung Cancer, 2004, 6, 11-16.	2.6	0
126	Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow. Cancer Cell, 2004, 5, 411-415.	16.8	73
128	A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Seminars in Oncology, 2004, 31, 83-92.	2.2	16
129	Gefitinib: phase II and III results in advanced non-small cell lung cancer. Seminars in Oncology, 2004, 31, 93-99.	2.2	19
130	Targeting the HER-kinase axis in cancer. Seminars in Oncology, 2004, 31, 9-20.	2.2	59
131	Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Seminars in Oncology, 2004, 31, 3-8.	2.2	38
132	Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Seminars in Oncology, 2004, 31, 23-30.	2.2	21
133	Drug development in patients with advanced non-small cell lung cancer and poor performance status. Seminars in Oncology, 2004, 31, 21-26.	2.2	21
134	Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Seminars in Oncology, 2004, 31, 27-31.	2.2	12
135	Gefitinib (†Îressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KlP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncology, 2004, 40, 43-51.	1.5	43

#	Article	IF	CITATIONS
136	Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer, 2004, 4, 51.	2.6	30
137	The in vitroeffect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer, 2004, 4, 83.	2.6	53
138	Gefitinib in Patients with Brain Metastases from Non–Small-Cell Lung Cancer: Review of 15 Clinical Cases. Clinical Lung Cancer, 2004, 6, 123-128.	2.6	135
139	Therapeutic Advances in Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 6, 154-161.	2.6	11
140	Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. Clinical Lung Cancer, 2004, 6, S7-S19.	2.6	31
141	Predictors of Sensitivity and Resistance to Epidermal Growth Factor Receptor Inhibitors. Clinical Lung Cancer, 2004, 6, S30-S34.	2.6	15
142	Effect of Epidermal Growth Factor Receptor Mutations on the Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Target-Based Populations for Target-Based Drugs. Clinical Lung Cancer, 2004, 6, S35-S42.	2.6	8
143	Role of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Bronchoalveolar Carcinoma. Clinical Lung Cancer, 2004, 6, S43-S47.	2.6	3
144	Current Development of Adjuvant Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2004, 6, S63-S70.	2.6	4
145	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressaâ,,¢, ZD1839). Biochemical Pharmacology, 2004, 68, 135-144.	4.4	54
146	Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochemical Pharmacology, 2004, 68, 1453-1464.	4.4	89
147	Tyrosine kinase inhibitors. Cancer Cell, 2004, 5, 525-531.	16.8	89
148	Targeting cell cycle and apoptosis for the treatment of human malignancies. Current Opinion in Cell Biology, 2004, 16, 670-678.	5.4	96
149	Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 2004, 350, 2129-2139.	27.0	10,632
150	A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 255-262.	2.8	55
151	Acute gefitinib-induced pneumonitis. International Journal of Clinical Oncology, 2004, 9, 406-409.	2.2	22
152	Chemoradiotherapy for lung cancer: current status and perspectives. International Journal of Clinical Oncology, 2004, 9, 435-443.	2.2	18
153	Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics, 2004, 59, S21-S26.	0.8	1,094

		CITATION R	EPORT	
#	Article		IF	Citations
154	Perspectives of Cellular and Molecular Neurosurgery. Journal of Neuro-Oncology, 2004	, 70, 255-269.	2.9	13
155	Potential role of molecularly targeted therapy in the management of advanced nonsma carcinoma in the elderly. Cancer, 2004, 101, 1733-1744.	all cell lung	4.1	9
156	Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. Journal of Ce Physiology, 2004, 201, 97-105.	(?Iressa?) Ilular	4.1	49
157	Advances in molecular carcinogenesis: current and future use of mouse models to scre validate molecularly targeted anticancer drugs. Molecular Carcinogenesis, 2004, 39, 18	en and 33-194.	2.7	18
158	Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation the tumors. International Journal of Radiation Oncology Biology Physics, 2004, 58, 941-94	erapy for solid 9.	0.8	50
159	Emerging role of epidermal growth factor receptor inhibition in therapy for advanced n focus on NSCLC. International Journal of Radiation Oncology Biology Physics, 2004, 58	nalignancy: 991-1002.	0.8	55
160	Epidermal growth factor receptor–targeted therapy with ZD1839: symptom improve non–small-cell lung cancer. International Journal of Radiation Oncology Biology Phys S39-S43.	ment in ics, 2004, 59,	0.8	4
161	The role of targeted therapy in non-small cell lung cancer. Critical Reviews in Oncology 2004, 51, 29-44.	Hematology,	4.4	21
162	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhib do we stand, where do we go. Critical Reviews in Oncology/Hematology, 2004, 50, 175	itors: where 5-186.	4.4	9
163	The therapeutic potential of agents targeting the type I insulin-like growth factor recep Opinion on Investigational Drugs, 2004, 13, 1569-1577.	tor. Expert	4.1	65
164	Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related (11, 689-708.	Cancer, 2004,	3.1	327
165	American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lu Guideline: Update 2003. Journal of Clinical Oncology, 2004, 22, 330-353.	ng Cancer	1.6	1,306
166	Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Res Molecular Therapeutics. Cancer Research, 2004, 64, 9093-9100.	sponse to	0.9	141
167	An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Ep Factor Receptor Inhibitors. Cancer Research, 2004, 64, 9139-9143.	vidermal Growth	0.9	242
168	Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—S Cancer. Journal of Clinical Oncology, 2004, 22, 3238-3247.	Small-Cell Lung	1.6	1,041
169	Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefit Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 1103	:inib in -1109.	1.6	725
171	Novel treatments in non–small cell lung cancer. Hematology/Oncology Clinics of Nor 2004, 18, 245-267.	th America,	2.2	14
173	Identification of epidermal growth factor receptor-derived peptides recognised by both humoral immune responses in HLA-A24+ non-small cell lung cancer patients*1. Europe Cancer, 2004, , .	cellular and an Journal of	2.8	0

#	Article	IF	CITATIONS
174	Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 2004, , .	2.0	0
175	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa?, ZD1839). Biochemical Pharmacology, 2004, 68, 135-135.	4.4	1
177	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we go. Critical Reviews in Oncology/Hematology, 2004, 50, 175-175.	4.4	0
178	Effect of gefitinib (â€~Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer, 2004, 46, 255-261.	2.0	175
183	Biomarkers in cancer management: a crucial bridge toward personalized medicine. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 305-311.	0.5	2
184	Targeted therapies for cancer – from tamoxifen to gefitinib (â€~Iressa'). Drug Discovery Today: Therapeutic Strategies, 2004, 1, 411-416.	0.5	3
185	Management of non-small cell lung cancer in elderly patients. European Journal of Cancer, Supplement, 2004, 2, 15-25.	2.2	2
186	New targets and new treatments in non-small cell lung cancer. European Journal of Cancer, Supplement, 2004, 2, 1-6.	2.2	1
187	New perspectives in the management of non-small cell lung cancer (NSCLC). European Journal of Cancer, Supplement, 2004, 2, 34-39.	2.2	1
188	Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer, 2004, 43, 317-322.	2.0	48
189	Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839,) Tj ETQq0 0 0 rg	BT /Overlc 2.0	ck 10 Tf 50 3
190	Severe myelotoxicity in a combination of gefitinib and vinorelbine. Lung Cancer, 2004, 45, 121-123.	2.0	18
191	Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer, 2004, 45, 93-104.	2.0	182
192	Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University Experience. Lung Cancer, 2004, 45, 221-225.	2.0	16
193	Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. Lung Cancer, 2004, 45, 255-262.	2.0	7
194	Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 2004, 45, 381-386.	2.0	161
195	The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer, 2004, 46, 135-148.	2.0	34
196	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer, 2004, 46, 247-254.	2.0	56

		CITATION REP	PORT	
#	Article		IF	CITATIONS
197	Invited Abstracts:. Lung Cancer, 2004, 46, S1-S30.		2.0	0
198	Therapy of advanced non-small-cell lung cancer (take home message). Lung Cancer, 2004	, 45, S259-S262.	2.0	2
199	New targeted treatments in lung cancer — overview of clinical trials. Lung Cancer, 2004 S199-S208.	, 45,	2.0	13
200	Signal transduction pathways as novel therapy targets in lung cancer. Lung Cancer, 2004 S177-S186.	, 45,	2.0	4
201	Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy. Drug Safety, 2004, 27,	1081-1092.	3.2	66
202	Gefitinib. Drugs, 2004, 64, 2475-2492.		10.9	21
203	Clinical Issues in the Management of Non–Small-Cell Lung Cancer and the Role of Platir Therapy. Clinical Lung Cancer, 2004, 5, 274-289.	ium-Based	2.6	15
204	Early-Stage Non–Small-Cell Lung Cancer: Current Perspectives in Combined-Modality Th Lung Cancer, 2004, 6, 85-98.	ierapy. Clinical	2.6	47
205	Adjuvant Therapy of Resected Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2004,	6, 162-169.	2.6	13
206	Pemetrexed in the Treatment of Advanced Non–Small-Cell Lung Cancer: A Review of the Clinical Lung Cancer, 2004, 5, S67-S74.	e Clinical Data.	2.6	8
207	Bronchoalveolar Carcinoma: Current Treatment and Future Trends. Clinical Lung Cancer, 2 S75-S79.	2004, 6,	2.6	3
208	Mutations of the <i>Epidermal Growth Factor Receptor</i> Gene in Lung Cance Research, 2004, 64, 8919-8923.	r. Cancer	0.9	1,168
209	Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell L Phase III Trial—INTACT 1. Journal of Clinical Oncology, 2004, 22, 777-784.	ung Cancer: A	1.6	1,663
210	Méthodologie d'évaluation des thérapeutiques ciblées dans les essais cliniq Revue De Pneumologie Clinique, 2004, 60, 72-78.	µes. perspectives d'a	venir. 0.0	0
212	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastat Colorectal Cancer. New England Journal of Medicine, 2004, 351, 337-345.	ic	27.0	4,721
213	Relative bioavailability and safety profile of gefitinib administered as a tablet or as a disper preparation via drink or nasogastric tube: results of a randomized, open-label, three-period study in healthy volunteers. Clinical Therapeutics, 2004, 26, 1630-1636.	sion I crossover	2.5	34
214	Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemo people with advanced non-small-cell lung cancerâ [*] †â [*] †â [*] †â [*] †Abstracted from: Herbst RS, G et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lu a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94 Cancer Treatment Reviews	ntherapy in Giaccone C, Schiller JH Ing cancer: , 2004, 30, 655-659.	7.7	77
215	Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible f non-small cell lung cancers. Cancer Letters, 2004, 214, 157-164.	actor-1α in	7.2	33

ARTICLE IF CITATIONS # Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell 217 2.8 30 lung cancer. European Journal of Cancer, 2004, 40, 667-672. Targeted therapy – How successful has it been?. European Journal of Cancer, 2004, 40, 2016-2021. 2.8 Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and 219 humoral immune responses in HLA-A24+ non-small cell lung cancer patients. European Journal of 2.8 17 Cancer, 2004, 40, 1776-1786. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?. European Journal of Cancer, 2004, 40, 1807-1809 Bone forming adenocarcinoma with pulmonary metastasis arising from the parotid gland. Oral 221 0.7 0 Oncology, 2004, 40, 46-49. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic 1.0 chemotherapy for muscle-invasive bladder cancer. Urology, 2004, 63, 619-624. Mutations and addiction to EGFR: the Achilles †heal' of lung cancers?. Trends in Molecular Medicine, 223 6.7 273 2004, 10, 481-486. Targeted therapy for malignant gliomas. Journal of Clinical Neuroscience, 2004, 11, 807-818. 1.5 224 Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in 225 1.1 119 rat, dog and man. Xenobiotica, 2004, 34, 917-934. Gefitinib-Sensitizing <i>EGFR</i> Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. Science, 12.6 1,573 2004, 305, 1163-1167. Adjuvant treatment of lung cancer: Current status and potential applications of new regimens. Lung 227 2.0 15 Cancer, 2004, 46, S33-S39. Epidermal growth factor receptor in tumor angiogenesis. Hematology/Oncology Clinics of North 228 2.2 149 America, 2004, 18, 1007-1021. <i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. 229 12.6 9,038 Science, 2004, 304, 1497-1500. Growth factor receptors as targets for lung cancer therapy. Seminars in Thoracic and Cardiovascular Surgery, 2004, 16, 3-12. 231Acute lung injury as an adverse event of gefitinib. Anti-Cancer Drugs, 2004, 15, 461-467. 1.4 44 Therapy for Stage IIIA, IIIB and IV Non–Small Cell Lung Cancer. Clinical Pulmonary Medicine, 2004, 11, 161-174. EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS: NOVEL THERAPY FOR THE TREATMENT OF 233 1.1 34 HIGH-GRADE GLIOMAS. Neurosurgery, 2004, 54, 1480-1489. 234 Session 5: Signalling Networks in Tumorigenesis. Toxicologic Pathology, 2004, 32, 737-738. 1.8

#	Article	IF	CITATIONS
235	Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (â€~Iressa', ZD1839). Oncology Reports, 2004, 12, 1053.	2.6	16
236	Weekly Vinorelbine and Docetaxel as Second-Line Chemotherapy for Pretreated Non-Small Cell Lung Cancer Patients: a Phase I-II Trial. Journal of Chemotherapy, 2004, 16, 392-399.	1.5	11
237	Small Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: An Overview. Journal of Chemotherapy, 2004, 16, 36-40.	1.5	10
238	The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness. Pancreas, 2004, 29, e1-e8.	1.1	216
239	Targeted therapies in the treatment of non small cell lung cancer: reality and hopes. Current Opinion in Oncology, 2004, 16, 126-129.	2.4	7
240	The role of EGFR inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology, 2004, 16, 130-135.	2.4	91
241	Gefitinib as a First Line of Therapy in Non-Small Cell Lung Cancer with Brain Metastases. Internal Medicine, 2004, 43, 718-720.	0.7	29
243	Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancerâ ⁺ , â ⁺ , â ⁺ , â ⁺ †â ⁺ †Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:	7.7	0
244	Clinical Symposium. Journal of Chemotherapy, 2004, 16, 69-98.	1.5	3
245	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010.	0.9	105
245 246	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262.	0.9	105 0
245 246 247	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262. Treatment of locally advanced non-small cell lung cancer in the elderly. Current Opinion in Oncology, 2005, 17, 130-134.	0.9 2.4	105 0 5
245 246 247 248	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262. Treatment of locally advanced non-small cell lung cancer in the elderly. Current Opinion in Oncology, 2005, 17, 130-134. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Current Opinion in Oncology, 2005, 17, 123-129.	0.9 2.4 2.4	105 0 5 8
245 246 247 248 248	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262. Treatment of locally advanced non-small cell lung cancer in the elderly. Current Opinion in Oncology, 2005, 17, 130-134. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Current Opinion in Oncology, 2005, 17, 123-129. Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer. Chest, 2005, 128, 3975-3984.	0.9 2.4 2.4 0.8	105 0 5 8 98
245 246 247 248 249 250	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262. Treatment of locally advanced non-small cell lung cancer in the elderly. Current Opinion in Oncology, 2005, 17, 130-134. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Current Opinion in Oncology, 2005, 17, 123-129. Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer. Chest, 2005, 128, 3975-3984. Emerging Trends in Combinations of Gefitinib and Cytotoxic Agents: New Opportunities. Oncology Research and Treatment, 2005, 28, 467-470.	0.9 2.4 2.4 0.8 1.2	 105 0 5 8 98 0
245 246 247 248 249 250 251	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. , 2005, 126, 243-262. Treatment of locally advanced non-small cell lung cancer in the elderly. Current Opinion in Oncology, 2005, 17, 130-134. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Current Opinion in Oncology, 2005, 17, 123-129. Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer. Chest, 2005, 128, 3975-3984. Emerging Trends in Combinations of Gefitinib and Cytotoxic Agents: New Opportunities. Oncology Research and Treatment, 2005, 28, 467-470. Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to ECFR Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 73-81.	0.9 2.4 2.4 0.8 1.2 1.1	 105 0 5 8 98 98 0 37
 245 246 247 248 249 250 251 252 	 Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. Cancer Research, 2005, 65, 3003-3010. Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer., 2005, 126, 243-262. Treatment of locally advanced non-small cell lung cancer in the elderly. Current Opinion in Oncology, 2005, 17, 130-134. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. Current Opinion in Oncology, 2005, 17, 123-129. Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer. Chest, 2005, 128, 3975-3984. Emerging Trends in Combinations of Gefitinib and Cytotoxic Agents: New Opportunities. Oncology Research and Treatment, 2005, 28, 467-470. Detection of Oncogenic Mutations in the ECFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 73-81. EGFR Mutations in Non-Small Cell Lung Carcinomas May Predict Response to Gefitinib. Advances in Anatomic Pathology, 2005, 12, 47-52. 	0.9 2.4 2.4 0.8 1.2 1.1 4.3	 105 0 5 8 98 98 0 37 2

#	Article	IF	CITATIONS
254	Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report. Anti-Cancer Drugs, 2005, 16, 747-749.	1.4	6
255	Treatment of non-small cell lung cancer and targeted therapies: where are we?. Current Opinion in Oncology, 2005, 17, 114-117.	2.4	2
256	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Current Opinion in Oncology, 2005, 17, 118-122.	2.4	60
257	The treatment of advanced non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2005, 11, 287-291.	2.6	41
258	EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma. American Journal of Surgical Pathology, 2005, 29, 633-639.	3.7	229
259	Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. , 2005, , 433-450.		2
260	Neutropenic Enterocolitis in Lung Cancer: A Report of Two Cases and a Review of the Literature. Internal Medicine, 2005, 44, 467-470.	0.7	16
261	Development of Precise Pharmocodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. Acta Histochemica Et Cytochemica, 2005, 38, 209-216.	1.6	1
262	Gefitinib Treatment Is Highly Effective in Non-Small-Cell Lung Cancer Patients Failing Previous Chemotherapy in Taiwan: A Prospective Phase II Study. Journal of Chemotherapy, 2005, 17, 679-684.	1.5	19
263	Female Sex and Bronchioloalveolar Pathologic Subtype Predict EGFR Mutations in Non-small Cell Lung Cancer. Chest, 2005, 128, 317-321.	0.8	109
264	11,11???-Dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity. Anti-Cancer Drugs, 2005, 16, 515-524.	1.4	46
265	Gefitinib (IressaTM, ZD1839) and Tyrosine Kinase Inhibitors. Cancer Nursing, 2005, 28, 481-486.	1.5	28
266	The Combination of the Selective Cyclooxygenase-2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second-Line Therapy for Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2005, 11, 209-216.	2.0	31
267	Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib. Cancer Journal (Sudbury, Mass), 2005, 11, 417-424.	2.0	68
269	Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs, 2005, 16, 1123-1128.	1.4	32
270	Treatment of non-small cell lung cancer with gefitinib (???Iressa???, ZD1839): the Greek experience with a compassionate-use program. Anti-Cancer Drugs, 2005, 16, 191-198.	1.4	9
271	Simultaneous Bilateral Spontaneous Pneumothorax Observed during the Administration of Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases. Internal Medicine, 2005, 44, 862-864.	0.7	30
273	Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Investigational New Drugs, 2005, 23, 73-77.	2.6	36

#	Article	IF	CITATIONS
274	Evolving Molecular-Based Targeted Therapy for Cancer: An Exciting Field. Comprehensive Therapy, 2005, 31, 299-305.	0.2	0
275	Gefitinib (ZD1839, IressaR) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundamental and Clinical Pharmacology, 2005, 19, 385-393.	1.9	44
276	LOW VITAMIN B6 LEVELS ARE ASSOCIATED WITH WHITE MATTER LESIONS IN ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 2005, 53, 1073-1074.	2.6	22
277	ACUPUNCTURE FOR DYSPHAGIA IN POSTSTROKE PATIENTS: A VIDEOFLUOROSCOPIC STUDY. Journal of the American Geriatrics Society, 2005, 53, 1083-1084.	2.6	28
278	HYPERIMMUNOGLOBULIN A AND CELIAC DISEASE IN THE ELDERLY. Journal of the American Geriatrics Society, 2005, 53, 1074-1075.	2.6	2
279	EFFECTS OF PHYSICAL EXERCISE ON PLASMA CONCENTRATIONS OF SEX HORMONES IN ELDERLY WOMEN WITH DEMENTIA. Journal of the American Geriatrics Society, 2005, 53, 1076-1077.	2.6	5
280	RACIAL DIFFERENCES IN PRESSURE ULCER PREVALENCE IN NURSING HOMES. Journal of the American Geriatrics Society, 2005, 53, 1077-1078.	2.6	8
281	NON-SMALL-CELL LUNG CANCER PATIENTS UNSUITABLE FOR FIRST-LINE CHEMOTHERAPY: A NEW CATEGORY OF PATIENTS FOR CLINICAL STUDIES?. Journal of the American Geriatrics Society, 2005, 53, 1078-1079.	2.6	0
282	TREATMENT OF VALPROATE-INDUCED HYPERAMMONEMIA. Journal of the American Geriatrics Society, 2005, 53, 1080-1080.	2.6	10
283	FUNCTIONAL ASSESSMENT AND INFECTIOUS DISEASES. Journal of the American Geriatrics Society, 2005, 53, 1080-1081.	2.6	7
284	AN ELDERLY MAN WITH MULTIPLE HEPATIC LESIONS: OTHER CONCEPTS ON AMEBIC LIVER ABSCESS. Journal of the American Geriatrics Society, 2005, 53, 1082-1082.	2.6	1
285	Therapeutic approaches in metastatic renal cell carcinoma. BJU International, 2005, 95, 1153-1161.	2.5	14
286	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Alimentary Pharmacology and Therapeutics, 2005, 21, 321-339.	3.7	46
287	A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment. British Journal of Cancer, 2005, 92, 15-20.	6.4	63
288	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). British Journal of Cancer, 2005, 92, 1711-1719.	6.4	128
289	Role of novel targeted therapies in the clinic. British Journal of Cancer, 2005, 92, S21-S27.	6.4	12
290	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. British Journal of Cancer, 2005, 93, 23-28.	6.4	50
291	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. British Journal of Cancer, 2005, 93, 1334-1340.	6.4	73

#	Article	IF	CITATIONS
292	Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (â€~Iressa', ZD1839) in Phase I and II clinical trials. Eye, 2005, 19, 729-738.	2.1	59
293	The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene, 2005, 24, 4433-4441.	5.9	120
294	PSEUDODIARRHEA CAUSED BY VAGINAL PESSARY IN AN ELDERLY PATIENT. Journal of the American Geriatrics Society, 2005, 53, 1083-1083.	2.6	23
295	A WARM BATH. Journal of the American Geriatrics Society, 2005, 53, 1075-1076.	2.6	0
296	Targeted therapies for non-small cell lung cancer. International Journal of Clinical Practice, 2005, 59, 1055-1062.	1.7	14
297	2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004. Clinical Lung Cancer, 2005, 6, 272-275.	2.6	0
298	Updated Data from the Iressa® Survival in Lung Cancer Trial. Clinical Lung Cancer, 2005, 6, 340-342.	2.6	3
299	Relevance of Epidermal Growth Factor Receptor Genomic Gain in Predicting Clinical Response to Kinase Inhibitors in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2005, 7, 163-165.	2.6	3
300	Clinical Development of Gefitinib in Non–Small-Cell Lung Cancer and the Iressa® Survival Evaluation in Lung Cancer Trial. Clinical Lung Cancer, 2005, 6, 214-216.	2.6	1
301	Redefining Bronchioloalveolar Carcinoma. Seminars in Oncology, 2005, 32, 329-335.	2.2	25
302	Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars in Oncology, 2005, 32, 315-328.	2.2	43
303	Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment?. Seminars in Oncology, 2005, 32, 25-34.	2.2	8
304	Inhibition of the Epidermal Growth Factor Receptor in Combined Modality Treatment for Locally Advanced Non-Small Cell Lung Cancer. Seminars in Oncology, 2005, 32, 35-41.	2.2	26
305	Other Compounds and Targets in Non–Small Cell Lung Cancer. Seminars in Oncology, 2005, 32, 30-36.	2.2	5
306	An Update on the Role of Epidermal Growth Factor Receptor Inhibitors in Non–Small Cell Lung Cancer. Seminars in Oncology, 2005, 32, 3-8.	2.2	84
307	Ongoing First-Line Studies of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Select Patient Populations. Seminars in Oncology, 2005, 32, 9-15.	2.2	72
308	A Pilot Trial of Gefitinib in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2005, 6, 343-349.	2.6	18
309	Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial. Clinical Lung Cancer, 2005, 7, 127-132.	2.6	31

		CITATION R	EPORT	
#	Article		IF	Citations
310	An Approach to Evaluating Drug-Nutrient Interactions. Pharmacotherapy, 2005, 25, 178	39-1800.	2.6	55
311	Recent Advances and Future Perspectives in the Management of Lung Cancer. Current Surgery, 2005, 42, 548-610.	Problems in	1.1	3
312	Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrc inhibitors in non-small cell lung cancer. Journal of Cellular Physiology, 2005, 205, 355-3	sine kinase 63.	4.1	28
313	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Inter of Cancer, 2005, 113, 109-115.	markers for national Journal	5.1	152
314	Absence ofEGFR mutation in the kinase domain in common human cancers besides nor cancer. International Journal of Cancer, 2005, 113, 510-511.	ı-small cell lung	5.1	90
315	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Inter Journal of Cancer, 2005, 116, 36-44.	national	5.1	127
316	Absence of theERBB2 kinase domain mutation in lung adenocarcinomas in Korean patie International Journal of Cancer, 2005, 116, 652-653.	nts.	5.1	5
317	Laminin 5 expression protects against anoikis at aerogenous spread and lepidic growth adenocarcinoma. International Journal of Cancer, 2005, 116, 876-884.	of human lung	5.1	37
318	High incidence of disease recurrence in the brain and leptomeninges in patients with no lung carcinoma after response to gefitinib. Cancer, 2005, 103, 2344-2348.	onsmall cell	4.1	223
319	Distribution according to histologic type and outcome by gender and age group in Taiw with lung carcinoma. Cancer, 2005, 103, 2566-2574.	vanese patients	4.1	74
320	Targeted agents for the treatment of advanced renal cell carcinoma. Cancer, 2005, 104	, 2323-2333 .	4.1	105
321	Chronic myeloid leukemia: a model for oncology. Annals of Hematology, 2005, 84, 487	497.	1.8	49
322	A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a sing dose of gefitinib (IRESSA) in healthy male volunteers. Cancer Chemotherapy and Pharm 56, 557-562.	e 250Âmg oral acology, 2005,	2.3	8
326	Blockade of epidermal growth factor receptor (EGFR) activity. Critical Reviews in Oncology/Hematology, 2005, 53, 179-192.		4.4	23
328	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Archiv Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 483-48	/ Fur 8.	2.8	102
329	Impact of gefitinib (†Tressa') treatment on the quality of life of patients with adva lung cancer. Journal of Cancer Research and Clinical Oncology, 2005, 131, 783-788. –––––––––––––––––––––––––––––––––––	nced non-small-cell	2.5	10
331	Clinical review of Iressa for the treatment of NSCLC. Chinese Journal of Clinical Oncolog 829-833.	;y, 2005, 2,	0.0	0
332	Gefitinib therapy for non-small cell lung cancer. Current Treatment Options in Oncology 75-81.	<i>I</i> , 2005, 6,	3.0	25

#	Article	IF	CITATIONS
333	Targeted therapies for gynecologic malignancies. Current Treatment Options in Oncology, 2005, 6, 121-132.	3.0	3
334	Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Current Oncology Reports, 2005, 7, 241-247.	4.0	23
335	Gefitinib (â€~Iressa', ZD1839) is active against brain metastases in a 77 year old patient. Journal of Neuro-Oncology, 2005, 71, 277-280.	2.9	14
336	Metastatic Tumors of the Nervous System. Journal of Neuro-Oncology, 2005, 75, 1-3.	2.9	13
337	A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Research and Treatment, 2005, 89, 165-172.	2.5	161
338	EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients. Pharmaceutical Research, 2005, 22, 1757-1761.	3.5	18
339	A Case of Adenocarcinoma of the Lung Successfully Treated With Alternate Day Administration of Gefitinib. Japanese Journal of Lung Cancer, 2005, 45, 833-837.	0.1	0
341	Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer. Chest, 2005, 128, 308-316.	0.8	18
342	The Role of EGFR-TK Inhibition in Non-Small Cell Lung Cancer. Oncology Research and Treatment, 2005, 28, 619-620.	1.2	1
343	Lung Cancer Chemotherapy for Radiation Oncologists. , 2005, , 135-154.		0
343 344	Lung Cancer Chemotherapy for Radiation Oncologists. , 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188.	1.8	0
343 344 345	Lung Cancer Chemotherapy for Radiation Oncologists. , 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188. Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601.	1.8	0 4 128
343 344 345 346	Lung Cancer Chemotherapy for Radiation Oncologists., 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188. Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 165-174.	1.8 3.7 1.6	0 4 128 178
343 344 345 346 347	Lung Cancer Chemotherapy for Radiation Oncologists. , 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188. Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 165-174. Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects. Cancer Research, 2005, 65, 1459-1470.	1.8 3.7 1.6 0.9	0 4 128 178 283
343 344 345 346 347 348	Lung Cancer Chemotherapy for Radiation Oncologists. , 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188. Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 165-174. Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects. Cancer Research, 2005, 65, 1459-1470. Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 499-506.	1.8 3.7 1.6 0.9 6.3	0 4 128 178 283 138
 343 344 345 346 347 348 349 	Lung Cancer Chemotherapy for Radiation Oncologists. , 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188. Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 165-174. Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non〓Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects. Cancer Research, 2005, 65, 1459-1470. Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 499-506. Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities. Journal of Clinical Oncology, 2005, 23, 328-3293.	1.8 3.7 1.6 0.9 6.3 1.6	0 4 128 178 283 138 68
 343 344 345 346 347 348 349 350 	Lung Cancer Chemotherapy for Radiation Oncologists., 2005, , 135-154. An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. International Journal of Biological Markers, 2005, 20, 184-188. Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601. Practical Management of Patients With Nonâ€"Small-Cell Lung Cancer Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 165-174. Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Nonâ€"Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects. Cancer Research, 2005, 65, 1459-1470. Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 499-506. Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities. Journal of Clinical Oncology, 2005, 23, 3288-3293. Epidermal Growth Factor Receptor Mutations in Patients with Nonâ€"Small Cell Lung Cancer. Cancer Research, 2005, 65, 7525-7529.	1.8 3.7 1.6 0.9 6.3 1.6 0.9	0 4 128 178 283 138 68 143

#	Article	IF	CITATIONS
352	Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?. Journal of the National Cancer Institute, 2005, 97, 868-869.	6.3	23
353	Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers. Clinical Cancer Research, 2005, 11, 3032-3037.	7.0	122
354	Gene Mutations in Lung Cancer: Promising Predictive Factors for the Success of Molecular Therapy. PLoS Medicine, 2005, 2, e13.	8.4	24
355	Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Annals of Oncology, 2005, 16, 1817-1823.	1.2	28
356	Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Annals of Oncology, 2005, 16, 1867-1873.	1.2	22
357	Pharmacogenomics steps toward personalized medicine. Personalized Medicine, 2005, 2, 325-337.	1.5	72
358	Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non–Small Cell Lung Cancers. Cancer Research, 2005, 65, 9176-9184.	0.9	172
359	Improving Cancer Therapeutics by Molecular Profiling. Current Drug Metabolism, 2005, 6, 553-568.	1.2	4
360	Receptor Tyrosine Kinases and Anticancer Therapy. Current Pharmaceutical Design, 2005, 11, 1139-1149.	1.9	42
362	HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells. Cancer Research, 2005, 65, 4253-4260.	0.9	102
363	EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCycler. Clinical Cancer Research, 2005, 11, 2924-2929.	7.0	116
364	Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study. Clinical Cancer Research, 2005, 11, 5539-5548.	7.0	259
365	Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 3750-3757.	7.0	295
366	Drug Interaction Between Gefitinib and Warfarin. Japanese Journal of Clinical Oncology, 2005, 35, 478-482.	1.3	23
367	Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines. Clinical Cancer Research, 2005, 11, 1572-1578.	7.0	86
368	Italian clinical research in non-small-cell lung cancer. Annals of Oncology, 2005, 16, iv110-iv115.	1.2	3
369	Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer, 2005, 12, S173-S182.	3.1	33
370	Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel. Clinical Cancer Research, 2005, 11, 1983-1989.	7.0	128

#	Article	IF	CITATIONS
371	Gefitinib Affects Functions of Platelets and Blood Vesselsvia Changes in Prostanoids Balance. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 429-434.	1.7	17
372	Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs <i>In vivo</i> . Cancer Research, 2005, 65, 11631-11638.	0.9	365
373	Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology. Journal of Clinical Oncology, 2005, 23, 3227-3234.	1.6	378
374	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Annals of Oncology, 2005, 16, 538-548.	1.2	47
375	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. Clinical Cancer Research, 2005, 11, 8105-8108.	7.0	125
376	One Hundred Years of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 523-529.	5.6	319
377	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 3235-3242.	1.6	206
378	Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy. Clinical Cancer Research, 2005, 11, 5300-5309.	7.0	92
379	The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts. Molecular Cancer Therapeutics, 2005, 4, 1349-1357.	4.1	158
380	Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics, 2005, 4, 641-649.	4.1	121
381	Gefitinib in Colorectal Cancer: If Wishes Were Horses. Journal of Clinical Oncology, 2005, 23, 5446-5449.	1.6	15
382	Inhibitors of growth factor signalling. Endocrine-Related Cancer, 2005, 12, S183-S187.	3.1	48
383	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Annals of Oncology, 2005, 16, 1906-1914.	1.2	59
384	Lung Cancer in Women. Journal of Clinical Oncology, 2005, 23, 3212-3218.	1.6	137
385	Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib. Clinical Cancer Research, 2005, 11, 8872-8879.	7.0	33
386	Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology, 2005, 23, 2534-2543.	1.6	379
387	HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum. Oncologist, 2005, 10, 345-356.	3.7	257
388	Medical treatment of non-small-cell lung cancer. Annals of Oncology, 2005, 16, ii229-ii232.	1.2	10

#	Article	IF	CITATIONS
389	How Today's Developments in the Treatment of Nonâ€6mall Cell Lung Cancer Will Change Tomorrow's Standards of Care. Oncologist, 2005, 10, 23-29.	3.7	21
390	Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. Journal of Clinical Pathology, 2005, 58, 700-704.	2.0	100
391	Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 5323-5333.	1.6	334
392	Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial. Journal of Clinical Oncology, 2005, 23, 2946-2954.	1.6	107
393	Developing an Oncology Portfolio of Anticancer Drugs: The Experience of one Pharmaceutical Company. Zentralblatt Fur Gynakologie, 2005, 127, 385-388.	0.6	0
395	Factors Predicting Response to EGFR Tyrosine Kinase Inhibitors. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 314-322.	2.1	24
396	Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 342-352.	2.1	21
397	Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. Radiology, 2005, 237, 342-347.	7.3	84
398	Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncology, 2005, 1, 221-234.	2.4	58
399	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. Expert Review of Anticancer Therapy, 2005, 5, 727-735.	2.4	2
400	Clinical Advancement of EGFR Inhibitors in Cancer Therapy. , 2006, 327, 189-202.		6
401	A man whose scapula was spared a drug-associated rash. Cmaj, 2005, 172, 745-745.	2.0	10
402	Erlotinib in the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2005, 5, 767-775.	2.4	21
403	The future of adjuvant chemotherapy for resected non-small cell lung cancer. Expert Review of Anticancer Therapy, 2005, 5, 165-175.	2.4	12
404	Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biology and Therapy, 2005, 4, 1381-1386.	3.4	35
405	Gefitinib in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 985-993.	1.8	55
406	Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. British Journal of Cancer, 2005, 92, 1877-1880.	6.4	20
407	ZD6474 – clinical experience to date. British Journal of Cancer, 2005, 92, S14-S20.	6.4	66

	CITAT	ION REPORT	
#	Article	IF	CITATIONS
408	Targeted antitumour therapy – future perspectives. British Journal of Cancer, 2005, 92, S28-S31.	6.4	14
409	Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. British Journal of Cancer, 2005, 92, 1063-1068.	6.4	48
410	EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 554-561.	4.3	77
411	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2005, 97, 339-346.	6.3	2,194
412	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7665-7670). 7.1	907
413	Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 4289-4294.	7.0	120
414	Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2005, 11, 8418-8424.	7.0	224
415	Dominant-Negative Notch3 Receptor Inhibits Mitogen-Activated Protein Kinase Pathway and the Growth of Human Lung Cancers. Cancer Research, 2005, 65, 3555-3561.	0.9	156
416	Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6172-6180.	; 1.6	98
417	Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy. Clinical Cancer Research, 2005, 11, 7480-7489.	7.0	95
418	Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2005, 23, 921-922.	1.6	5
419	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3788-3793.	7.1	472
420	Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 2005, 97, 1185-1194.	6.3	294
421	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6838-6845.	1.6	574
422	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2005, 10, 855-874.	2.4	8
423	Molecularly-targeted therapies for non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 2667-2679.	1.8	7
424	Side Effects Related to Cancer Treatment. Journal of Clinical Oncology, 2005, 23, 8531-8533.	1.6	37
425	Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?. Journal of Clinical Oncology, 2005, 23, 5235-5246.	1.6	476

#	Article	IF	CITATIONS
426	Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology, 2005, 23, 455-460.	1.6	195
427	Modern Treatment of Lung Cancer. Journal of Clinical Oncology, 2005, 23, 7738-7740.	1.6	36
428	Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. Journal of Clinical Oncology, 2005, 23, 235-237.	1.6	11
429	Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 9868-9875.	0.9	122
430	Impact of Molecular Pathology on the Clinical Management of Lung Cancer. Respiration, 2005, 72, 229-232.	2.6	4
432	Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 533-559.	3.4	22
433	Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma. Clinical Cancer Research, 2005, 11, 1368-1371.	7.0	135
434	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. Current Cancer Therapy Reviews, 2005, 1, 51-61.	0.3	1
435	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11858-11863.	7.1	86
436	Therapy of breast cancer with molecular targeting agents. Annals of Oncology, 2005, 16, iv28-iv36.	1.2	41
437	Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B. Clinical Cancer Research, 2005, 11, 2300-2304.	7.0	250
438	Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8786-8793.	1.6	184
439	Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine Cytokines. Cell Cycle, 2005, 4, 822-830.	2.6	27
440	Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer. Chest, 2005, 128, 947-957.	0.8	71
441	Lung Cancer in Women. Chest, 2005, 128, 370-381.	0.8	155
442	Interferon-α Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines. Oncology, 2005, 69, 224-238.	1.9	15
443	Acute Myocardial Infarction with Lung Cancer during Treatment with Gefitinib: the Possibility of Gefitinib-Induced Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 48-50.	0.3	10
444	Clinical Benefit in NSCLC: Advanced-Stage Patients Require Symptom-Improving Palliation. Experiences from the †Tressa' Expanded Access Program. Oncology Research and Treatment, 2005, 28, 195-198.	1.2	8

#	Article	IF	CITATIONS
445	Inhibitors of Epidermoid Growth Factor Receptor Suppress Cell Growth and Enhance Chemosensitivity of Nasopharyngeal Cancer Cells in vitro. Oncology, 2005, 68, 538-547.	1.9	38
446	EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients. Oncology Research and Treatment, 2005, 28, 623-627.	1.2	3
448	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncology, 2005, 1, 461-466.	2.4	6
449	Strategies for enhanced radiation delivery in patients with lung cancer. Expert Opinion on Drug Delivery, 2005, 2, 103-113.	5.0	3
450	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important?. Cancer Biology and Therapy, 2005, 4, 1096-1097.	3.4	6
451	Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line. Cell Cycle, 2005, 4, 818-821.	2.6	11
452	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa) Tj ETQq0 0	0 rg₿.ি/O\	verløgdøs 120 Tf 5
453	Somatic Mutations of <i>EGFR</i> Gene in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2005, 11, 2879-2882.	7.0	246
454	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncology, The, 2005, 6, 383-391.	10.7	189
455	Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer, 2005, 50, S25-S32.	2.0	21
456	Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Community Oncology, 2005, 2, 492-496.	0.2	10
457	Third-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer — Is There Enough Evidence to Support Its Use?. Journal of the Chinese Medical Association, 2005, 68, 160-161.	1.4	1
458	Interstitial Pneumonia During Gefitinib Treatment of Non-Small-Cell Lung Cancer. Journal of the Chinese Medical Association, 2005, 68, 183-186.	1.4	15
459	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2005, 17, 199-204.	0.6	9
460	Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer, 2005, 50, 375-384.	2.0	148
461	Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology, 2005, 23, 8081-8092.	1.6	608
462	Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 6829-6837.	1.6	701
463	The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Annals of Oncology, 2005, 16, 1334-1342.	1.2	90

#	Article	IF	CITATIONS
464	Increased <i>HER2</i> Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018.	1.6	367
465	Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	27.0	1,787
466	Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2005, 97, 643-655.	6.3	1,517
467	Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence. Journal of Clinical Oncology, 2005, 23, 2513-2520.	1.6	922
468	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 2493-2501.	1.6	736
469	Race, gender and mutations in the prediction of anti-EGFR activity. Future Oncology, 2005, 1, 201-204.	2.4	Ο
470	Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 2106-2110.	7.0	141
471	Current Imaging Paradigms in Radiation Oncology. Radiation Research, 2005, 163, 1-25.	1.5	62
472	Le cancer bronchique chez la femme. Revue Des Maladies Respiratoires, 2005, 22, 55-62.	1.7	6
473	Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapy–Lung Scale. Hematology/Oncology Clinics of North America, 2005, 19, 389-420.	2.2	40
474	Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics, 2005, 7, 396-403.	2.8	221
475	Lung: Medical Oncology. Journal of Vascular and Interventional Radiology, 2005, 16, P8-P11.	0.5	Ο
476	Erlotinib in non-small cell lung cancer: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 995-1002.	1.8	11
477	Perspectives on novel therapies for bronchial carcinoma. Expert Opinion on Pharmacotherapy, 2005, 6, 1157-1167.	1.8	7
478	Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica, 2005, 35, 39-50.	1.1	124
479	Second-generation kinase inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 975-993.	3.4	55
480	Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of Pennsylvania. Cancer Investigation, 2005, 23, 296-302.	1.3	18
481	Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib. Journal of Clinical Oncology, 2005, 23, 5900-5909.	1.6	1,405

#	Article	IF	CITATIONS
482	An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 2855-2866.	1.8	8
483	State of the Art in Therapy for Non-Small Cell Lung Cancer. Cancer Investigation, 2005, 23, 427-442.	1.3	65
484	Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. Journal of Clinical Oncology, 2005, 23, 2445-2459.	1.6	676
485	Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases. Molecular Diagnosis and Therapy, 2005, 5, 101-112.	3.3	12
486	Spotlight on Gefitinib in Non-Small-Cell Lung Cancer1. Molecular Diagnosis and Therapy, 2005, 5, 133-136.	3.3	4
487	EGFR Pharmacogenomics. Molecular Diagnosis and Therapy, 2005, 5, 137-139.	3.3	1
488	Receptor-Targeted Cancer Therapy. DNA and Cell Biology, 2005, 24, 271-282.	1.9	31
489	Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas. Clinical Cancer Research, 2005, 11, 5878-5885.	7.0	324
490	Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 2244-2251.	7.0	171
491	Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Annals of Oncology, 2005, 16, 780-785.	1.2	79
492	Role of Tyrosine Kinase Inhibitors in Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 971-979.	2.5	846
493	Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience. Acta OncolA³gica, 2005, 44, 717-722.	1.8	19
494	Nano neodymium oxide induces massive vacuolization and autophagic cell death in non-small cell lung cancer NCI-H460 cells. Biochemical and Biophysical Research Communications, 2005, 337, 52-60.	2.1	151
495	Recent developments related to the EGFR as a target for cancer chemotherapy. Current Opinion in Pharmacology, 2005, 5, 343-349.	3.5	30
496	Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. European Journal of Cancer, 2005, 41, 1286-1290.	2.8	56
497	Antitumor activity of HER-2 inhibitors. Cancer Letters, 2005, 227, 9-23.	7.2	82
498	Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Letters, 2005, 225, 61-74.	7.2	13
499	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Letters, 2005, 230, 33-46.	7.2	34

#	Article	IF	CITATIONS
500	Antitumor effect of gefitinib (â€~Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Letters, 2005, 226, 37-47.	7.2	44
501	Gefitinib (â€~Iressa'): a new therapy for advanced non-small-cell lung cancer. Respiratory Medicine, 2005, 99, 298-307.	2.9	18
502	Interstitial Lung Disease in Lung Cancer. Drug Safety, 2005, 28, 103-113.	3.2	60
503	Single-Dose Clinical Pharmacokinetic Studies of Gefitinib. Clinical Pharmacokinetics, 2005, 44, 1165-1177.	3.5	127
504	Epidermal Growth Factor Receptor as a Target for Chemotherapy. Clinical Colorectal Cancer, 2005, 5, S19-S27.	2.3	59
505	Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Receptor—Targeted Agents. Clinical Colorectal Cancer, 2005, 5, S101-S106.	2.3	25
506	Computer-Assisted Image Analysis of Bronchioloalveolar Carcinoma. Clinical Lung Cancer, 2005, 6, 281-286.	2.6	11
507	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer, 2005, 47, 129-138.	2.0	132
508	Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer, 2005, 47, 253-259.	2.0	60
509	Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?. Lung Cancer, 2005, 47, 325-336.	2.0	21
510	Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer, 2005, 47, 421-423.	2.0	22
511	Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer, 2005, 48, 141-144.	2.0	46
512	Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer, 2005, 48, 267-273.	2.0	44
513	Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer, 2005, 48, 365-377.	2.0	21
514	Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer, 2005, 49, 225-231.	2.0	48
515	Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days. Lung Cancer, 2005, 49, 417-418.	2.0	3
516	Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer, 2005, 49, 337-343.	2.0	170
517	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer, 2005, 50, 1-8.	2.0	112

#	Article	IF	CITATIONS
518	Benefit in lung function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. Lung Cancer, 2005, 50, 107-114.	2.0	11
519	Consensus on medical treatment of non-small-cell lung cancer—update 2004. Lung Cancer, 2005, 50, 129-137.	2.0	3
520	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. Lung Cancer, 2005, 50, 259-263.	2.0	9
521	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer, 2005, 50, 25-33.	2.0	74
522	Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2005, 50, 417-418.	2.0	33
523	<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 2005, 352, 786-792.	27.0	3,715
524	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. New England Journal of Medicine, 2005, 353, 2012-2024.	27.0	1,376
525	Novel Therapies in Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 343-367.	2.2	4
526	Renal: Urologic Therapies. Journal of Vascular and Interventional Radiology, 2005, 16, P8.	0.5	0
527	Epidemiology of Lung Cancer: Looking to the Future. Journal of Clinical Oncology, 2005, 23, 3175-3185.	1.6	404
529	Current Advancements in Hard-To-Treat Cancers. American Journal of Cancer, 2005, 4, 105-113.	0.4	1
530	The Importance of Balancing Toxicity and Efficacy in Chemotherapy. American Journal of Cancer, 2005, 4, 127-136.	0.4	1
531	Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer. Treatments in Respiratory Medicine, 2005, 4, 71-84.	1.4	35
532	Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. British Journal of Cancer, 2005, 92, 1110-1116.	6.4	61
533	Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6816-6822.	7.0	135
534	Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions. Journal of Clinical Oncology, 2005, 23, 2556-2568.	1.6	579
535	TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS. Annual Review of Pharmacology and Toxicology, 2005, 45, 357-384.	9.4	115
536	Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Lung Cancer, 2005, 50, 393-399.	2.0	15

#	Article	IF	CITATIONS
537	Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2005, 353, 123-132.	27.0	5,267
538	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research, 2005, 7, R570-9.	5.0	112
539	Effectiveness of Cetuximab/Gefitinib in the Therapy of a Sacral Chordoma. Oncology Research and Treatment, 2006, 29, 572-574.	1.2	93
540	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer, 2006, 95, 998-1004.	6.4	271
542	Dissimilarity in gene expression profiles of lung adenocarcinoma in japanese men and women. Gender Medicine, 2006, 3, 223-235.	1.4	2
543	The place of targeted therapies in the management of non-small cell bronchial carcinoma. Revue Des Maladies Respiratoires, 2006, 23, 137-147.	1.7	2
544	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. Journal of Clinical Pathology, 2006, 60, 881-884.	2.0	39
545	Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. British Journal of Cancer, 2006, 95, 1070-1075.	6.4	47
546	Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. British Journal of Cancer, 2006, 95, 1483-1489.	6.4	165
547	Cancer Drug Resistance. , 2006, , .		21
548	Epidermal growth factor receptor as a major anticancer drug target. Expert Opinion on Therapeutic Targets, 2006, 10, 877-888.	3.4	7
549	Three Case Reports of Hand-Foot Syndrome with Gefitinib. Cancer Investigation, 2006, 24, 514-516.	1.3	14
550	Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets, 2006, 10, 789-791.	3.4	1
551	Is EGFR expression important in non-small cell lung cancer?. Thorax, 2006, 61, 98-99.	5.6	35
552	The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Review of Anticancer Therapy, 2006, 6, 531-544.	2.4	15
553	Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents, 2006, 16, 147-164.	5.0	3
554	The wind of change in the therapy of lung cancer. Expert Review of Anticancer Therapy, 2006, 6, 469-472.	2.4	0
555	Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. Oncologist, 2006, 11, 274-284.	3.7	86

#	Article	IF	CITATIONS
556	Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5034-5042.	1.6	701
557	Prospective Phase II Study of Gefitinib for Chemotherapy-NaÃ⁻ve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations. Journal of Clinical Oncology, 2006, 24, 3340-3346.	1.6	490
558	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 344-350.	1.3	29
559	Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer, 2006, 52, 47-52.	2.0	44
560	A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma. Japanese Journal of Clinical Oncology, 2006, 36, 69-75.	1.3	63
561	First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study. Journal of Clinical Oncology, 2006, 24, 64-69.	1.6	159
562	Where next for gefitinib in patients with lung cancer?. Lancet Oncology, The, 2006, 7, 499-507.	10.7	116
563	Targeted Therapy in Oncology. Medical Journal Armed Forces India, 2006, 62, 169-173.	0.8	2
564	Est-il nécessaire de sélectionner les patients pour prescrire des thérapeutiques ciblées dans les cancers bronchiques non à petites cellules de stade IV ?. Revue De Pneumologie Clinique, 2006, 62, 41-44.	0.0	0
565	Clinical Trials in a Molecular World. Neuroimaging Clinics of North America, 2006, 16, 681-694.	1.0	3
566	Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 379-396.	1.0	12
567	La place des thérapeutiques ciblées dans la prise en charge des CBNPC. Revue Des Maladies Respiratoires, 2006, 23, 148-157.	1.7	0
568	Novel Targeted Therapies for Non–Small Cell Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 353-366.	1.0	1
570	CBNPC stade IV. Revue Des Maladies Respiratoires, 2006, 23, 78-83.	1.7	2
571	Exploring the Relationship Between Expression of Cytochrome P450??Enzymes and Gefitinib Pharmacokinetics. Clinical Pharmacokinetics, 2006, 45, 633-644.	3.5	59
572	Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer. Drugs, 2006, 66, 1441-1463.	10.9	12
573	Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor—Based Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 59-65.	2.3	10
574	Lung Cancer in Women: Exploring Sex Differences in Susceptibility, Biology, and Therapeutic Response. Clinical Lung Cancer, 2006, 8, 22-29.	2.6	26

#	Article	IF	CITATIONS
575	Future Trends in Patient-Reported Outcomes Assessment for Patients with Advanced-Stage Lung Cancer Receiving Targeted Therapy. Clinical Lung Cancer, 2006, 8, 99-109.	2.6	6
576	Current Approaches to Advanced-Stage Non–Small-Cell Lung Cancer: First-Line Therapy in Patients with a Good Functional Status. Clinical Lung Cancer, 2006, 7, S111-S117.	2.6	27
577	Second-Line Treatment for Advanced-Stage Non–Small-Cell Lung Cancer: Current and Future Options. Clinical Lung Cancer, 2006, 7, S118-S125.	2.6	16
578	Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Carcinoma. Clinical Lung Cancer, 2006, 8, S31-S35.	2.6	24
579	Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2006, 24, 2158-2163.	1.6	143
580	A review of erlotinib and its clinical use. Expert Opinion on Pharmacotherapy, 2006, 7, 177-193.	1.8	74
581	Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors. Annals of Pharmacotherapy, 2006, 40, 261-269.	1.9	163
582	A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2006, 51, 115-121.	2.0	32
583	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer, 2006, 51, 71-77.	2.0	51
584	Second-line treatment for advanced non-small cell lung cancer: A systematic review. Lung Cancer, 2006, 51, 159-172.	2.0	49
585	Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer, 2006, 51, 89-96.	2.0	55
586	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer, 2006, 51, 363-368.	2.0	75
587	PPAR-Î ³ agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer, 2006, 51, 297-301.	2.0	90
588	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. Lung Cancer, 2006, 52, 75-81.	2.0	11
589	Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer, 2006, 52, 93-97.	2.0	96
590	Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2006, 52, 99-103.	2.0	23
591	Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer, 2006, 52, 135-140.	2.0	88
592	A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer, 2006, 52, 305-311.	2.0	8

#	Article	IF	CITATIONS
593	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer, 2006, 53, 117-121.	2.0	56
594	Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer, 2006, 53, 331-337.	2.0	15
595	Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer, 2006, 53, 157-164.	2.0	24
596	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients. Lung Cancer, 2006, 53, 339-345.	2.0	15
597	Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer, 2006, 53, 387-390.	2.0	32
598	L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer, 2006, 54, 103-108.	2.0	29
599	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer, 2006, 53, 311-322.	2.0	74
600	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer, 2006, 54, 201-207.	2.0	35
601	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer, 2006, 54, 193-199.	2.0	35
602	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer, 2006, 54, 387-398.	2.0	92
603	Integrating new targeted agents into the treatment of non-small-cell lung cancer. Lung Cancer, 2006, 54, S25-S31.	2.0	6
604	Second-line therapeutic options in non-small-cell lung cancer. Lung Cancer, 2006, 54, S15-S18.	2.0	5
605	Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines. Cancer Research, 2006, 66, 944-950.	0.9	482
606	Newer developments in immunohistology. Journal of Clinical Pathology, 2006, 59, 1117-1126.	2.0	32
607	A review of the benefit–risk profile of gefitinib in Asian patients with advanced nonâ€smallâ€cell lung cancer. Current Medical Research and Opinion, 2006, 22, 561-573.	1.9	85
608	Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2006, 24, 2549-2556.	1.6	348
609	Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?. Clinical Cancer Research, 2006, 12, 5919-5920.	7.0	3
610	Gefitinib Prevents Bleomycin-induced Lung Fibrosis in Mice. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 550-556.	5.6	99

ARTICLE IF CITATIONS # Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic 611 7.0 154 Adenocarcinomas. Clinical Cancer Research, 2006, 12, 4283-4287. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell 6.4 38 lung cancer. British Journal of Cancer, 2006, 94, 1599-1603. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical 613 1.3 36 implications. Annals of Diagnostic Pathology, 2006, 10, 306-315. Prognostic biomarkers in non-small-cell lung carcinoma. Current Diagnostic Pathology, 2006, 12, 614 418-428. Protein tyrosine kinase signaling diversity andÂsusceptibility toÂtargeted kinase inhibitors. Biomedicine 615 5.6 5 and Pharmacotherapy, 2006, 60, 629-632. Functional SNPs of the breast cancer resistance protein $\hat{a} \in \mathbf{A}$ therapeutic effects and inhibitor development. Cancer Letters, 2006, 234, 73-80. High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in 617 7.2 27 Thailand. Cancer Letters, 2006, 239, 292-297. Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?. Cancer 29 Treatment Reviews, 2006, 32, 630-636. Mutations of the epidermal growth factor receptor in non-small cell lung cancer $\hat{a} \in$ Search and destroy. European Journal of Cancer, 2006, 42, 17-23. 619 2.8 153 Targeted kinase inhibitors in lung cancer: From EGFR to patients. European Journal of Cancer, 2006, 42, 2.8 124-125. (CA)n Microsatellite polymorphism of ERBB-1 in breast cancer. European Journal of Cancer, 2006, 42, 621 2 2.8 1698-1701. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non–small cell lung carcinomas. Human 104 Pathology, 2006, 37, 542-546. Interstitial lung disease associated with gefitinib. Respiratory Medicine, 2006, 100, 698-704. 623 2.9 40 Emerging Dermatologic Issues in the Oncology Patient. Seminars in Cutaneous Medicine and Surgery, 2006, 25, 179-189. 1.6 14 626 EGFR as a Target: Rationale for Therapy. Seminars in Oncology Nursing, 2006, 22, 5-9. 1.5 16 Clinical Experience With Anti-EGFR Therapy. Seminars in Oncology Nursing, 2006, 22, 10-19. Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics, 2006, 1, 299-310. 628 0.4 6 629 Drugs for Lung Cancer Treatment. Tuberculosis and Respiratory Diseases, 2006, 60, 123. 1.8

		CITATION REPORT		
#	Article		IF	CITATIONS
630	Epidermal Growth Factor Receptor-Targeted Agents for Lung Cancer. Cancer Control,	2006, 13, 129-140.	1.8	22
631	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Subset Analysis from the ISEL Study. Journal of Thoracic Oncology, 2006, 1, 847-855.	Lung Cancer:	1.1	108
632	Novel Mutations of Epidermal Growth Factor Receptor in Localized Prostate Cancer. Fi Bioscience - Landmark, 2006, 11, 2518.	ontiers in	3.0	36
633	Current Update on the Management of Locally Advanced Non-small Cell Lung Cancer. Cancer, 2006, 5, 1.	Journal of Lung	0.2	0
634	Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced no lung cancer. Chinese Medical Journal, 2006, 119, 63-68.	n-small cell	2.3	8
635	Bronchioloalveolar Carcinoma of the Lung. , 2006, , 313-320.			0
636	Contemporary Issues in the Systemic Treatment of Lung Cancer. , 2006, , 99-119.			0
640	EGF Receptor Testing for Nonâ€Small Cell Lung Carcinomas. Current Protocols in Hum 50, Unit 10.9.	ian Genetics, 2006,	3.5	1
641	Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic S Discovery with Immediate Clinical Impact. American Journal of the Medical Sciences, 2	cience 006, 331, 139-149.	1.1	11
642	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cel Patients. Journal of Thoracic Oncology, 2006, 1, 520-525.	l Lung Cancer	1.1	22
643	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV No Cancer: Report of a Phase II Open-Label Multicenter Trial. Journal of Thoracic Oncology 984-990.	n-small Cell Lung v, 2006, 1,	1.1	31
644	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tume Oncology Reports, 2006, 15, 1205.	or cell lines.	2.6	3
645	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic in Patients with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 31-37.	Chemotherapy	1.1	16
646	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the T Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 2006,	reatment of 1, 367-376.	1.1	28
647	Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small C Cancer: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology, 200	ell Lung 06, 1, 1042-1058.	1.1	41
648	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findin Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 413-416.	gs in Peripheral	1.1	43
649	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Fac Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanc Cell Lung Cancer?. Journal of Thoracic Oncology, 2006, 1, 684-691.	ctor Receptor ed Non-small	1.1	5
650	Evaluation of the epidermal growth factor receptor gene mutation and copy number in lung cancer with gefitinib therapy. Oncology Reports, 2006, 16, 533.	n non-small cell	2.6	6

#	Article	IF	CITATIONS
651	Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. International Journal of Oncology, 2006, 29, 615-23.	3.3	9
652	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 582-587.	1.1	10
653	EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 260-267.	1.1	64
654	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60.	1.1	6
655	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 2006, 1, 367-376.	1.1	36
656	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. Journal of Thoracic Oncology, 2006, 1, 1002-1009.	1.1	86
657	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology, 2006, 1, 847-855.	1.1	157
658	Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group. Journal of Thoracic Oncology, 2006, 1, 447-453.	1.1	10
659	A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy. Chest, 2006, 129, 1031-1038.	0.8	81
660	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 413-416.	1.1	73
661	Rational Development of Targeted Cancer Therapies Using Biomarkers. Laboratory Medicine, 2006, 37, 482-489.	1.2	0
662	Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics. Current Drug Targets, 2006, 7, 387-395.	2.1	5
663	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. Journal of Thoracic Oncology, 2006, 1, 545-550.	1.1	5
664	Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 231-239.	1.1	121
665	Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology, 2006, 1, 1042-1058.	1.1	79
666	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525.	1.1	32
667	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. Journal of Thoracic Oncology, 2006, 1, 965-971.	1.1	19
668	A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non???small-cell Lung Carcinoma. Diagnostic Molecular Pathology, 2006, 15, 101-108.	2.1	31
#	Article	IF	CITATIONS
-----	---	-----	-----------
669	Rapid Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Using Real-Time Polymerase Chain Reaction with TaqMan-MGB Probes. Cancer Journal (Sudbury, Mass), 2006, 12, 33-39.	2.0	28
670	Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 417-424.	1.1	11
671	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 31-37.	1.1	16
672	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. Journal of Thoracic Oncology, 2006, 1, 984-990.	1.1	34
673	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.8	44
674	Matching patients with drugs: triumphs and challenges. Personalized Medicine, 2006, 3, 335-344.	1.5	2
675	New developments in chemotherapy for advanced non-small cell lung cancer. Current Opinion in Internal Medicine, 2006, 5, 305-310.	1.5	15
676	Antiangiogenic drugs in non-small cell lung cancer treatment. Current Opinion in Oncology, 2006, 18, 151-155.	2.4	17
677	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. Current Opinion in Oncology, 2006, 18, 609-614.	2.4	4
678	Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs, 2006, 17, 401-409.	1.4	133
679	Aspirin reduces adverse effects of gefitinib. Anti-Cancer Drugs, 2006, 17, 423-427.	1.4	19
680	New molecular targeted therapies in thyroid cancer. Anti-Cancer Drugs, 2006, 17, 869-879.	1.4	21
681	Targeted therapies and non-small-cell lung cancer: work in progress?. Current Opinion in Oncology, 2006, 18, 132-134.	2.4	2
682	Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Current Opinion in Oncology, 2006, 18, 144-150.	2.4	8
683	Advances in Chemotherapy of Non-small Cell Lung Cancer. Chest, 2006, 130, 1211-1219.	0.8	157
684	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Topics in Medicinal Chemistry, 2006, , 83-132.	0.8	1
685	Effect of Gefitinib on Brain Metastases From Non-Small Cell Lung Cancer-Two Case Reports Neurologia Medico-Chirurgica, 2006, 46, 504-507.	2.2	8
686	Management of transitional cell carcinoma by targeting the epidermal growth factor receptor. Therapy: Open Access in Clinical Medicine, 2006, 3, 407-416.	0.2	0

#	Article	IF	CITATIONS
687	Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatric Blood and Cancer, 2006, 46, 614-623.	1.5	48
688	Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. Pediatric Blood and Cancer, 2006, 47, 293-298.	1.5	6
689	Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology, 2006, 11, 113-116.	2.3	19
690	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. Respirology, 2006, 11, 287-291.	2.3	6
691	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology, 2006, 11, 687-692.	2.3	32
692	Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. Respirology, 2006, 11, 693-698.	2.3	22
693	Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. International Journal of Urology, 2006, 13, 587-592.	1.0	62
694	Molecular Medicine, the Medicare Drug Benefit, and the Need for Cost Control. Journal of the American Geriatrics Society, 2006, 54, 1442-1446.	2.6	10
695	The management of PS2 patients with advanced non-small cell lung cancer. International Journal of Clinical Practice, 2006, 60, 1493-1496.	1.7	2
696	Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 22-31.	1.1	2
697	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Cytopathology, 2006, 17, 3-9.	0.7	10
698	The role of pharmacogenetics in cancer therapeutics. British Journal of Clinical Pharmacology, 2006, 62, 35-46.	2.4	62
699	New targets and challenges in the molecular therapeutics of cancer. British Journal of Clinical Pharmacology, 2006, 62, 5-14.	2.4	33
700	SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells. Cancer Science, 2006, 97, 84-89.	3.9	16
701	Recent trends in the treatment of advanced lung cancer. Cancer Science, 2006, 97, 448-452.	3.9	16
702	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Science, 2006, 97, 753-759.	3.9	73
703	Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer, 2006, 6, 714-727.	28.4	661
704	Impact of genetic diagnostics on drug development strategy. Nature Reviews Drug Discovery, 2006, 5, 459-462.	46.4	12

#	Article	IF	CITATIONS
705	Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. British Journal of Cancer, 2006, 94, 85-92.	6.4	64
706	Gefitinib (ZD1839, Iressaâ,,¢) as palliative treatment in recurrent or metastatic head and neck cancer. British Journal of Cancer, 2006, 94, 631-636.	6.4	95
707	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. British Journal of Cancer, 2006, 94, 896-903.	6.4	132
708	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. British Journal of Cancer, 2006, 95, 1390-1395.	6.4	126
709	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Modern Pathology, 2006, 19, 986-998.	5.5	17
710	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene, 2006, 25, 1205-1215.	5.9	127
711	Epidermal growth factor receptor directed therapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 25-43.	4.4	46
712	Non-small-cell lung cancer in the elderly. Critical Reviews in Oncology/Hematology, 2006, 57, 183-190.	4.4	9
713	Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology, 2006, 57, 79-101.	4.4	16
714	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	4.4	50
715	Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. Critical Reviews in Oncology/Hematology, 2006, 59, 150-158.	4.4	30
716	In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1969-1974.	2.2	75
717	Lymphangitis Carcinomatosis as a Potential Predictor for a Response to Gefitinib. Clinical Oncology, 2006, 18, 573-574.	1.4	1
718	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer. Clinical Pharmacology and Therapeutics, 2006, 80, 136-145.	4.7	195
720	Interstitial Lung Disease in Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors. Medical Oncology, 2006, 23, 161-170.	2.5	41
721	Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics. Journal of Clinical Oncology, 2006, 24, 2151-2157.	1.6	44
722	Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Investigational New Drugs, 2006, 24, 117-123.	2.6	15
723	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Investigational New Drugs, 2006, 24, 291-297.	2.6	70

#	Article	IF	CITATIONS
724	Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer and Metastasis Reviews, 2006, 25, 279-292.	5.9	25
725	Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. Journal of Cancer Research and Clinical Oncology, 2006, 132, 719-725.	2.5	18
726	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2006, 133, 93-102.	2.5	25
727	Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. International Journal of Clinical Oncology, 2006, 11, 243-245.	2.2	38
728	Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. International Journal of Clinical Oncology, 2006, 11, 73-81.	2.2	24
729	Current topics and the clinical effects of target-based antineoplastic agents. International Journal of Clinical Oncology, 2006, 11, 164-166.	2.2	1
730	Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology, 2006, 11, 190-198.	2.2	194
731	Resistance to gefitinib. International Journal of Clinical Oncology, 2006, 11, 487-491.	2.2	31
733	Cancer management can be personalized? — Cancer genomic research in China. Chinese-German Journal of Clinical Oncology, 2006, 5, 156-158.	0.1	2
734	Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1-5.	6.4	11
735	A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemotherapy and Pharmacology, 2006, 57, 533-539.	2.3	57
736	Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 577-584.	2.3	42
737	Impact of EGFR mutations on treatment of non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 5-9.	2.3	4
738	Defining clinically relevant molecular subsets of lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 11-15.	2.3	17
739	Molecular classification of tumors with special reference to EGFR mutation in lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 17-23.	2.3	6
740	The impact and role of EGFR gene mutation on non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 25-31.	2.3	7
741	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. Cancer Chemotherapy and Pharmacology, 2006, 58, 33-37.	2.3	1
743	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. Targeted Oncology, 2006, 1, 23-33.	3.6	1

#	Article	IF	CITATIONS
744	Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. Targeted Oncology, 2006, 1, 13-22.	3.6	1
745	Aims and difficulties of targeting. Targeted Oncology, 2006, 1, 69-70.	3.6	1
746	Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring. Targeted Oncology, 2006, 1, 114-122.	3.6	0
747	Second- and third-line treatments in non-small cell lung cancer. Current Treatment Options in Oncology, 2006, 7, 37-49.	3.0	17
748	Emerging approaches to advanced bronchioloalveolar carcinoma. Current Treatment Options in Oncology, 2006, 7, 69-76.	3.0	10
749	Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. Gynecologic Oncology, 2006, 101, 18-23.	1.4	31
750	Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cellular Signalling, 2006, 18, 2089-2097.	3.6	257
751	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 217-229.	7.4	32
752	Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochemical Pharmacology, 2006, 71, 1422-1434.	4.4	73
753	Geographic Variation in the Second-Line Treatment of Non–Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 39-44.	2.2	6
754	Second-Line Treatment Options in Non–Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies. Seminars in Oncology, 2006, 33, 17-24.	2.2	7
755	Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 9-16.	2.2	27
756	Second-Line Treatment Options in Advanced Non–Small Cell Lung Cancer: Current Status. Seminars in Oncology, 2006, 33, 3-8.	2.2	11
757	Epidermal Growth Factor Receptor Targeting in Cancer. Seminars in Oncology, 2006, 33, 369-385.	2.2	645
758	Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer. BMC Cancer, 2006, 6, 288.	2.6	5
759	Interactions Between Hypoxia and Epidermal Growth Factor Receptor in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 7, 250-256.	2.6	80
760	Asian Ethnicity as a Predictor of Response in Patients with Non–Small-Cell Lung Cancer Treated with Gefitinib on an Expanded Access Program. Clinical Lung Cancer, 2006, 7, 326-331.	2.6	27
761	Gefitinib Monotherapy in Chemotherapy-Naive Patients with Inoperable Stage III/IV Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2006, 7, 406-411.	2.6	33

#	Article	IF	CITATIONS
762	Rash as a Surrogate Marker for Efficacy of Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. Clinical Lung Cancer, 2006, 8, S7-S14.	2.6	95
763	Managing Dermatologic Toxicities of Epidermal Growth Factor Receptor Inhibitors. Clinical Lung Cancer, 2006, 8, S15-S22.	2.6	13
764	Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. Journal of Cellular Biochemistry, 2006, 97, 724-734.	2.6	60
765	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer, 2006, 107, 1207-1218.	4.1	165
766	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 1866-1872.	4.1	3
767	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 1873-1882.	4.1	54
768	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer, 2006, 107, 2858-2865.	4.1	59
769	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. International Journal of Cancer, 2006, 118, 963-969.	5.1	151
770	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 2006, 118, 257-262.	5.1	601
771	Impact of IGFâ€1R/EGFR crossâ€ŧalks on hepatoma cell sensitivity to gefitinib. International Journal of Cancer, 2006, 119, 2557-2566.	5.1	113
772	Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: Experience at a single institution. American Journal of Hematology, 2006, 81, 349-354.	4.1	11
773	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?. Journal of Thoracic Oncology, 2006, 1, 684-691.	1.1	12
774	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nature Clinical Practice Oncology, 2006, 3, 170-171.	4.3	16
775	Expression of Tyrosine Kinase Receptors in Malignant Midgut Carcinoid Tumors. Neuroendocrinology, 2006, 84, 42-48.	2.5	32
776	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.9	112
777	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Annals of Oncology, 2006, 17, 981-985.	1.2	118
778	Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 2243-2261.	1.8	27
779	Expression biomarkers for clinical efficacy and outcome prediction in cancer. Pharmacogenomics, 2006, 7, 105-115.	1.3	12

		CITATION REPORT		
#	Article		IF	Citations
780	Recent Clinical Trials in Non-Small Cell Lung Cancer. Current Cancer Therapy Reviews, 2	2006, 2, 81-99.	0.3	0
783	Can reproductive pattern explain better survival of women with lung cancer?. Acta One 45, 47-53.	cológica, 2006,	1.8	14
784	Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Pro Current Cancer Drug Targets, 2006, 6, 271-294.	omises	1.6	28
786	Gefitinib Therapy in Advanced Bronchioloalveolar Carcinoma: Southwest Oncology Gro S0126. Journal of Clinical Oncology, 2006, 24, 1807-1813.	up Study	1.6	149
787	Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of ge epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobio 29-39.	fitinib, to tica, 2006, 36,	1.1	25
788	Different Responses to Gefitinib in Lung Adenocarcinoma Coexpressing Mutant- and W Epidermal Growth Factor Receptor Genes. Japanese Journal of Clinical Oncology, 2006,	Vild-Type , 36, 523-526.	1.3	10
789	Targeting the EGFR Pathway for Cancer Therapy. Current Medicinal Chemistry, 2006, 1	.3, 3483-3492.	2.4	176
790	Interaction between the epidermal growth factor receptor (EGFR) and the vascular enc growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy Oncology, 2006, 17, vii109-vii114.	lothelial y. Annals of	1.2	100
791	Role of Epidermal Growth Factor Receptor Pathway–Targeted Therapy in Patients W and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical 0 2006, 24, 2659-2665.	ith Recurrent Oncology,	1.6	144
792	Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Car Molecular Cancer Research, 2006, 4, 521-528.	ncer Cell Lines.	3.4	129
793	Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefi Non–Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3078-3084.	tinib Sensitivity in	7.0	97
794	Salvage Therapy for Advanced Nonâ€6mall Cell Lung Cancer: Factors Influencing Treat Oncologist, 2006, 11, 655-665.	ment Selection.	3.7	47
795	Update on <i>Epidermal Growth Factor Receptor</i> Mutations in Non–Small Cell Lur Clinical Cancer Research, 2006, 12, 7232-7241.	ng Cancer.	7.0	357
796	Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt A Non–Small-Cell Lung Cancer Tumors. Journal of Clinical Oncology, 2006, 24, 306-31	ctivation in 4.	1.6	167
797	Chemotherapy-induced epidermal growth factor receptor activation determines respor gefitinib/chemotherapy treatment in non–small cell lung cancer cells. Molecular Can Therapeutics, 2006, 5, 1154-1165.	nse to combined cer	4.1	90
798	CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Ir of the National Cancer Institute, 2006, 98, 1714-1723.	hibitors. Journal	6.3	102
799	Interstitial Shadow on Chest CT is Associated with the Onset of Interstitial Lung Diseas Chemotherapeutic Drugs. Japanese Journal of Clinical Oncology, 2006, 36, 269-273.	e Caused by	1.3	24
800	Detection of <i>EGFR</i> Gene Mutation in Lung Cancer by Mutant-Enriched Polymeras Assay. Clinical Cancer Research, 2006, 12, 43-48.	e Chain Reaction	7.0	191

#	ARTICLE	IF	CITATIONS
801	Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gentinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels. Clinical Cancer Research, 2006, 12, 7117-7125.	7.0	118
802	Detection ofEGFRMutations in Archived Cytologic Specimens of Non–Small Cell Lung Cancer Using High-Resolution Melting Analysis. American Journal of Clinical Pathology, 2006, 126, 608-615.	0.7	138
803	Molecular On/Off Switch. Journal of Clinical Oncology, 2006, 24, 4940-4942.	1.6	11
804	Exercise induced bronchoconstriction in elite athletes: measuring the fall. Thorax, 2006, 61, 94-96.	5.6	24
805	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. Journal of Medical Genetics, 2006, 44, 166-172.	3.2	47
806	Expanding role of chemotherapy in lung cancer. Annals of Oncology, 2006, 17, x101-x107.	1.2	2
807	Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5025-5033.	1.6	154
808	Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. Clinical Cancer Research, 2006, 12, 4645-4651.	7.0	32
809	Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 839-844.	7.0	688
810	Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo. Clinical Cancer Research, 2006, 12, 617-625.	7.0	88
811	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Annals of Oncology, 2006, 17, 450-456.	1.2	211
812	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. European Respiratory Journal, 2006, 29, 128-133.	6.7	12
813	Second-line chemotherapy for non-small cell lung cancer. Annals of Oncology, 2006, 17, v68-v71.	1.2	10
814	Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 4416s-4420s.	7.0	127
815	Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax, 2006, 61, 140-145.	5.6	120
816	Erlotinib-Induced Breast Cancer Regression. Annals of Pharmacotherapy, 2006, 40, 2043-2047.	1.9	17
817	Phase I Study of Amrubicin Hydrochloride and Cisplatin in Patients Previously Treated for Advanced Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 12-16.	1.3	4
818	Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment. , 2006, , 57-66.		0

#	ARTICLE	IF	CITATIONS
819	Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non‧mall Cell Lung Cancer. Oncologist, 2006, 11, 358-373.	3.7	60
820	Expression Profile–Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors. Journal of Clinical Oncology, 2006, 24, 1679-1688.	1.6	296
821	Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?. Clinical Cancer Research, 2006, 12, 4409s-4415s.	7.0	52
822	Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 4451s-4457s.	7.0	20
823	Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients: Fig. 1 Clinical Cancer Research, 2006, 12, 4403s-4408s.	7.0	74
824	Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clinical Cancer Research, 2006, 12, 5764-5769.	7.0	577
825	High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). Journal of Clinical Pathology, 2006, 59, 255-259.	2.0	35
826	Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. Clinical Cancer Research, 2006, 12, 6186-6193.	7.0	79
827	Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Annals of Oncology, 2006, 17, ii46-ii48.	1.2	23
828	Responses of Human Colorectal Tumor Cells to Treatment with the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib. Cancer Research, 2006, 66, 7708-7715.	0.9	35
829	Chemoresistance in solid tumours. Annals of Oncology, 2006, 17, x315-x324.	1.2	150
830	PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib. Cancer Research, 2006, 66, 5346-5353.	0.9	62
831	Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Cancer Research, 2006, 12, 3652-3656.	7.0	62
832	Women and lung cancer. Annals of Oncology, 2006, 17, ii79-ii82.	1.2	6
833	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 3908-3914.	7.0	550
834	Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma. Cancer Research, 2006, 66, 981-988.	0.9	71
835	Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 1689-1699.	1.6	78
836	Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. Journal of the National Cancer Institute, 2006, 98, 1739-1742.	6.3	232

#	Article	IF	CITATIONS
837	Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research, 2006, 12, 2538-2544.	7.0	245
838	Mutational Analysis of <i>AKT1, AKT2</i> and <i>AKT3</i> Genes in Common Human Carcinomas. Oncology, 2006, 70, 285-289.	1.9	69
839	Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2006, 24, 3831-3837.	1.6	292
840	The new drugs advent: clinical or economic outcomes?. Annals of Oncology, 2006, 17, ii88-ii90.	1.2	1
841	Promising New Treatment Schedule for Gefitinib Responders After Severe Hepatotoxicity With Daily Administration. Journal of Clinical Oncology, 2006, 24, 3213-3214.	1.6	34
842	Important Bias in the Astragalus Meta-Analysis. Journal of Clinical Oncology, 2006, 24, 3215-3216.	1.6	5
844	Genomic Approaches to Lung Cancer: Fig. 1 Clinical Cancer Research, 2006, 12, 4384s-4391s.	7.0	49
845	Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 5659-5667.	7.0	199
846	Lung cancer genetics and pharmacogenomics. Cytogenetic and Genome Research, 2006, 115, 298-302.	1.1	2
847	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Annals of Oncology, 2006, 17, ii42-ii45.	1.2	28
848	Novel targeted approaches in non-small cell lung cancer (NSCLC). Annals of Oncology, 2006, 17, v91-v93.	1.2	3
849	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	1.2	93
850	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. Current Cancer Therapy Reviews, 2006, 2, 67-72.	0.3	0
851	The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors: Fig. 1 Clinical Cancer Research, 2006, 12, 4372s-4376s.	7.0	77
852	Non-small cell lung cancer: second-line and beyond. Annals of Oncology, 2006, 17, x96-x100.	1.2	7
853	Treatment of advanced non-small cell lung cancer. Annals of Oncology, 2006, 17, ii36-ii41.	1.2	31
854	Chemotherapy of advanced NSCLC in special patient population. Annals of Oncology, 2006, 17, v72-v78.	1.2	18
855	Gefitinib: an adverse effects profile. Expert Opinion on Drug Safety, 2006, 5, 469-479.	2.4	42

#	Article	IF	CITATIONS
856	The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line. DNA and Cell Biology, 2006, 25, 246-251.	1.9	13
857	Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 291-323.	6.1	15
858	Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer. Molecular Cancer Research, 2006, 4, 971-981.	3.4	34
859	Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays. Nature Clinical Practice Oncology, 2006, 3, 256-268.	4.3	119
860	A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy. Expert Review of Anticancer Therapy, 2006, 6, 1411-1419.	2.4	1
861	HER2 expression as a potential marker for response to therapy targeted to the EGFR. British Journal of Cancer, 2006, 94, 1144-1153.	6.4	30
862	131I-chTNT Radioimmunotherapy of 43 Patients with Advanced Lung Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 5-14.	1.0	38
863	Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors. Japanese Journal of Clinical Oncology, 2006, 37, 44-48.	1.3	29
864	Amplification ofMETmay identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2316-2321.	7.1	473
865	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Present and Future Role in Gastrointestinal Cancer Treatment: A Review. Oncologist, 2006, 11, 602-611.	3.7	29
866	EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro-Oncology, 2006, 8, 137-144.	1.2	80
867	Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients. Journal of Clinical Oncology, 2006, 24, 1612-1619.	1.6	203
868	Clinical Trials for Lung Cancer in Progress in Japan. , 2006, , 463-469.		0
869	Secondâ€Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€Small Cell Lung Cancer. Oncologist, 2007, 12, 325-330.	3.7	61
870	Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. International Journal of Radiation Biology, 2007, 83, 793-802.	1.8	29
871	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	3.1	12
872	Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib. Clinical Cancer Research, 2007, 13, 2795-2803.	7.0	248
873	Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 3936-3944.	1.6	113

#	Article	IF	CITATIONS
874	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Molecular Cancer Therapeutics, 2007, 6, 2642-2651.	4.1	53
875	Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2007, 71, 508-518.	2.3	24
876	Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma. Molecular Cancer Therapeutics, 2007, 6, 1683-1691.	4.1	249
877	Targeting HER proteins in cancer therapy and the role of the non-target HER3. British Journal of Cancer, 2007, 97, 453-457.	6.4	234
878	Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. British Journal of Cancer, 2007, 97, 183-193.	6.4	31
879	New targets for non-small-cell lung cancer therapy. Expert Review of Anticancer Therapy, 2007, 7, 1423-1437.	2.4	35
880	Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab. Clinical Cancer Research, 2007, 13, 4597s-4601s.	7.0	40
881	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer, 2007, 96, 1047-1051.	6.4	179
882	â€~Classical' but not â€~other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British Journal of Cancer, 2007, 97, 1560-1566.	6.4	74
883	Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. British Journal of Cancer, 2007, 97, 494-501.	6.4	68
884	The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib. Clinical Cancer Research, 2007, 13, 5170-5175.	7.0	35
885	Feasibility Study of Single Agent Cisplatin and Concurrent Radiotherapy in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck: Preliminary Results. Japanese Journal of Clinical Oncology, 2007, 37, 725-729.	1.3	54
886	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. Annals of Oncology, 2007, 18, ix150-ix155.	1.2	12
887	Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 87-101.	0.3	3
888	Optimizing Anti-EGFR Strategies in Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 267-275.	0.3	0
889	Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas. JAMA - Journal of the American Medical Association, 2007, 298, 70.	7.4	141
890	Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 523-531.	7.0	23
891	Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 6518-6526.	7.0	21

#	Article	IF	CITATIONS
892	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 378-381.	7.0	114
893	Targeted Therapies for Non-Small Cell Lung Cancer. Current Pharmaceutical Design, 2007, 13, 2810-2831.	1.9	14
894	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2007, 12, 211-220.	3.7	44
895	Targeted Therapy of Breast Cancer. Current Pharmaceutical Design, 2007, 13, 497-517.	1.9	26
896	Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. Journal of the National Cancer Institute, 2007, 99, 838-846.	6.3	303
897	A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 1216-1223.	7.0	75
898	Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus. Clinical Cancer Research, 2007, 13, 5150-5155.	7.0	279
899	Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer. Chest, 2007, 131, 1628-1634.	0.8	106
900	Review of targeted cancer therapies for the palliative care provider: Part 1: small molecules. Progress in Palliative Care, 2007, 15, 171-176.	1.2	0
901	A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 327-343.	1.1	274
902	Independent Review of Interstitial Lung Disease Associated with Death in TRIBUTE (Paclitaxel and) Tj ETQq0 0 0 r of Thoracic Oncology, 2007, 2, 537-543.	gBT /Over 1.1	ock 10 Tf 50 37
903	EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 423-429.	1.1	84
904	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. Expert Opinion on Drug Discovery, 2007, 2, 335-348.	5.0	5
905	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics, 2007, 8, 1211-1220.	1.3	2
906	Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine, 2007, 4, 33-43.	1.5	4
907	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 1287-1298.	3.4	24
908	Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors. Current Cancer Drug Targets, 2007, 7, 666-673.	1.6	19
909	Assessing the roles ofEGFRgene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine, 2007, 1, 203-207.	1.4	2

#	Article	IF	CITATIONS
910	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncology, 2007, 3, 277-283.	2.4	32
911	Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 245-257.	3.4	26
912	Absence of Activating Mutations in the <i>EGFR</i> Kinase Domain in Spanish Head and Neck Cancer Patients. Tumor Biology, 2007, 28, 273-279.	1.8	34
913	Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis. DNA and Cell Biology, 2007, 26, 178-185.	1.9	18
914	Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 7086-7092.	7.0	68
915	Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized. Cancer Research, 2007, 67, 7695-7702.	0.9	39
916	A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response. Clinical Cancer Research, 2007, 13, 5869-5875.	7.0	120
917	Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing <i>EGFR</i> Gene Mutation and Amplification. Cancer Research, 2007, 67, 2046-2053.	0.9	166
918	NF-κB Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 5663-5664.	7.0	23
919	Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Annals of Oncology, 2007, 18, 317-323.	1.2	557
920	p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non–Small Cell Lung Cancer. Cancer Research, 2007, 67, 1163-1169.	0.9	97
921	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib. Cancer Research, 2007, 67, 11924-11932.	0.9	674
922	Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib. Journal of Clinical Oncology, 2007, 25, 2528-2533.	1.6	140
923	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Molecular Cancer Therapeutics, 2007, 6, 277-285.	4.1	60
924	Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib. Clinical Cancer Research, 2007, 13, 5385-5390.	7.0	103
925	HKI-272 in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4593s-4596s.	7.0	47
926	The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage. Clinical Cancer Research, 2007, 13, 6555-6560.	7.0	180
927	Targeted therapies in lung cancer. Annals of Oncology, 2007, 18, ix135-ix142.	1.2	35

#	Article	IF	CITATIONS
928	Can Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Be Overcome by Different Small-Molecule Tyrosine Kinase Inhibitors?. Journal of Clinical Oncology, 2007, 25, 2504-2505.	1.6	6
929	Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 4606s-4612s.	7.0	51
930	clairvoyance or reliable prediction of the future?. Annals of Oncology, 2007, 18, 407-408.	1.2	2
931	Current Status and Future of Target-Based Therapeutics. Current Cancer Drug Targets, 2007, 7, 273-284.	1.6	6
932	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. Current Cancer Therapy Reviews, 2007, 3, 236-241.	0.3	0
933	Pharmacogenomics of Non-Small Cell Lung Cancer. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 228-234.	0.3	0
934	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 226-235.	0.3	0
935	Methodological Issues of Clinical Research with EGFR Inhibitors. Current Cancer Therapy Reviews, 2007, 3, 292-302.	0.3	3
936	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Molecular Cancer Therapeutics, 2007, 6, 1079-1088.	4.1	30
937	The potential of gender-specific tumor pharmacology. Pharmacogenomics, 2007, 8, 271-274.	1.3	3
938	Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America. Journal of Thoracic Oncology, 2007, 2, S125-S127.	1.1	7
939	Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 299-305.	1.1	55
940	The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib. Journal of Thoracic Oncology, 2007, 2, 414-422.	1.1	36
941	Gender Differences: Implications for Clinical Trials and Practice. Journal of Thoracic Oncology, 2007, 2, S15-S18.	1.1	18
942	Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials. Journal of Thoracic Oncology, 2007, 2, 402-407.	1.1	67
943	Remarkable Effect of Gefitinib Retreatment in a Patient with Nonsmall Cell Lung Cancer Who Had a Complete Response to Initial Gefitinib. American Journal of the Medical Sciences, 2007, 333, 221-225.	1.1	31
944	Amrubicin for the Treatment of Small Cell Lung Cancer: Does Effectiveness Cross the Pacific?. Journal of Thoracic Oncology, 2007, 2, 160-165.	1.1	26
945	P3-160: Histoculture drug response assay for gefitinib in non–small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S747-S748.	1.1	0

#	ARTICLE	IF	CITATIONS
946	Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 758-761.	1.1	38
947	EGFR Targeting of Solid Tumors. Cancer Control, 2007, 14, 295-304.	1.8	245
948	Significance of an Epidermal Growth Factor Receptor Mutation in Cerebrospinal Fluid for Carcinomatous Meningitis. Internal Medicine, 2007, 46, 1651-1655.	0.7	16
949	Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 632-637.	1.1	62
950	Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology, 2007, 2, 430-439.	1.1	180
951	Pharmacology of Epidermal Growth Factor Inhibitors. International Journal of Biological Markers, 2007, 22, 24-39.	1.8	10
952	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. International Journal of Biological Markers, 2007, 22, 10-23.	1.8	5
953	Prolonged Response to Oral Gefitinib, Cyclophophamide, and Topotecan in Heavily Pretreated Relapsed Stage 4 Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2007, 29, 799-803.	0.6	4
954	Terminal Respiratory Unit Type Lung Adenocarcinoma is Associated With Distinctive EGFR Immunoreactivity and EGFR Mutations. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 242-247.	1.2	3
955	Targeted therapies and non-small-cell lung cancer: new developments. Current Opinion in Oncology, 2007, 19, 75-77.	2.4	3
956	Signal Transduction Therapy: Challenges to Clinical Trial Design. Current Signal Transduction Therapy, 2007, 2, 21-30.	0.5	1
957	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	1.1	71
958	Bronchioloalveolar Lung Cancer. Chest, 2007, 132, 306S-313S.	0.8	51
959	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa) Tj ETQq1 1 ().7 84 314	rg&T /Overloc
960	Ethnic Disparities in the Treatment of Stage I Non-Small Cell Lung Cancer. Yearbook of Pulmonary Disease, 2007, 2007, 146-149.	0.4	0
961	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Current Opinion in Oncology, 2007, 19, 98-102.	2.4	20
962	Proteomics in Pediatric Research and Practice. Advances in Pediatrics, 2007, 54, 9-28.	1.4	7
963	Identification of EGFR mutations in esophageal cancer. European Journal of Surgical Oncology, 2007, 33, 44-48.	1.0	37

#	ARTICLE	IF	CITATIONS
964	Rational bases for the development of EGFR inhibitors for cancer treatment. International Journal of Biochemistry and Cell Biology, 2007, 39, 1416-1431.	2.8	115
965	Targeting novel and established therapies for non-small cell lung cancer. Cancer Letters, 2007, 250, 9-16.	7.2	10
966	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Letters, 2007, 254, 165-177.	7.2	143
968	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer, 2007, 58, 30-35.	2.0	20
969	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial. Journal of Clinical Oncology, 2007, 25, 2248-2255.	1.6	218
970	Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing Somatic <i>EGFR</i> Mutation Testing. Oncologist, 2007, 12, 90-98.	3.7	156
971	Kinase Inhibitors for Cancer. , 2007, , 183-220.		1
972	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2007, 18, 752-760.	1.2	257
973	Phase II Clinical Trial of Chemotherapy-NaÃ⁻ve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 760-766.	1.6	306
974	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Annals of Oncology, 2007, 18, 99-103.	1.2	136
975	Apoptosis, Senescence, and Cancer. , 2007, , .		8
976	Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. Journal of Medical Case Reports, 2007, 1, 138.	0.8	19
977	In Vivo Imaging of Cancer Therapy. , 2007, , .		6
978	<i>KRAS</i> Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 2890-2896.	7.0	597
979	Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice. Journal of Pharmacy Practice, 2007, 20, 246-251.	1.0	3
980	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
981	Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non‣mall Cell Lung Cancer—A Review of the Literature. Oncologist, 2007, 12, 201-210.	3.7	79
982	Perspectives in adjuvant chemotherapy in NSCLC. Expert Review of Respiratory Medicine, 2007, 1, 99-110.	2.5	1

CITATION REPORT ARTICLE IF CITATIONS Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based 1.9 32 analysis. Current Medical Research and Opinion, 2007, 23, 1509-1515. The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis. Pharmacoeconomics, 2007, 25, 3.3 591-603. Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic 1.3 11 Carcinoma. Cancer Investigation, 2007, 25, 366-371. Targeted Agents: The Rules of Combination. Clinical Cancer Research, 2007, 13, 5232-5237. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs, 2007, 4.1 131 16. 239-249. Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Clinical Cancer Research, 2007, 13, 799-805. Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed 1.6 46 Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 3266-3273. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and 3.116 prognosis. Expert Review of Molecular Diagnostics, 2007, 7, 77-86. Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors. Cancer 1.3 16 Investigation, 2007, 25, 347-365. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in 1.6 Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 587-595. Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated 286 1.6 Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 4270-4277. Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non à petites cellules (CBNPC). Revue Des Maladies Respiratoires, 2007, 24, 120-124. Sunshine and Rash: Testing the Role of Sunscreen to Prevent Epidermal Growth Factor Receptor 0.3 5 Inhibitor–Induced Rash. Supportive Cancer Therapy, 2007, 4, 198-202. Les inhibiteurs de tyrosine kinase de l'EGFR dans le traitement du CBNPC. Revue Des Maladies Respiratoires, 2007, 24, 188-197. 1.7 Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in 2.0 5 patients with advanced NSCLC: A multicenter phase II trial. Lung Cancer, 2007, 55, 101-107.

1001	Cancer, 2007, 55, 125-127.	2.0	9
1002	Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer, 2007, 55, 115-121.	2.0	29
1003	Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: Multicenter phase II trial. Lung Cancer, 2007, 56, 371-376.	2.0	6

Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Lung

983

984

985

986

987

988

989

990

991

992

993

998

999

	_
CITAT	
CHAL	NEPUKI

#	Article	IF	CITATIONS
1004	Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with ECFR mutations, irrespective of previous chemotherapy. Lung Cancer, 2007, 56, 383-389.	2.0	131
1005	Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: Correlation with clinical outcome. Lung Cancer, 2007, 57, 193-200.	2.0	21
1006	Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer, 2007, 57, 359-364.	2.0	149
1007	Validation of the Functional Assessment of Cancer Therapy—Lung Symptom Index-12 (FLSI-12). Lung Cancer, 2007, 57, 339-347.	2.0	17
1008	Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer, 2007, 58, 149-155.	2.0	52
1009	Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer, 2007, 58, 414-417.	2.0	37
1010	Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer, 2007, 58, 422-424.	2.0	16
1011	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents. Molecular Cancer Research, 2007, 5, 203-220.	3.4	378
1012	Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung Cancer. Oncology, 2007, 72, 234-242.	1.9	22
1014	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-11±. Molecular Cancer, 2007, 6, 63.	19.2	55
1015	Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Drugs, 2007, 67, 1125-1138.	10.9	15
1016	EGFR, HER2 and VEGF Pathways. Drugs, 2007, 67, 2045-2075.	10.9	125
1017	Gefitinib Cytotoxicity in Non-small Cell Lung Cancer Cells is Enhanced by Low Dose Cisplatin Due to Ligand-independent EGFR Autophosphorylation. The Showa University Journal of Medical Sciences, 2007, 19, 155-164.	0.1	0
1018	Targeted Therapeutics in Cancer Treatment. , 2007, , 117-148.		0
1019	Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer. Journal of Korean Medical Science, 2007, 22, 393.	2.5	11
1020	Sex-related Clinicopathologic Differences in Patients with Adenocarcinoma of the Lung. Tuberculosis and Respiratory Diseases, 2007, 62, 203.	1.8	0
1021	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S12-S14.	1.1	6
1022	Gefitinib-Related Interstitial Pneumonia. Tuberculosis and Respiratory Diseases, 2007, 62, 134.	1.8	0

# 1023	ARTICLE Urinary Neopterin in Patients Treated with Gefitinib. Pteridines, 2007, 18, 95-100.	IF 0.5	CITATIONS
1024	Clinical and Preclinical Experience with Gefitinib and Sunitinib. Breast Care, 2007, 2, 68-73.	1.4	2
1025	Pharmacogenomics: clinical applications. , 0, , 516-528.		0
1026	Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Human Mutation, 2007, 28, 760-770.	2.5	51
1027	Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. International Journal of Cancer, 2007, 120, 1579-1590.	5.1	27
1028	Cetuximab induce antibodyâ€dependent cellular cytotoxicity against EGFRâ€expressing esophageal squamous cell carcinoma. International Journal of Cancer, 2007, 120, 781-787.	5.1	147
1029	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. International Journal of Cancer, 2007, 120, 1239-1247.	5.1	120
1030	Impact ofHER2 andEGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. International Journal of Cancer, 2007, 121, 1162-1167.	5.1	29
1031	Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry, 2007, 102, 580-592.	2.6	127
1032	Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. Journal of Cellular Physiology, 2007, 210, 549-559.	4.1	37
1033	Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer, 2007, 109, 1836-1844.	4.1	69
1034	Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer, 2007, 109, 1821-1828.	4.1	25
1035	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer, 2007, 110, 599-605.	4.1	97
1036	Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, 2007, 110, 581-589.	4.1	251
1037	Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer, 2007, 110, 1321-1328.	4.1	19
1039	Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 2007, 110, 2793-2798.	4.1	35
1040	Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. Journal of Surgical Oncology, 2007, 95, 63-69.	1.7	30
1041	Metabolic functional imaging for tumor radiosensitivity monitoring. Critical Reviews in Oncology/Hematology, 2007, 62, 227-239.	4.4	16

#	Article	IF	CITATIONS
1042	EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology, 2007, 62, 53-61.	4.4	123
1043	Targeting mTOR signaling in lung cancer. Critical Reviews in Oncology/Hematology, 2007, 63, 172-182.	4.4	70
1044	Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics. Current Problems in Cancer, 2007, 31, 315-366.	2.0	5
1045	Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients. Clinical Oncology, 2007, 19, 499-506.	1.4	47
1046	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatric Blood and Cancer, 2007, 49, 352-357.	1.5	12
1047	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene, 2007, 26, 1567-1576.	5.9	78
1048	The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene, 2007, 26, 5023-5027.	5.9	105
1049	Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181.	28.4	2,741
1050	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. British Journal of Cancer, 2007, 96, 857-863.	6.4	90
1051	Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. British Journal of Cancer, 2007, 96, 1191-1196.	6.4	46
1052	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British Journal of Cancer, 2007, 97, 778-784.	6.4	198
1053	Predictive markers in breast cancer – the future. Histopathology, 2008, 52, 91-98.	2.9	26
1054	Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients. European Journal of Cancer Care, 2007, 16, 263-267.	1.5	5
1055	Reliability of the peptide nucleic acidâ€locked nucleic acid polymerase chain reaction clampâ€based test for epidermal growth factor receptor mutations integrated into the clinical practice for nonâ€small cell lung cancers. Cancer Science, 2007, 98, 246-252.	3.9	99
1056	Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Science, 2007, 98, 226-230.	3.9	35
1057	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Science, 2007, 98, 357-363.	3.9	48
1058	GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Science, 2007, 98, 1625-1632.	3.9	19
1059	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98, 1817-1824.	3.9	554

#	Article	IF	CITATIONS
1060	Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics, 2007, 25, 1253-1269.	3.7	24
1061	Mutational analysis of PTPRT phosphatase domains in common human cancers. Apmis, 2007, 115, 47-51.	2.0	21
1062	Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 66-78.	1.1	14
1063	Epidermal growth factor receptor mutations in lung cancers. Pathology International, 2007, 57, 233-244.	1.3	72
1064	CCND1 Messenger RNA Expression Is Correlated with EGFR Mutation Status in Lung Cancer. Clinical Lung Cancer, 2007, 8, 493-496.	2.6	5
1065	Epidermal Growth Factor Receptor Inhibitors plus Chemotherapy in Non–Small-Cell Lung Cancer: Biologic Rationale for Combination Strategies. Clinical Lung Cancer, 2007, 8, S61-S67.	2.6	24
1066	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer, 2007, 7, 128.	2.6	36
1067	Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer, 2007, 7, 150.	2.6	59
1068	Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer, 2007, 7, 51.	2.6	76
1069	The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. European Journal of Pharmacology, 2007, 570, 175-181.	3.5	41
1070	Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR) Tj ETQ	q Q_A O rgE	3T \$Øverlock
1071	Targeted Agents and Esophageal Cancer—The Next Step?. Seminars in Radiation Oncology, 2007, 17, 62-69.	2.2	25
1072	Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery, 2007, 141, 464-469.	1.9	60
1073	The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. European Radiology, 2007, 17, 1700-1713.	4.5	72
1074	Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments. Annals of Surgical Oncology, 2007, 14, 942-953.	1.5	128
1075	A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemotherapy and Pharmacology, 2007, 60, 53-59.	2.3	2
1078	Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell lines. Journal of Cancer Research and Clinical Oncology, 2007, 133, 169-176.	2.5	13
1079	"Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?― Current Treatment Options in Oncology, 2007, 8, 28-37	3.0	18

#	Article	IF	CITATIONS
1080	Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?. Current Oncology Reports, 2007, 9, 255-264.	4.0	19
1081	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Internal and Emergency Medicine, 2007, 2, 3-12.	2.0	12
1082	Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study. Targeted Oncology, 2007, 2, 63-71.	3.6	1
1083	Lapatinib: a novel dual tyrosine kinase inhibitor. Targeted Oncology, 2007, 2, 107-112.	3.6	2
1084	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Targeted Oncology, 2007, 2, 145-151.	3.6	3
1085	Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology, 2007, 2, 199-210.	3.6	6
1086	Phase II, randomized trial of preoperative epirubicin-paclitaxelÂ+/â~ʾÂgefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Research and Treatment, 2008, 110, 127-134.	2.5	19
1087	Targeted therapy for oesophageal cancer: an overview. Cancer and Metastasis Reviews, 2008, 27, 273-288.	5.9	23
1088	Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1089-1099.	6.4	104
1089	Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2008, 62, 465-470.	2.3	7
1090	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?. Cancer Chemotherapy and Pharmacology, 2008, 63, 139-148.	2.3	12
1091	Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology, 2008, 3, 87-99.	3.6	1
1092	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology, 2008, 3, 173-186.	3.6	3
1093	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. Onkopipeline, 2008, 1, 101-108.	0.0	0
1094	The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). Current Treatment Options in Oncology, 2008, 9, 313-325.	3.0	4
1095	EGFR Inhibitor Enhances Cisplatin Sensitivity of Oral Squamous Cell Carcinoma Cell Lines. Pathology and Oncology Research, 2008, 14, 39-43.	1.9	41
1096	The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Medical Oncology, 2008, 25, 408-414.	2.5	7
1097	Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients. International Journal of Clinical Oncology, 2008, 13, 442-446.	2.2	14

#	Article	IF	Citations
1098	Place des thérapeutiques biologiques ciblées. Oncologie, 2008, 10, 540-544.	0.7	0
1099	EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 440-446.	0.1	1
1100	Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients. Chinese-German Journal of Clinical Oncology, 2008, 7, 677-681.	0.1	0
1101	Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 569-577.	2.5	64
1102	A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1371-1376.	2.5	12
1103	Allene as an Alternative Functional Group for Drug Design: Effect of Cĩ½¿C Multiple Bonds Conjugated with Quinazolines on the Inhibition of EGFR Tyrosine Kinase. ChemMedChem, 2008, 3, 1094-1103.	3.2	19
1104	Epidermal growth factor receptor immunohistochemistry. Cancer, 2008, 112, 1114-1121.	4.1	69
1105	Phase 2 trial of docetaxel and gefitinib in the firstâ€ŀine treatment of patients with advanced nonsmallâ€cell lung cancer (NSCLC) who are 70 years of age or older. Cancer, 2008, 112, 2021-2029.	4.1	25
1106	Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer, 2008, 113, 826-833.	4.1	96
1107	Reversed mutation rates of <i>KRAS</i> and <i>EGFR</i> genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 2008, 113, 3199-3208.	4.1	84
1108	EGFR inhibition in the treatment of nonâ€small cell lung cancer. Drug Development Research, 2008, 69, 359-372.	2.9	51
1109	Usefulness of monitoring the circulating Krebs von den Lungenâ€6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. International Journal of Cancer, 2008, 122, 2612-2620.	5.1	44
1110	EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. International Journal of Cancer, 2008, 123, 2480-2486.	5.1	78
1111	Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head and Neck, 2008, 30, 863-867.	2.0	104
1112	Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 285-288.	2.2	41
1113	Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers. Annals of Surgical Oncology, 2008, 15, 889-899.	1.5	99
1114	Synthesis and Characterization of Novel Quinazoline Type Inhibitors for Mutant and Wild-Type EGFR and RICK Kinases. Journal of Receptor and Signal Transduction Research, 2008, 28, 361-373.	2.5	6
1115	Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow), 2008, 73, 605-618.	1.5	35

#	Article	IF	CITATIONS
1116	Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. British Journal of Cancer, 2008, 98, 1533-1535.	6.4	128
1117	A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). British Journal of Cancer, 2008, 98, 716-719.	6.4	10
1118	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer, 2008, 98, 907-914.	6.4	200
1119	Emerging ethnic differences in lung cancer therapy. British Journal of Cancer, 2008, 99, 1757-1762.	6.4	122
1120	Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib. Clinical Pharmacology and Therapeutics, 2008, 83, 477-484.	4.7	49
1121	SELECTIVE TARGETING OF THE TUMOUR VASCULATURE*. ANZ Journal of Surgery, 2008, 78, 955-967.	0.7	11
1122	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinibâ€ŧreated patients with lung adenocarcinoma. Cancer Science, 2008, 99, 303-308.	3.9	37
1123	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Science, 2008, 99, 929-935.	3.9	239
1124	Exon 19 of <i>EGFR</i> mutation in relation to the CAâ€repeat polymorphism in intron 1. Cancer Science, 2008, 99, 1180-1187.	3.9	14
1125	<i>N</i> â€Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Science, 2008, 99, 1611-1617.	3.9	73
1126	Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation. Cancer Science, 2008, 99, 1679-1684.	3.9	16
1127	Induction of lung adenocarcinoma in transgenic mice expressing activated <i>EGFR</i> driven by the SP promoter. Cancer Science, 2008, 99, 1747-1753.	3.9	27
1128	Clinical significance of pretreatment serum amphiregulin and transforming growth factorâ€Î±, and an epidermal growth factor receptor somatic mutation in patients with advanced nonâ€squamous, nonâ€small cell lung cancer. Cancer Science, 2008, 99, 2295-2301.	3.9	29
1129	Association of epidermal growth factor receptor (<i>ECFR</i>) gene mutations with <i>ECFR</i> amplification in advanced nonâ€small cell lung cancer. Cancer Science, 2008, 99, 2455-2460.	3.9	37
1130	A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology, 2008, 108, 42-46.	1.4	128
1131	Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status. BMC Research Notes, 2008, 1, 102.	1.4	6
1132	Induction Chemotherapy with Cisplatin, Vinorelbine, and Mitomycin-C Followed by Surgery for Patients with Pathologic N2 Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, 44-50.	2.6	3
1133	Will FLEX Allow Us Flexibility in the Therapy of Advanced Non–Small-Cell Lung Cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. Clinical Lung Cancer, 2008, 9, 249-251.	2.6	6

#	Article	IF	CITATIONS
1134	Integrating Epidermal Growth Factor Receptor–Targeted Therapies into Platinum-Based Chemotherapy Regimens for Newly Diagnosed Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, S109-S115.	2.6	15
1135	Targeted agents in cancer therapy. Medicine, 2008, 36, 33-37.	0.4	6
1136	Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2008, 11, 1-15.	6.5	339
1137	Cancer Pharmacogenetics. Methods in Molecular Biology, 2008, 448, 437-446.	0.9	4
1138	Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer, 2008, 59, 81-87.	2.0	18
1139	Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer, 2008, 59, 203-210.	2.0	125
1140	Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer, 2008, 60, 175-182.	2.0	77
1141	Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?. Lung Cancer, 2008, 61, 73-81.	2.0	22
1142	Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients. Lung Cancer, 2008, 61, 328-339.	2.0	45
1143	Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: A prospective study. Lung Cancer, 2008, 61, 378-384.	2.0	9
1144	Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer, 2008, 61, 262-265.	2.0	14
1145	The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysis. Lung Cancer, 2008, 62, 242-252.	2.0	13
1146	Epidermal Growth Factor Receptor Inhibitor–Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker. Clinical Colorectal Cancer, 2008, 7, 33-43.	2.3	53
1147	Multitargeted Inhibitors in Lung Cancer: New Clinical Data. Clinical Lung Cancer, 2008, 9, S92-S99.	2.6	10
1148	siRNA Targeting against <i>EGFR,</i> a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma. Pathobiology, 2008, 75, 2-8.	3.8	20
1149	Biochemical Assay-Based Selectivity Profiling of Clinically Relevant Kinase Inhibitors on Mutant Forms of EGF Receptor. Journal of Receptor and Signal Transduction Research, 2008, 28, 295-306.	2.5	5
1150	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Review of Respiratory Medicine, 2008, 2, 167-178.	2.5	56
1151	Molecular Profiling of Non-Small Cell Lung Cancer: Of What Value in Clinical Practice?. Heart Lung and Circulation, 2008, 17, 451-462.	0.4	1

ARTICLE IF CITATIONS EGFR Signaling Networks in Cancer Therapy., 2008,,. 11 1152 Le traitement de la rechute d'un cancer bronchique non à petites cellules de stade IV. Revue Des 1.7 Maladies Respiratoires, 2008, 25, 3S113-3S118. Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology, 2008, 448, 1154 0.9 8 v-vii. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy., 2008, , . Phosphorylation status of epidermal growth factor receptor is closely associated with 1156 2.0 22 responsiveness to gefitinib in pulmonary adenocarcinoma. Human Pathology, 2008, 39, 316-323. EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer. Journal of Surgical Research, 2008, 1.6 16 148, 260-263. Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 1158 1.2 231 2008, 58, 545-570. Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar 1.3 Components. Annals of Thoracic Surgery, 2008, 85, 216-223. EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Nonâ€"Small Cell Lung Cancer. Seminars in 1160 1.5 11 Oncology Nursing, 2008, 24, 27-33. Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer. Annals of Pharmacotherapy, 2008, 42, 1640-1652. EGFR Antagonists in Cancer Treatment. New England Journal of Medicine, 2008, 358, 1160-1174. 1162 27.0 1.869 The characteristics and failure pattern of gefitinib responders with postoperative recurrence of 1164 1.0 pulmonary adenocarcinoma. European Journal of Surgical Oncology, 2008, 34, 89-93. Pharmacogenetics: improving drug and dose selection. Current Opinion in Pharmacology, 2008, 8, 1165 3.5 20 639-646. Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews, 2008, 34, 61-80. 1167 Advances in the treatment of non-small cell lung cancer. Cancer Treatment Reviews, 2008, 34, 521-526. 7.7 6 Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer, 2008, 60, S3-S9. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and 1169 2.0 21 tyrosine kinase inhibitors. Lung Cancer, 2008, 60, S10-S18. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung 1170 46 Cancer, 2008, 60, S23-S30.

#	Article	IF	CITATIONS
1171	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in Diagnostic Pathology, 2008, 25, 288-294.	1.5	16
1172	Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor. Seminars in Thoracic and Cardiovascular Surgery, 2008, 20, 217-223.	0.6	9
1173	Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	1.6	674
1174	First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations. Journal of Clinical Oncology, 2008, 26, 2442-2449.	1.6	812
1175	Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 2008, 19, 739-745.	1.2	38
1176	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, The, 2008, 372, 1809-1818.	13.7	1,248
1177	Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. Journal of Clinical Oncology, 2008, 26, 1472-1478.	1.6	284
1178	Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics Journal, 2008, 8, 129-138.	2.0	101
1179	Molecular genetics of lung cancer in people who have never smoked. Lancet Oncology, The, 2008, 9, 676-682.	10.7	113
1180	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncology, The, 2008, 9, 962-972.	10.7	709
1181	Cutaneous Reactions to Chemotherapy: Commonly Seen, Less Described, Little Understood. Dermatologic Clinics, 2008, 26, 103-119.	1.7	45
1182	Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics. Dermatologic Clinics, 2008, 26, 121-159.	1.7	29
1183	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 2895-2899.	7.0	649
1184	Antitumor Activity of a New N-Substituted Thiourea Derivative, an EGFR Signaling-Targeted Inhibitor against a Panel of Human Lung Cancer Cell Lines. Chemotherapy, 2008, 54, 463-474.	1.6	28
1186	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	1.5	12
1187	Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Lung Cancer, 2008, 59, 227-231.	2.0	12
1188	EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine, 2008, 59, 429-442.	12.2	152
1189	Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy, 2008, 9, 1321-1337.	1.8	4

#	Article	IF	CITATIONS
1190	Implications of EGFR PharmDxâ,,¢ Kit for cetuximab eligibility. Expert Review of Molecular Diagnostics, 2008, 8, 141-148.	3.1	15
1191	Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. Journal of Molecular Diagnostics, 2008, 10, 160-168.	2.8	58
1192	First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 847-853.	5.6	66
1193	Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023. Journal of Clinical Oncology, 2008, 26, 2450-2456.	1.6	555
1194	Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 5407-5415.	1.6	214
1195	Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. European Respiratory Journal, 2008, 32, 924-930.	6.7	112
1196	Fluorescence <i>In situ</i> Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 6317-6323.	7.0	63
1197	Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. Oncologist, 2008, 13, 1166-1176.	3.7	46
1198	Gefitinib: a consideration of cost. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 223-232.	1.4	0
1199	Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. Oncologist, 2008, 13, 933-944.	3.7	40
1200	Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. Clinical Cancer Research, 2008, 14, 957-960.	7.0	125
1201	Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. Clinical Cancer Research, 2008, 14, 6867-6876.	7.0	51
1202	A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clinical Cancer Research, 2008, 14, 6277-6283.	7.0	69
1203	Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells. Cancer Research, 2008, 68, 3803-3809.	0.9	170
1204	Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations with the Classical Mutation Pattern. Oncologist, 2008, 13, 1276-1284.	3.7	70
1205	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, S146-S149.	1.1	66
1206	Targeting Growth Factors in Lung Cancer. Chest, 2008, 133, 1209-1216.	0.8	39
1207	The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review. Journal of Thoracic Oncology, 2008, 3, 1468-1481.	1.1	188

#	Article	IF	CITATIONS
1208	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annals of Oncology, 2008, 19, 362-369.	1.2	247
1209	Gefitinib Versus Vinorelbine in Chemotherapy-NaÃ⁻ve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. Journal of Clinical Oncology, 2008, 26, 4253-4260.	1.6	220
1210	Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 4244-4252.	1.6	363
1211	Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. British Journal of Cancer, 2008, 98, 154-160.	6.4	100
1212	The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2008, 17, 401-411.	4.1	12
1213	Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. Journal of Clinical Oncology, 2008, 26, 1119-1127.	1.6	207
1214	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers. Clinical Cancer Research, 2008, 14, 6963-6973.	7.0	112
1215	Considerations for Secondâ€Line Therapy of Nonâ€6mall Cell Lung Cancer. Oncologist, 2008, 13, 28-36.	3.7	98
1216	18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non–Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 2036-2041.	7.0	41
1217	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research, 2008, 68, 9479-9487.	0.9	574
1218	Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 1135-1141.	1.6	66
1219	EGFR-targeting agents in oncology. Expert Opinion on Therapeutic Patents, 2008, 18, 889-901.	5.0	23
1221	Other Endpoints in Screening Studies for Soft Tissue Sarcomas. Oncologist, 2008, 13, 27-31.	3.7	22
1222	Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting. Journal of Clinical Oncology, 2008, 26, 983-994.	1.6	287
1223	SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology, 2008, 26, 2745-2753.	1.6	249
1224	Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research, 2008, 14, 4877-4882.	7.0	294
1225	The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or) Tj ETQq0 0	0 rgBT /O\ 7:0	verlock 10 Tf

1226	Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 4418-4425.	1.6	86
------	--	-----	----

		CITATION REPORT		
#	Article	IF		CITATIONS
1227	Carcinoma of the bronchus 60 years later. Postgraduate Medical Journal, 2008, 84, 182-187.	1.8	3	8
1228	Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective. Japanese Journal of C Oncology, 2008, 39, 137-150.	linical 1.8	3	72
1229	Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lun Cancer. Oncologist, 2008, 13, 14-20.	g 3.7	7	73
1230	A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasia–Associated Foci Genotypically Related. American Journal of Clinical Pathology, 2008, 129, 202-210.	Are o.	7	46
1231	[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatme Predicts Response in Patients with Advanced Adenocarcinoma of the Lung. Clinical Cancer Rese 2008, 14, 7423-7429.	nt arch, 7.0	C	151
1232	The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointe Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Ce Clinical Cancer Research, 2008, 14, 2088-2094.	stinal ecoxib. 7.0	C	47
1233	Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III. Journal of Clinical Oncology, 2008, 26, 1346-1354.	1.6	5	137
1234	MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosin Kinase Inhibitor NaÃ ⁻ ve Cohort. Journal of Thoracic Oncology, 2008, 3, 331-339.	ne 1.1	L	181
1235	<i>EGFR</i> Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approv Japan. Journal of Clinical Oncology, 2008, 26, 5589-5595.	al in 1.6	5	210
1236	Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral D Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors. Japanese Jou Clinical Oncology, 2008, 39, 116-123.	ual rnal of 1.3	3	18
1237	Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor–β Signaling. American Journal of Respiratory Cell and Molecular Biology, 2008 95-104.	, 38, 2.9	9	236
1238	Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cance therapy. Nature Clinical Practice Oncology, 2008, 5, 268-278.	er 4.:	3	96
1239	Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opinion Investigational Drugs, 2008, 17, 1013-1028.	on 4.3	1	46
1240	Somatic pharmacogenomics in cancer. Pharmacogenomics Journal, 2008, 8, 305-314.	2.0	0	22
1241	Case 23-2008. New England Journal of Medicine, 2008, 359, 405-414.	27	2.0	2
1242	Targeted Therapy in Advanced Non-Small-Cell Lung Cancer. Seminars in Respiratory and Critical Medicine, 2008, 29, 291-301.	Care 2.1	1	31
1243	Speeding up the Evaluation of New Agents in Cancer. Journal of the National Cancer Institute, 2 100, 1204-1214.	.008, 6.3	3	126
1244	From Nihilism to Individualism. American Journal of Respiratory and Critical Care Medicine, 2008 1299-1300.	3, 177, 5.0	6	2

#	Article	IF	Citations
1245	Lung cancer and women. Future Oncology, 2008, 4, 705-716.	2.4	14
1246	Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Molecular Cancer Therapeutics, 2008, 7, 599-606.	4.1	67
1247	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. Thyroid, 2008, 18, 317-323.	4.5	185
1248	Gefitinib Plus Celecoxib in Chemotherapy-NaÃ ⁻ ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology, 2008, 3, 374-379.	1.1	20
1249	Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study. Journal of Thoracic Oncology, 2008, 3, 1446-1453.	1.1	97
1250	Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib. Oncology Reports, 0, , .	2.6	4
1251	Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 250-257.	1.1	76
1252	EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 303-310.	1.1	35
1253	First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation; Positive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2008, 3, S143-S145.	1.1	22
1254	Epidermal Growth Factor Receptor Mutations in Multicentric Lung Adenocarcinomas and Atypical Adenomatous Hyperplasias. Journal of Thoracic Oncology, 2008, 3, 467-471.	1.1	35
1255	E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Oncology Reports, 0, , .	2.6	6
1256	A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 386-393.	1.1	88
1257	Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. Molecular Medicine Reports, 0, , .	2.4	0
1258	Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database. Journal of Thoracic Oncology, 2008, 3, 832-839.	1.1	137
1259	A Phase II Trial of Gefitinib Monotherapy in Chemotherapy-NaÃ⁻ve Patients of 75 Years or Older with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1166-1171.	1.1	47
1260	Recurrent Gefitinib-induced Interstitial Lung Disease. Internal Medicine, 2008, 47, 533-536.	0.7	28
1261	Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncology Reports, 0, , .	2.6	7
1262	Clinical Experience with Gefitinib in Indian Patients. Journal of Thoracic Oncology, 2008, 3, 380-385.	1.1	24

#	Article	IF	CITATIONS
1263	Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study. Journal of Thoracic Oncology, 2008, 3, 1439-1445.	1.1	73
1264	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. Current Signal Transduction Therapy, 2008, 3, 234-243.	0.5	0
1266	Evidence for Disease Control with Erlotinib after Gefitinib Failure in Typical Gefitinib-Sensitive Asian Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 400-404.	1.1	56
1267	First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay. Journal of Thoracic Oncology, 2008, 3, S138-S142.	1.1	10
1268	Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib. Journal of Thoracic Oncology, 2008, 3, 912-914.	1.1	39
1269	New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs, 2008, 19, 435-446.	1.4	36
1270	Impact of Preexisting Pulmonary Fibrosis Detected on Chest Radiograph and CT on the Development of Gefitinib-Related Interstitial Lung Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 340-344.	1.3	22
1271	A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anti-Cancer Drugs, 2008, 19, 739-744.	1.4	23
1272	Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology, 2008, 20, 162-175.	2.4	46
1273	Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine, 2008, 15, 352-358.	0.3	0
1274	Cell Signaling Modifiers in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 40-45.	2.0	7
1275	Biological treatments in cancer. , 0, , 13-22.		0
1276	HER1-4 expression status correlates with the efficacy of gefitinib treatment and tumor cell proliferative activity in non-small cell lung cancer. Molecular Medicine Reports, 0, , .	2.4	0
1277	Effects of Gefitinib on Radiation-induced Lung Injury in Mice. Journal of Nippon Medical School, 2008, 75, 96-105.	0.9	11
1278	Molecularly Targeted Therapy for Lung Cancer: Recent Topics. Journal of Lung Cancer, 2008, 7, 1.	0.2	2
1279	Clinical trial designs for more rapid proof-of-principle and approval. , 2008, , 53-87.		1
1280	New insights in drug development for the non-small cell lung cancer therapy. Frontiers in Bioscience - Landmark, 2008, Volume, 5108.	3.0	4
1281	Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer. International Journal of Medical Sciences, 2008, 5, 209-217	2.5	67

#	Article	IF	Citations
1282	Targeted therapies in non-small cell lung cancer. Cancer Imaging, 2008, 8, 199-205.	2.8	6
1283	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics: Targets and Therapy, 0, , 215.	3.2	12
1284	Divide and Conquer: Progress in the Molecular Stratification of Cancer. Yonsei Medical Journal, 2009, 50, 464.	2.2	4
1285	Clinical Proteomics and Molecular Pathology. , 2009, , 165-183.		2
1286	Two Cases of Lung Cancer with Carcinomatous Meningitis in Which Erlotinib Was Effective After Gefitinib Therapy. Japanese Journal of Lung Cancer, 2009, 49, 207-213.	0.1	1
1287	Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung. Journal of Korean Medical Science, 2009, 24, 448.	2.5	52
1288	Metastatic Bone Disease in Patients with Solid Tumors–-Burden of Bone Disease and the Role of Zoledronic Acid. Clinical Medicine Therapeutics, 2009, 1, CMT.S1958.	0.1	0
1291	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology, 2009, 2009, 1-17.	1.3	29
1292	Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. Journal of Oncology, 2009, 2009, 1-8.	1.3	35
1293	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology, 2009, 2009, 2009, 1-14.	1.3	99
1294	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. OncoTargets and Therapy, 2009, 2, 209.	2.0	15
1295	Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature. Reviews on Recent Clinical Trials, 2009, 4, 27-33.	0.8	8
1296	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	1.3	2
1297	The Role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic, and Recurrent Non-Small-Cell Lung Cancer: A Canadian National Consensus Statement. Current Oncology, 2009, 16, 27-48.	2.2	24
1298	Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. Journal of Thoracic Oncology, 2009, 4, 988-993.	1.1	3
1299	V15-32 and INTEREST. Japanese Journal of Lung Cancer, 2009, 49, 944-949.	0.1	0
1300	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. Clinical Medicine Therapeutics, 2009, 1, CMT.S2122.	0.1	0
1301	Small-molecule inhibitors of the human epidermal receptor family. Expert Opinion on Investigational Drugs, 2009, 18, 1829-1842.	4.1	25

#	Article	IF	CITATIONS
1302	Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. American Journal of Physiology - Cell Physiology, 2009, 296, C954-C976.	4.6	140
1303	First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. Journal of Clinical Oncology, 2009, 27, 1394-1400.	1.6	480
1304	Micropapillary Histology. American Journal of Clinical Pathology, 2009, 131, 615-617.	0.7	7
1305	Impact of Epidermal Growth Factor Receptor and <i>KRAS</i> Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. Clinical Cancer Research, 2009, 15, 5267-5273.	7.0	382
1306	A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16996-17001.	7.1	255
1307	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. International Journal of Surgical Pathology, 2009, 17, 206-218.	0.8	84
1308	Proteasome Inhibition Blocks Ligand-Induced Dynamic Processing and Internalization of Epidermal Growth Factor Receptor via Altered Receptor Ubiquitination and Phosphorylation. Cancer Research, 2009, 69, 976-983.	0.9	34
1309	Review Article: Targeted Therapy: Comprehensive Review. American Journal of Hospice and Palliative Medicine, 2009, 26, 137-146.	1.4	7
1310	SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome. Nucleic Acids Research, 2009, 37, W406-W412.	14.5	57
1311	Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 137-144.	3.2	21
1312	Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology, 2009, 20, 1813-1817.	1.2	53
1313	Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 233-241.	3.5	130
1314	Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status. Journal of Clinical Oncology, 2009, 27, 2253-2260.	1.6	118
1315	Lung cancer in women: the differences in epidemiology, biology and treatment outcomes. Expert Review of Respiratory Medicine, 2009, 3, 627-634.	2.5	15
1316	Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Annals of Oncology, 2009, 20, 1455-1457.	1.2	3
1317	Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts. Cancer Research, 2009, 69, 873-878.	0.9	164
1318	Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with <i>MET</i> Amplification. Clinical Cancer Research, 2009, 15, 907-913.	7.0	47
1319	Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 5040-5048.	7.0	26

#	Article	IF	CITATIONS
1320	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy, 2009, 9, 663-670.	2.4	28
1321	Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras. Oncology, 2009, 76, 239-246.	1.9	18
1322	Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer Patients: A Feasible Therapeutic Option?. Oncology, 2009, 77, 113-121.	1.9	75
1323	Review: Adjuvant therapy for resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 109-118.	3.2	11
1324	Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. Cancer Biology and Therapy, 2009, 8, 206-212.	3.4	10
1325	EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1466-1472.	1.1	65
1326	Targeted Therapies in Lung Cancer. Current Pharmaceutical Design, 2009, 15, 188-206.	1.9	39
1327	Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties. Current Cancer Drug Targets, 2009, 9, 1-18.	1.6	6
1328	Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Biomarkers in Medicine, 2009, 3, 139-151.	1.4	4
1329	New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing. Current Cancer Therapy Reviews, 2009, 5, 1-19.	0.3	Ο
1330	I Am No One. No One Is Perfect…Therefore I Am Perfect. Journal of Clinical Oncology, 2009, 27, e128-e129.	1.6	1
1331	Anti-Apoptotic Mechanisms of Drug Resistance in Cancer. Current Cancer Drug Targets, 2009, 9, 307-319.	1.6	157
1332	Role of Tyrosine Kinase Inhibitors in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 569-575.	1.7	25
1333	Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 66-76.	1.7	100
1334	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature Reviews Clinical Oncology, 2009, 6, 287-294.	27.6	21
1335	A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization. Acta Oncológica, 2009, 48, 471-473.	1.8	1
1336	Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. PLoS ONE, 2009, 4, e4576.	2.5	177
1337	First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Review of Anticancer Therapy, 2009, 9, 425-435.	2.4	25
#	Article	IF	CITATIONS
------	---	-----	-----------
1338	Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Annals of Oncology, 2009, 20, 835-841.	1.2	60
1339	EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics, 2009, 10, 59-68.	1.3	67
1340	The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2009, 14, 1116-1130.	3.7	57
1341	Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 4481-4486.	1.6	223
1342	A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. Clinical Cancer Research, 2009, 15, 2552-2558.	7.0	269
1343	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 7502-7509.	7.0	136
1344	Bridging Study versus Prespecified Regions Nested in Global Trials. Drug Information Journal, 2009, 43, 27-34.	0.5	7
1345	Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clinical Cancer Research, 2009, 15, 5646-5661.	7.0	137
1346	Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. Journal of Clinical Oncology, 2009, 27, 5650-5659.	1.6	115
1347	<i>EGFR</i> and K- <i>ras</i> Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors. American Journal of Clinical Pathology, 2009, 131, 478-489.	0.7	67
1348	Comparison of FISH, PCR, and Immunohistochemistry in Assessing EGFR Status in Lung Adenocarcinoma and Correlation With Clinicopathologic Features. Diagnostic Molecular Pathology, 2009, 18, 133-137.	2.1	15
1349	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 2009, 20, 213-226.	1.2	37
1350	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Annals of Oncology, 2009, 20, 696-702.	1.2	206
1351	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2009, 27, 1864-1871.	1.6	353
1352	Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations. Clinical Cancer Research, 2009, 15, 4493-4498.	7.0	182
1353	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. European Respiratory Journal, 2009, 33, 1485-1497.	6.7	151
1354	Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02. BMC Research Notes, 2009, 2, 157.	1.4	22
1355	Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy. Clinical Lung Cancer, 2009, 10, 20-27.	2.6	17

		CITATION R	EPORT	
#	Article		IF	CITATIONS
1356	Second-Line Therapy for Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10,	91-98.	2.6	5
1357	S-1: A New Oral Fluoropyrimidine in the Treatment of Patients with Advanced Non–Sm Cancer. Clinical Lung Cancer, 2009, 10, 290-294.	all-Cell Lung	2.6	26
1358	Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 ir Experimental Cell Research, 2009, 315, 2658-2672.	nactivation.	2.6	25
1359	Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons Japanese non–small cell lung cancer patients. Cancer Genetics and Cytogenetics, 2009	19 and 21 in 9, 195, 179-182.	1.0	10
1360	The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tu Seminars in Oncology, 2009, 36, S55-S68.	mors.	2.2	8
1361	Lung Cancer Outcomes in Women. Seminars in Oncology, 2009, 36, 532-541.		2.2	15
1362	EGFR protein overexpression and mutation in areca quid–associated oral cavity squam carcinoma in Taiwan. Head and Neck, 2009, 31, 1068-1077.	ious cell	2.0	28
1363	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for a treatment of a rare lung malignancy. International Journal of Cancer, 2009, 125, 2479-24	ntiâ€EGFR 482.	5.1	103
1364	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with a salvage treatment. Cancer, 2009, 115, 1518-1530.	ı gefitinib as	4.1	20
1365	<i>EGFR</i> mutations are detected comparably in cytologic and surgical pathology spe nonsmall cell lung cancer. Cancer Cytopathology, 2009, 117, 67-72.	cimens of	2.4	136
1366	Sex difference in the influence of smoking status on the responsiveness to gefitinib mon adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. Journal of Research and Clinical Oncology, 2009, 135, 117-123.	otherapy in Cancer	2.5	7
1367	Epidermal growth factor receptor mutations in non-small cell lung cancer influence down Akt, MAPK and Stat3 signaling. Journal of Cancer Research and Clinical Oncology, 2009,	nstream 135, 723-730.	2.5	47
1368	Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treate platinum-based chemotherapy. International Journal of Clinical Oncology, 2009, 14, 125	d with -129.	2.2	1
1369	Effect of gefitinib on warfarin antithrombotic activity. International Journal of Clinical On 2009, 14, 332-336.	icology,	2.2	16
1370	Improvements of quality of life in patients with advanced non-small cell lung cancer treat gefitinib. Chinese-German Journal of Clinical Oncology, 2009, 8, 495-497.	ted with	0.1	2
1371	Gefitinib is effective for pathological fracture of metastatic non-small cell lung cancer. Eu Journal of Orthopaedic Surgery and Traumatology, 2009, 19, 181-185.	ıropean	1.4	0
1372	Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinon and in vivo. Investigational New Drugs, 2009, 27, 1-11.	na in vitro	2.6	8
1373	Prolonged response to gefitinib in bone metastasis. Medical Oncology, 2009, 26, 101-10	02.	2.5	5

#	Article	IF	CITATIONS
1374	A population-based study of gefitinib in patients with non-small cell lung cancer. Medical Oncology, 2009, 26, 222-227.	2.5	9
1375	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. Oncology Reviews, 2009, 3, 137-148.	1.8	1
1376	Histoculture drug response assay for gefitinib in non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery, 2009, 57, 138-143.	0.9	13
1377	Investigational agents in the management of non-small cell lung cancer. Current Oncology Reports, 2009, 11, 275-284.	4.0	5
1378	Maximum tolerated dose: clinical endpoint for a bygone era?. Targeted Oncology, 2009, 4, 143-147.	3.6	50
1379	The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Targeted Oncology, 2009, 4, 235-252.	3.6	52
1380	Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom. Onkopipeline, 2009, 2, 80-85.	0.0	0
1381	A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research 2009 21 1-12	2.2	2
1382	Molecular markers and pathogenically targeted therapy in non-small cell lung cancer. Frontiers of Medicine in China, 2009, 3, 245-255.	0.1	1
1383	Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in Recurrent Glioblastoma. Pathology and Oncology Research, 2009, 15, 225-229.	1.9	18
1384	Radiosensitizing effects of gefitinib at different administration times <i>in vitro</i> . Cancer Science, 2009, 100, 1520-1525.	3.9	42
1385	Usefulness of cumulative smoking dose for identifying the <i>EGFR</i> mutation and patients with nonâ€smallâ€cell lung cancer for gefitinib treatment. Cancer Science, 2009, 100, 1931-1934.	3.9	15
1386	Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Science, 2009, 100, 2054-2059.	3.9	80
1387	P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Therapy, 2009, 16, 498-507.	4.6	19
1388	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology, 2009, 6, 352-366.	27.6	207
1389	The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Oncogene, 2009, 28, S1-S3.	5.9	5
1390	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene, 2009, 28, S14-S23.	5.9	179
1391	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 2009, 28, S24-S31.	5.9	799

#	Article	IF	CITATIONS
1392	Gefitinibâ€induced autologous antitumor immunity. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 119-122.	1.1	0
1393	Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose―and sequenceâ€dependent manner. BJU International, 2009, 103, 1729-1737.	2.5	24
1394	Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology, 2009, 69, 223-236.	4.4	11
1395	Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development. Current Problems in Cancer, 2009, 33, 73-111.	2.0	17
1396	Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer, 2009, 33, 245-294.	2.0	9
1397	Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1391-1396.	0.8	61
1398	Cell Adhesion Molecules. Molecular Pathology Library, 2009, , 19-28.	0.1	1
1399	Current Clinical Management of Metastatic Lung Cancer. , 2009, , 317-350.		0
1400	Gefitinib - a potential new treatment option in lung cancer. Future Prescriber, 2009, 10, 7-13.	0.1	1
1401	Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research, 2009, 15, 2076-2084.	7.0	371
1402	Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology, 2009, 27, 2523-2529.	1.6	208
1403	Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 264-270.	1.6	55
1404	Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Letters, 2009, 278, 17-26.	7.2	28
1405	Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. Cancer Letters, 2009, 279, 213-220.	7.2	13
1406	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 326-335.	2.0	27
1407	Activated Akt Prevents Antitumor Activity of Gefitinib in Renal Cancer Cells. Urology, 2009, 74, 209-215.	1.0	13
1409	Efficacy of Signal Pathway Inhibitors Alone and in Combination With Cisplatin Varies Between Human Non-Small Cell Lung Cancer Lines. Journal of Surgical Research, 2009, 154, 9-12.	1.6	12
1410	The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence―with meta-analysis. Human Pathology, 2009, 40, 356-365.	2.0	42

#	Article	IF	CITATIONS
1411	Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2653-2659.	1.6	281
1412	Treatment of non-small cell lung cancer patients with performance status2 (PS2). Lung Cancer, 2009, 63, 10-15.	2.0	10
1413	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 2009, 63, 219-226.	2.0	203
1414	Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer, 2009, 63, 418-424.	2.0	47
1415	EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: Investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung Cancer, 2009, 64, 179-186.	2.0	31
1416	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer, 2009, 64, 199-206.	2.0	20
1417	Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer, 2009, 64, 341-345.	2.0	11
1418	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer, 2009, 64, 346-351.	2.0	43
1419	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer, 2009, 65, 204-207.	2.0	29
1420	Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer, 2009, 66, 114-119.	2.0	65
1421	Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor?. Lung Cancer, 2009, 66, 262-267.	2.0	82
1422	Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. Platelets, 2009, 20, 70-71.	2.3	5
1423	Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer. Journal of Nanjing Medical University, 2009, 23, 392-397.	0.1	2
1424	Next generation oncology drug development: opportunities and challenges. Nature Reviews Clinical Oncology, 2009, 6, 259-265.	27.6	64
1425	Gefitinib. Drugs, 2009, 69, 2303-2328.	10.9	55
1426	Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?. Clinical Lung Cancer, 2009, 10, 295-300.	2.6	23
1427	Recent advances of novel targeted therapy in non-small cell lung cancer. Journal of Hematology and Oncology, 2009, 2, 2.	17.0	69
1428	Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 17-35.	2.4	46

#	Article	IF	CITATIONS
1429	Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Annals of Oncology, 2009, 20, 1483-1488.	1.2	29
1430	EGFR-directed therapies to treat non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 2009, 18, 1133-1145.	4.1	12
1432	ls there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncológica, 2009, 48, 578-583.	1.8	153
1433	Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2009, 18, 293-301.	4.1	15
1434	The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. Journal of Experimental and Clinical Cancer Research, 2009, 28, 123.	8.6	16
1435	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. Breast Cancer Research, 2009, 11, 201.	5.0	9
1436	Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones. Neoplasia, 2009, 11, 1084-1092.	5.3	92
1437	Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy, 2009, 9, 1365-1378.	2.4	44
1438	ls there a need to take ethnicity into account when considering lung cancer treatment?. Expert Review of Respiratory Medicine, 2009, 3, 1-4.	2.5	0
1439	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Review of Neurotherapeutics, 2009, 9, 1815-1836.	2.8	39
1440	Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocrine-Related Cancer, 2009, 16, 565-572.	3.1	41
1441	Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 243-257.	3.3	106
1442	The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies. Oncologist, 2009, 14, 253-263.	3.7	669
1443	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236.	1.6	93
1444	Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Recep tor–Targeted Agents. Clinical Colorectal Cancer, 2009, 8, 3-8.	2.3	0
1445	Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer, 2009, 45, 332-342.	2.8	25
1446	Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 401-412.	2.4	25
1447	Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Organic and Biomolecular Chemistry, 2009, 7, 4415.	2.8	40

#	Article	IF	CITATIONS
1448	EGFR Signaling and Drug Discovery. Oncology, 2009, 77, 400-410.	1.9	387
1449	Application of Laser Microdissection and Reverse-Phase Protein Microarrays to the Molecular Profiling of Cancer Signal Pathway Networks in the Tissue Microenvironment. Clinics in Laboratory Medicine, 2009, 29, 1-13.	1.4	30
1450	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 338-341.	1.3	46
1451	The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care?. Current Opinion in Pulmonary Medicine, 2009, 15, 321-326.	2.6	13
1452	Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine, 2009, 16, 157-171.	0.3	2
1453	Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells. Anti-Cancer Drugs, 2009, 20, 832-837.	1.4	15
1454	Overall Survival: Still the Gold Standard. Cancer Journal (Sudbury, Mass), 2009, 15, 401-405.	2.0	126
1455	Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 684-688.	1.1	75
1456	Laser capture microdissection: A tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. International Journal of Molecular Medicine, 2009, 24, 473-9.	4.0	3
1457	Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 809-815.	1.1	145
1458	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology, 2009, 36, .	3.3	1
1459	Medical management of brain metastases from lung cancer (Review). Oncology Reports, 2009, 22, 1269-76.	2.6	54
1460	Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005. Journal of Thoracic Oncology, 2009, 4, 1524-1529.	1.1	80
1461	Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group. Journal of Thoracic Oncology, 2009, 4, 1136-1143.	1.1	25
1462	Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib. Journal of Thoracic Oncology, 2009, 4, 994-1001.	1.1	41
1463	Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib. Journal of Thoracic Oncology, 2009, 4, 1415-1419.	1.1	151
1464	NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-5-S-21.	4.9	102
1465	IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype. Journal of Thoracic Oncology, 2009, 4,	1.1	51

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1466	Tumor Shrinkage and Objective Response Rates. Cancer Journal (Sudbury, Mass), 2009	9, 15, 354-360.	2.0	14
1467	Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers. Currer Pharmaceutical Design, 2009, 15, 758-776.	ht	1.9	57
1468	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anti- Drugs, 2009, 20, 856-866.	Cancer	1.4	54
1469	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epiderma factor receptor and multikinase inhibitors. Anti-Cancer Drugs, 2010, 21, 151-168.	al growth	1.4	9
1470	Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Pe Current Clinical Pharmacology, 2010, 5, 166-177.	rspectives.	0.6	8
1471	Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatn With Carcinoma of Unknown Primary Site. Cancer Journal (Sudbury, Mass), 2010, 16,	ient of Patients 70-75.	2.0	60
1472	Personalized cancer therapy coming of age: clinical highlights in 2009 and future direc Personalized Medicine, 2010, 7, 121-124.	tions.	1.5	2
1473	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a Eu Workshop. Journal of Thoracic Oncology, 2010, 5, 1706-1713.	ropean	1.1	273
1474	Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Re Non-Small-Cell Lung Cancer. Current Drug Targets, 2010, 11, 851-864.	ceptor in	2.1	46
1475	Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan. Journal of Thoracic 2010, 5, 1011-1017.	of 1499 Oncology,	1.1	76
1476	Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinon of the Mucinous Subtype of Bronchioloalveolar Carcinoma. Journal of Thoracic Oncolog 1197-1200.	na with Features gy, 2010, 5,	1.1	66
1477	Molecular Diagnostics Testing for Lung Adenocarcinoma. , 2010, 15, 103-110.			1
1478	Phase II Study of Paclitaxel and Irinotecan With Intercalated Gefitinib in Patients With A Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical 1 66-69.	Advanced Trials, 2010, 33,	1.3	9
1479	Immunohistology—Past, Present, and Future. Advances in Anatomic Pathology, 2010	, 17, 404-418.	4.3	43
1480	First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer w Performance Status. Journal of Thoracic Oncology, 2010, 5, 361-368.	ith Poor	1.1	29
1481	Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine, 2 1923-1934.	010, 49,	0.7	6
1482	1. Basic and Clinical Practice of Molecular Target Therapy for Lung Cancers The Journa Japanese Society of Internal Medicine, 2010, 99, 2035-2051.	l of the	0.0	0
1483	Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Journal of Thoracic Oncology, 2010, 5, 1404-1409.	ung Cancer.	1.1	50

#	Article	IF	CITATIONS
1484	Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. Journal of Thoracic Oncology, 2010, 5, 491-496.	1.1	51
1485	Compassionate Use Programs or Phase IV Trials of Innovative Molecular Targeted Drugs in Lung Cancer: Deal or No Deal?. Journal of Thoracic Oncology, 2010, 5, 1495-1497.	1.1	2
1486	Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. Journal of Thoracic Oncology, 2010, 5, 1424-1429.	1.1	28
1487	Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503. Journal of Thoracic Oncology, 2010, 5, 169-178.	1.1	70
1488	Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma. Multidisciplinary Respiratory Medicine, 2010, 5, 305.	1.5	8
1489	Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. Oncology Reports, 2010, 23, .	2.6	8
1490	Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1939-1948.	1.1	25
1491	Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial. Journal of Thoracic Oncology, 2010, 5, 1382-1390.	1.1	138
1492	Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis. Internal Medicine, 2010, 49, 103-107.	0.7	36
1493	Japanese Lung Cancer Research Trends and Performance in Science Citation Index. Internal Medicine, 2010, 49, 2219-2228.	0.7	130
1494	Personalizing therapy for ovarian cancer. Therapy: Open Access in Clinical Medicine, 2010, 7, 229-239.	0.2	2
1495	Prognostic Implications of Epidermal Growth Factor Receptor and KRAS Gene Mutations and Epidermal Growth Factor Receptor Gene Copy Numbers in Patients with Surgically Resectable Non-small Cell Lung Cancer in Taiwan. Journal of Thoracic Oncology, 2010, 5, 1175-1184.	1.1	50
1496	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology, 2010, 65, 353-361.	2.3	172
1497	Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 1023-1028.	2.3	25
1498	Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non–small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 691-698.	2.3	33
1499	Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemotherapy and Pharmacology, 2010, 65, 803-806.	2.3	37
1501	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Journal of Cancer Research and Clinical Oncology, 2010, 136, 527-535.	2.5	15
1502	Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1341-1347.	2.5	67

		CITATION REPOR	Т	
#	Article	IF	Сітаті	IONS
1503	Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology, 2010, 5, 5-	17. 3.6	17	
1504	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Targeted Oncology, 2010, 5, 245-255.	2 3.6	56	
1505	Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-ce cancer patients treated with gefitinib. Medical Oncology, 2010, 27, 950-957.	ll lung 2.5	13	
1506	Biology and Therapy of Neoplastic Meningitis. Current Oncology Reports, 2010, 12, 41-49.	4.0	31	
1507	A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China. Chinese Journal of Cancer Research: Official Journal of Chir Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 1-9.	1a 2.2	1	
1508	EGFR mutations and the terminal respiratory unit. Cancer and Metastasis Reviews, 2010, 29, 2	13-36. 5.9	109	
1509	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 2010, 29, 49-60.	5.9	191	
1510	Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Investigational New Drugs, 2010, 28, 791-799.	2.6	67	
1511	Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after sur A retrospective case-matching cohort study. Surgical Oncology, 2010, 19, e144-e149.	gery: 1.6	11	
1512	Subsequent Chemotherapy Improves Survival Outcome in Advanced Non–Small-Cell Lung C Acquired Tyrosine Kinase Inhibitor Resistance. Clinical Lung Cancer, 2010, 11, 51-56.	ancer With 2.6	28	
1513	Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Clinical Lung Cancer, 2010, 11, 257-263.	Cancer. 2.6	8	
1514	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. Cancer, 2010, 10, 376.	BMC 2.6	70	
1515	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discovery Today, 2010, 15, 88-97.	6.4	69	
1516	Molecular imaging and targeted therapies. Biochemical Pharmacology, 2010, 80, 731-738.	4.4	38	
1517	Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochemic Pharmacology, 2010, 80, 613-623.	cal 4.4	83	
1518	Kinases as targets in the treatment of solid tumors. Cellular Signalling, 2010, 22, 984-1002.	3.6	88	
1519	Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer thera Letters, 2010, 584, 2699-2706.	ру. FEBS 2.8	141	
1520	Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecologic Oncology, 2010, 157-162.	therapy 116, 1.4	47	

#	Article	IF	CITATIONS
1521	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmallâ€cell lung cancer. Cancer, 2010, 116, 1336-1343.	4.1	99
1522	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer, 2010, 116, 3025-3033.	4.1	34
1523	Epidermal growth factor receptor mutations detected by denaturing highâ€performance liquid chromatography in nonsmall cell lung cancer. Cancer, 2010, 116, 4309-4317.	4.1	20
1524	Cell typeâ€dependent biomarker expression in adenoid cystic carcinoma. Cancer, 2010, 116, 5749-5756.	4.1	54
1525	The effects of gefitinib in tamoxifenâ€resistant and hormoneâ€insensitive breast cancer: A phase II study. International Journal of Cancer, 2010, 126, 1806-1816.	5.1	51
1526	Integrin beta1 overâ€expression associates with resistance to tyrosine kinase inhibitor gefitinib in nonâ€small cell lung cancer. Journal of Cellular Biochemistry, 2010, 111, 1565-1574.	2.6	67
1527	Validation of Recursive Partitioning Analysis Classification in Patients with Brain Metastases from Non-small Cell Lung Cancer Treated with Short-course Accelerated Radiotherapy. Clinical Oncology, 2010, 22, 837-843.	1.4	6
1528	Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorganic and Medicinal Chemistry, 2010, 18, 3812-3822.	3.0	51
1529	A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 42-49.	0.8	20
1530	Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours. BMC Biotechnology, 2010, 10, 91.	3.3	15
1531	Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: Pharmacological rationale and clinical response. Pediatric Blood and Cancer, 2010, 54, 55-61.	1.5	19
1532	Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in ILâ€1R2 in keratinocytes. Experimental Dermatology, 2010, 19, 730-735.	2.9	23
1533	Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. British Journal of Dermatology, 2010, 162, 371-379.	1.5	28
1534	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells. Oncogene, 2010, 29, 2616-2627.	5.9	87
1535	C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer. British Journal of Cancer, 2010, 102, 325-331.	6.4	36
1536	Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. British Journal of Cancer, 2010, 103, 987-992.	6.4	18
1537	Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nature Genetics, 2010, 42, 893-896.	21.4	165
1538	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer, 2010, 10, 241-253.	28.4	506

#	Article	IF	CITATIONS
1539	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 2010, 10, 760-774.	28.4	943
1540	Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery, 2010, 9, 523-535.	46.4	53
1541	Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU International, 2010, 105, 317-321.	2.5	99
1542	The current status of targeted therapy for nonâ€small cell lung cancer. Internal Medicine Journal, 2010, 40, 611-618.	0.8	43
1543	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Drug Design, Development and Therapy, 2010, 4, 81.	4.3	42
1544	Management of patients with advanced non-small cell lung cancer: role of gefitinib. Biologics: Targets and Therapy, 2010, 4, 83.	3.2	2
1545	Refining the treatment of advanced nonsmall cell lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 9.	2.7	1
1546	Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 37.	2.7	0
1547	EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Pharmaceuticals, 2010, 3, 2238-2247.	3.8	37
1548	Estrogen Receptor Î ² Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib. PLoS ONE, 2010, 5, e14110.	2.5	56
1549	The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics: Targets and Therapy, 2010, 4, 289.	3.2	30
1550	The Effect of Autophagy to Cell Death in Nutrient-Deprived H460 Cells. Tuberculosis and Respiratory Diseases, 2010, 69, 81.	1.8	0
1551	The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer. Current Drug Targets, 2010, 11, 2-11.	2.1	6
1552	Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer. Korean Journal of Internal Medicine, 2010, 25, 294.	1.7	25
1553	Massive Hematuria from the Bilateral Upper Urinary Tract in a Patient Treated for Advanced Lung Cancer with Gefitinib. Japanese Journal of Clinical Oncology, 2010, 40, 263-266.	1.3	5
1554	Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape. Molecular Cancer Therapeutics, 2010, 9, 1931-1944.	4.1	74
1555	Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases. Journal of Clinical Oncology, 2010, 28, 4616-4620.	1.6	313
1556	Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis. Clinical Cancer Research, 2010, 16, 3163-3170.	7.0	108

#	Article	IF	Citations
1557	Tyrosine Kinase Inhibitors. Current Cancer Drug Targets, 2010, 10, 462-483.	1.6	37
1558	Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans. Drug Metabolism and Disposition, 2010, 38, 2049-2059.	3.3	19
1559	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. European Respiratory Review, 2010, 19, 186-196.	7.1	35
1560	<i>EGFR</i> Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry. American Journal of Clinical Pathology, 2010, 133, 922-934.	0.7	110
1561	Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I). Japanese Journal of Clinical Oncology, 2010, 40, 1105-1109.	1.3	50
1562	Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Annals of Thoracic Medicine, 2010, 5, 153.	1.8	8
1563	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer. Current Gerontology and Geriatrics Research, 2010, 2010, 1-8.	1.6	2
1564	Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 101-106.	1.3	73
1565	Non–Small Cell Carcinomas of the Lung. , 2010, , 51-110.		0
1566	Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Modern Pathology, 2010, 23, 159-168.	5.5	105
1567	Somatic <i>EGFR</i> Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 291-303.	7.0	134
1568	Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 180-187.	1.2	7
1569	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. Cancer Investigation, 2010, 28, 413-423.	1.3	21
1570	A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Review of Anticancer Therapy, 2010, 10, 955-965.	2.4	14
1571	Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	27.6	593
1572	EGF receptor in lung cancer: a successful story of targeted therapy. Expert Review of Anticancer Therapy, 2010, 10, 1577-1587.	2.4	12
1573	The Sequence-Dependent Cytotoxic Effect of Trastuzumab in Combination With 5-Fluorouracil or Cisplatin on Gastric Cancer Cell Lines. Cancer Investigation, 2010, 28, 1038-1047.	1.3	7
1574	Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. British Journal of Cancer, 2010, 103, 1325-1330.	6.4	13

#	Article	IF	Citations
1575	Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2010, 10, 1589-1599.	2.4	8
1576	Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics, 2010, 10, 547-561.	2.8	20
1577	Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma. Clinical Cancer Research, 2010, 16, 4616-4624.	7.0	71
1578	The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5311-5320.	1.6	247
1579	Metabolism and Disposition of [¹⁴ C]BMS-690514 after Oral Administration to Rats, Rabbits, and Dogs. Drug Metabolism and Disposition, 2010, 38, 1189-1201.	3.3	5
1580	Therapy and prophylaxis of brain metastases. Expert Review of Anticancer Therapy, 2010, 10, 1763-1777.	2.4	40
1581	Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Annals of Oncology, 2010, 21, 2324-2332.	1.2	106
1582	Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Experimental Lung Research, 2010, 36, 531-537.	1.2	12
1583	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. Cancer Investigation, 2010, 28, 413-423.	1.3	35
1584	Geftinib. Journal of Cancer Research and Therapeutics, 2010, 6, 249.	0.9	9
1585	Cytokines and Growth Factors Stimulate Hyaluronan Production: Role of Hyaluronan in Epithelial to Mesenchymal-Like Transition in Non-Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-11.	3.0	46
1586	Delivering on the promise of personalized healthcare. Personalized Medicine, 2010, 7, 327-337.	1.5	12
1587	Lung Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i7-i12.	1.3	17
1588	Successful Treatment With Erlotinib After Gefitinib-Related Severe Hepatotoxicity. Journal of Clinical Oncology, 2010, 28, e273-e274.	1.6	35
1589	Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle, 2010, 9, 4098-4105.	2.6	19
1590	Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. Oncology, 2010, 79, 78-84.	1.9	14
1591	Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biology and Therapy, 2010, 9, 572-582.	3.4	59
1592	Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers. Molecular Therapy, 2010, 18, 528-535.	8.2	49

#	Article	IF	CITATIONS
1594	Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncology, 2010, 6, 741-767.	2.4	24
1595	The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making. Current Medicinal Chemistry, 2010, 17, 1030-1038.	2.4	24
1596	EGFR Mutation Testing in Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2010, 6, 310-321.	0.2	2
1597	Safety profile of new anticancer drugs. Expert Opinion on Drug Safety, 2010, 9, 301-317.	2.4	21
1598	Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation. Molecular Therapy, 2010, 18, 536-543.	8.2	38
1599	Novel Agents in the Management of Lung Cancer. Current Medicinal Chemistry, 2010, 17, 4291-4325.	2.4	21
1600	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets, 2010, 10, 799-812.	1.6	28
1601	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 2363-2389.	1.8	19
1602	Targeted Therapies for Solid Tumors. BioDrugs, 2010, 24, 303-316.	4.6	18
1605	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67, 355-360.	2.0	76
1606	Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer, 2010, 68, 185-191.	2.0	77
1607	Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68, 198-203.	2.0	105
1608	Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer, 2010, 68, 269-272.	2.0	57
1609	Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer, 2010, 67, 4-11.	2.0	70
1610	Targeted therapies for non-small cell lung cancer. Lung Cancer, 2010, 67, 257-274.	2.0	140
1611	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer, 2010, 69, 272-278.	2.0	289
1612	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer, 2010, 69, 1-12.	2.0	59
1613	Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer, 2010, 70, 94-102.	2.0	43

#	Article	IF	CITATIONS
1614	Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2010, 70, 57-62.	2.0	39
1615	Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer, 2010, 69, 265-271.	2.0	12
1616	Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung Cancer, 2010, 70, 200-204.	2.0	5
1617	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer, 2010, 70, 301-307.	2.0	40
1618	Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer, 2010, 70, 223-225.	2.0	25
1619	Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology, 2010, 7, 401-414.	27.6	231
1620	Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib. Oncology, 2010, 79, 355-362.	1.9	20
1621	Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs, 2010, 70, 167-179.	10.9	18
1622	Supersensitive Mutation: Two Case Reports of Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2010, 11, E5-E8.	2.6	3
1623	Cisplatin-based Chemotherapy in Elderly Patients with Non-small Cell Lung Cancer. International Journal of Gerontology, 2010, 4, 28-36.	0.6	0
1624	Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy. Clinical Cancer Research, 2010, 16, 1307-1314.	7.0	173
1625	Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). Journal of Clinical Oncology. 2010. 28. 753-760.	1.6	174
1626	Identification of Tyrosine-Phosphorylated Proteins Associated with Lung Cancer Metastasis using Label-Free Quantitative Analyses. Journal of Proteome Research, 2010, 9, 4102-4112.	3.7	15
1627	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Human Pathology, 2010, 41, 94-102.	2.0	81
1628	Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews, 2010, 36, 235-248.	7.7	52
1629	Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009. Thoracic Cancer, 2010, 1, 83-86.	1.9	100
1630	Gefitinib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 1343-1357.	1.8	20
1631	Gefitinib as Firstâ€line Therapy for Advanced or Metastatic Nonâ€small Cell Lung Cancer Patients in Southern Taiwan. Kaohsiung Journal of Medical Sciences, 2010, 26, 1-7.	1.9	0

ARTICLE IF CITATIONS Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment 128 1632 7.7 of lung adenocarcinoma. Cancer Treatment Reviews, 2010, 36, S21-S29. Clinical Applications of Kinase Inhibitors in Solid Tumors., 2010, , 615-631. Gefitinib or Chemotherapy for Nonâ€"Small-Cell Lung Cancer with Mutated EGFR. New England Journal 1634 27.0 5,032 of Medicine, 2010, 362, 2380-2388. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy 2.0 according to EGFR and K-RAS mutation status. Lung Cancer, 2010, 69, 110-115. Association of Polymorphisms in<i>AKT1</i>and<i>EGFR</i>with Clinical Outcome and Toxicity in 1636 Nonâ€"Small Cell Lung Cancer Patients Treated with Gefitinib. Molecular Cancer Therapeutics, 2010, 9, 4.1 67 581-593. Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. Journal of Clinical Oncology, 2010, 28, 1637 489 1.6 744-752. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128. 1638 10.7 3,794 Molecularly Targeted Therapies for Astrocytomas., 2010, , 231-265. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. 1642 8.6 12 Journal of Experimental and Clinical Cancer Research, 2010, 29, 126. Comparison of the epidermal growth factor receptor protein expression between primary non-small 1643 cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy. 8.6 Journal of Experimental and Clinical Cancer Research, 2010, 29, 7. Clinical Protein Science and Bioanalytical Mass Spectrometry with an Emphasis on Lung Cancer. 1644 47.7 33 Chemical Reviews, 2010, 110, 3278-3298. Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer. Onkologie, 2010, 33, 1645 0.8 704-709 1646 Principles of Clinical Cancer Genetics., 2010,,. 3 Epidermal Growth Factor Receptor Signaling in Nonsmall Cell Lung Cancer. Cancer Investigation, 1647 1.3 2010, 28, 515-525. A "MiniPool―Approach for Combined Phase IIB/III Trial in Patients With Life-Threatening Disease: An 1648 2 0.8 Application of the Closed Testing Principle. Statistics in Biopharmaceutical Research, 2010, 2, 62-71. Selective inhibition of EGFR and VEGFR2 tyrosine kinases controlled by a boronic acid substituent on 1649 19 4-anilinoquinazolines. MedChemComm, 2010, 1, 282. Bridging Diversity. Pharmaceutical Medicine, 2010, 24, 349-362. 1650 1.9 8 The challenges of integrating molecular imaging into the optimization of cancer therapy. Integrative 1.3 Biology (United Kingdom), 2011, 3, 603.

#	Article	IF	CITATIONS
1652	A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 1553-1560.	7.0	117
1653	Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1059-1066.	1.6	281
1654	Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology, 2011, 29, 1067-1074.	1.6	268
1655	Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS). Journal of Clinical Oncology, 2011, 29, 2866-2874.	1.6	1,368
1656	¹⁸ F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Nuclear Medicine, 2011, 52, 1684-1689.	5.0	94
1657	A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 839-851.	2.1	58
1658	Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine, 2011, 364, 947-955.	27.0	375
1659	Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Acta Óncológica, 2011, 50, 582-588.	1.8	16
1660	Recomendaciones para la determinación de las mutaciones del gen EGFR en el carcinoma de pulmón no microcÃtico. Revista Espanola De Patologia, 2011, 44, 17-31.	0.2	2
1661	Prognostic implications of hypoxia-inducible factor- $1\hat{l}$ in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer, 2011, 72, 100-107.	2.0	26
1662	The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer, 2011, 73, 45-50.	2.0	71
1663	The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer, 2011, 73, 203-210.	2.0	25
1664	Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience. Lung Cancer, 2011, 73, 189-194.	2.0	57
1665	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer, 2011, 71, 249-257.	2.0	113
1666	Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer, 2011, 72, 9-15.	2.0	78
1667	Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung Cancer, 2011, 74, 268-273.	2.0	66
1668	Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials. Lung Cancer, 2011, 74, 469-473.	2.0	70
1669	Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology, 2011, 8, 661-668.	27.6	145

		CITATION R	EPORT	
#	Article		IF	CITATIONS
1670	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 201	1, 50, 371-403.	3.5	95
1671	Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Grov Receptor Mutations. Drugs, 2011, 71, 79-88.	wth Factor	10.9	6
1672	Targeted Therapies for Gastric Cancer. Drugs, 2011, 71, 1367-1384.		10.9	37
1673	Comparison of KRAS and EGFR gene status between primary non-small cell lung cance lymph node metastases: implications for clinical practice. Journal of Experimental and Research, 2011, 30, 30.	r and local Clinical Cancer	8.6	77
1674	Drug-induced liver injury: a summary of recent advances. Expert Opinion on Drug Meta Toxicology, 2011, 7, 875-890.	abolism and	3.3	49
1675	Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the E Receptor Tyrosine Kinases. Cancers, 2011, 3, 1195-1231.	rbB Family of	3.7	21
1676	Principles of Anticancer Drug Development. , 2011, , .			0
1678	The landscape of <i>EGFR</i> pathways and personalized management of non-small-c Future Oncology, 2011, 7, 519-541.	ell lung cancer.	2.4	47
1679	Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Trea Journal of Pathology, 2011, 178, 1940-1948.	tment. American	3.8	42
1680	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	: Where do we	7.7	31
1681	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Reviews, 2011, 37, 456-64.	Treatment	7.7	69
1682	Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic Treatment Reviews, 2011, 37, 599-610.	review. Cancer	7.7	27
1683	P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatme and Pharmacotherapy, 2011, 65, 151-156.	ent. Biomedicine	5.6	26
1684	Effect of gefitinib challenge to initial treatment with non-small cell lung cancer. Biome Pharmacotherapy, 2011, 65, 542-546.	dicine and	5.6	5
1685	Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lu and ovarian cancer: A systematic review. Drug Resistance Updates, 2011, 14, 177-190	ing cancer	14.4	50
1686	A Novel Peptide Probe for Imaging and Targeted Delivery of Liposomal Doxorubicin to Molecular Pharmaceutics, 2011, 8, 430-438.	Lung Tumor.	4.6	59
1687	EGFR and KRAS mutations in metastatic lung adenocarcinomas. Human Pathology, 20	11, 42, 1447-1453.	2.0	57
1688	Second-line treatment options in advanced non-small cell lung cancer. European Journ 2011, 47, S258-S271.	al of Cancer,	2.8	2

ARTICLE IF CITATIONS Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology, 2011, 18, 424-436. 2.5 37 1689 Cancer broncho-pulmonaire chez le non-fumeur., 2011, , 163-194. Gender and smoking differences in cell cycle marker expressions and p-TNM stage in non-small cell 1692 0.2 0 lung carcinoma. Basic and Applied Pathology, 2011, 4, 1-8. Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptorâ Etyrosine kinase inhibitor therapy and association with the characteristics of patients with 1.9 nonå€smallấ€cell lung cancer: A metaâ€analysis. Thoracic Cancer, 2011, 2, 101-108. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor 1694 2.0 45 receptor (EGFR) mutations. Lung Cancer, 2011, 72, 333-339. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: Rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer, 2011, 74, 35-40. 64 Sex and Gender Differences in Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular 1696 0.6 57 Surgery, 2011, 23, 137-145. Prospective Study of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Concurrent With Individualized Radiotherapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung 0.8 57 Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e59-e65. Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in 1698 2.2 116 Advanced Non-Small-Cell Lung Cancer. Current Oncology, 2011, 18, 126-138. EGFR pathway in advanced non-small cell lung cancer. Frontiers in Bioscience - Scholar, 2011, S3, 1699 2.1 501-517. 1700 Systemic Therapy for Lung Cancer for the Radiation Oncologist. Medical Radiology, 2011, , 247-266. 0 0.1 Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma. Current Cancer Therapy Reviews, 2011, 7, 65-77. Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. Pharmacogenomics 1702 0.7 4 and Personalized Medicine, 2011, Volume 4, 1-9. Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. Journal of Lung Cancer, 1703 0.2 2011, 10, 1. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in Bioscience -1704 3.0 15 Landmark, 2011, 16, 1811. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. OncoTargets and Therapy, 1706 2.0 2011, 4, 43. Medical Management of Brain Metastases from Lung Cancer., 0, , . 1707 4 Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung 1708 Adenocarcinoma Refractory to Intermittently Administered Gefitinib. Case Reports in Pulmonology, 2011, 2011, 1-4.

#	Δρτιςι ε	IF	
π 1709	The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases. Pulmonary Medicine, 2011, 2011, 1-5.	1.9	25
1710	Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells. PLoS ONE, 2011, 6, e21428.	2.5	77
1711	Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction. PLoS ONE, 2011, 6, e23303.	2.5	50
1712	Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 1889-1894.	1.1	7
1713	EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells. Journal of Immunotherapy, 2011, 34, 372-381.	2.4	50
1714	Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer. Medicine (United States), 2011, 90, 168-170.	1.0	6
1715	Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 707-715.	1.1	160
1716	Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clinical Investigation, 2011, 1, 33-44.	0.0	2
1717	Long-term Outcome after Multidisciplinary Approach for Leptomeningeal Carcinomatosis in a Non-small Cell Lung Cancer Patient with Poor Performance Status. Internal Medicine, 2011, 50, 3019-3022.	0.7	8
1718	Mutations of the epidermal growth factor receptor gene in NSCLC patients. Oncology Letters, 2011, 2, 1233-1237.	1.8	19
1719	Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). Journal of Thoracic Oncology, 2011, 6, 1872-1880.	1.1	132
1720	Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 1016-1021.	1.1	18
1721	Pitfalls in the Design, Analysis, Presentation, and Interpretation of Randomized Clinical Trials. Medical Radiology, 2011, , 819-826.	0.1	0
1723	Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology, 2011, 6, 1413-1417.	1.1	53
1724	Comparison of Nedaplatin and Irinotecan for Patients with Squamous and Nonsquamous Cell Carcinoma of the Lung: Meta-Analysis of Four Trials. Journal of Thoracic Oncology, 2011, 6, 128-131.	1.1	8
1725	Targeted therapy: An evolving world of lung cancer. Respirology, 2011, 16, 13-21.	2.3	21
1726	KLâ€6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced nonâ€small cell lung cancer. Respirology, 2011, 16, 976-982.	2.3	9
1727	Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Ecological Management and Restoration, 2011, 24, 374-380.	0.4	24

#	Article	IF	CITATIONS
1728	Synthesis and Studies on Threeâ€Compartment Flavoneâ€Containing Combiâ€Molecules Designed to Target EGFR, DNA, and MEK. Chemical Biology and Drug Design, 2011, 77, 309-318.	3.2	3
1729	Detection of low-level EGFR T790M mutation in lung cancer tissues. Apmis, 2011, 119, 403-411.	2.0	27
1730	Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1. Oncogene, 2011, 30, 3821-3832.	5.9	26
1731	Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report. Journal of Medical Case Reports, 2011, 5, 553.	0.8	3
1732	Lung cancer: New biological insights and recent therapeutic advances. Ca-A Cancer Journal for Clinicians, 2011, 61, 91-112.	329.8	413
1733	Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy. Clinical Lung Cancer, 2011, 12, 56-61.	2.6	7
1734	Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 1-9.	4.4	42
1735	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine, 2011, 5, 413-424.	2.5	24
1736	Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i> -Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. Clinical Cancer Research, 2011, 17, 6298-6303.	7.0	383
1737	Multi-targeted therapies in non-small cell lung cancer. Clinical Oncology and Cancer Research, 2011, 8, 220-223.	0.1	0
1738	Gender and haemato-oncology: Aspects of pharmacokinetics and pharmacodynamics. Memo - Magazine of European Medical Oncology, 2011, 4, 227-231.	0.5	0
1739	Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: Report of a case. Surgery Today, 2011, 41, 255-257.	1.5	3
1740	The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma. Surgery Today, 2011, 41, 818-823.	1.5	4
1741	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. European Respiratory Journal, 2011, 37, 183-193.	6.7	37
1742	Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast Cancer Research and Treatment, 2011, 128, 165-170.	2.5	3
1743	The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2011, 137, 687-694.	2.5	34
1744	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1397-1408.	2.5	17
1745	The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials. Lung, 2011, 189, 437-443.	3.3	29

#	Article	IF	CITATIONS
1746	Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 331-338.	2.3	16
1747	Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemotherapy and Pharmacology, 2011, 67, 837-845.	2.3	54
1748	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology, 2011, 68, 1485-1495.	2.3	28
1749	The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Medical Oncology, 2011, 28, 697-702.	2.5	42
1751	Pulmonary toxicities from targeted therapies: a review. Targeted Oncology, 2011, 6, 235-243.	3.6	94
1752	EGFR inhibitor enhances cisplatin sensitivity of human glioma cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 773-778.	1.0	11
1753	Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 2011, 11, 1.	2.6	260
1754	KRAS and BRAF: drug targets and predictive biomarkers. Journal of Pathology, 2011, 223, 220-230.	4.5	133
1755	Insulinâ€like growth factorâ€1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Journal of Pathology, 2011, 225, 83-95.	4.5	43
1756	Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer, 2011, 117, 3069-3080.	4.1	18
1757	Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial. International Journal of Radiation Oncology Biology Physics, 2011, 80, 126-132.	0.8	46
1758	Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology Biology Physics, 2011, 80, 347-353.	0.8	146
1759	First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan. Clinical Lung Cancer, 2011, 12, 116-124.	2.6	6
1760	Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2155-2161.	2.3	30
1761	"Un-Slugging―Resistance to Epidermal Growth Factor Receptor Inhibition. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 970-972.	5.6	1
1762	EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors. Current Cancer Drug Targets, 2011, 11, 1082-1097.	1.6	38
1763	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Annals of Pharmacotherapy, 2011, 45, 263-275.	1.9	0
1764	Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer. Current Medicinal Chemistry, 2011, 18, 4440-4453.	2.4	22

#	Article	IF	CITATIONS
1765	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. Current Drug Targets, 2011, 12, 922-933.	2.1	25
1766	Chemotherapy for Non-Small-Cell Lung Carcinoma: From a Blanket Approach to Individual Therapy. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 078-093.	2.1	14
1767	Bronchioloalveolar Carcinoma. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 052-061.	2.1	10
1768	EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. Journal of Clinical Pathology, 2011, 64, 884-892.	2.0	32
1769	Gefitinib for non-small-cell lung cancer treatment. Expert Opinion on Drug Safety, 2011, 10, 987-996.	2.4	13
1770	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	2.0	91
1771	EGFR Mutant Lung Cancer. Current Topics in Microbiology and Immunology, 2011, 355, 59-81.	1.1	8
1772	Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy, 2011, 3, 107-116.	2.0	13
1773	Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma. Oncology Letters, 2011, 2, 257-264.	1.8	10
1774	The Effects of Artesunate on the Expression of EGFR and ABCG2 in A549 Human Lung Cancer Cells and a Xenograft Model. Molecules, 2011, 16, 10556-10569.	3.8	52
1775	EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment. Cancer Research, 2011, 71, 1103-1114.	0.9	249
1776	Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1307-1315.	3.7	27
1777	The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab. Clinical Cancer Research, 2011, 17, 6766-6777.	7.0	30
1778	Gefitinib in Non Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-14.	3.0	19
1779	MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-15.	3.0	12
1780	Deciphering Squamous Cell Carcinoma Using Multidimensional Genomic Approaches. Journal of Skin Cancer, 2011, 2011, 1-16.	1.2	9
1781	Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With <i>EGFR</i> -Activating Mutations. Journal of Clinical Oncology, 2011, 29, 3435-3442.	1.6	33
1782	Gefitinib versus Docetaxel for Previously Treated NSCLC—Response. Clinical Cancer Research, 2011, 17, 4611-4611.	7.0	0

#	Article	IF	CITATIONS
1783	Monitoring Response to Antiangiogenic Therapy in Non–Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI. Journal of Nuclear Medicine, 2011, 52, 48-55.	5.0	98
1784	Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncology Reports, 2011, 26, 877-85.	2.6	16
1785	Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer. Oncology Reports, 2011, 26, 795-803.	2.6	14
1786	Three Cheers for Targeted Therapy in Non-Small Cell Lung Cancer… When We Hit the Target!. Journal of Chemotherapy, 2011, 23, 245-246.	1.5	3
1787	Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1603-1608.	7.1	89
1788	Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders. Molecular Pharmacology, 2011, 80, 466-475.	2.3	43
1789	Corneal Complications in Streptozocin-Induced Type I Diabetic Rats. , 2011, 52, 6589.		80
1790	Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British Journal of Cancer, 2011, 105, 1131-1136.	6.4	10
1791	PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. British Journal of Cancer, 2011, 105, 1850-1855.	6.4	68
1792	Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 993-999.	2.4	5
1793	Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	108
1794	Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients. Japanese Journal of Clinical Oncology, 2011, 41, 1366-1372.	1.3	14
1795	Target Therapies in Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-5.	3.0	9
1796	The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1498-1507.	3.7	44
1797	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. Cancers, 2011, 3, 2014-2031.	3.7	29
1798	Whole-Body Biodistribution Kinetics, Metabolism, and Radiation Dosimetry Estimates of ¹⁸ F-PEG ₆ -IPQA in Nonhuman Primates. Journal of Nuclear Medicine, 2011, 52, 934-941.	5.0	15
1799	Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	2
1800	A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology, 2012, 19, 78-90.	2.2	9

#	Article	IF	CITATIONS
1801	Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmacogenomics and Personalized Medicine, 2012, 5, 113.	0.7	18
1802	Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7340.	1.3	32
1803	Design and Evaluation of Multiregional Trials with Heterogeneous Treatment Effect Across Regions. Journal of Biopharmaceutical Statistics, 2012, 22, 1037-1050.	0.8	15
1804	The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. OncoTargets and Therapy, 2012, 5, 349.	2.0	12
1805	Targeted Therapy for Brain Metastases. Advances in Pharmacology, 2012, 65, 109-142.	2.0	11
1806	Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung. Clinical Cancer Research, 2012, 18, 220-228.	7.0	88
1807	Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics, 2012, 11, 795-804.	4.1	79
1808	Personalized management of patients with solid cancers. Current Opinion in Oncology, 2012, 24, 297-304.	2.4	16
1809	Neuropilin-1–Dependent Regulation of EGF-Receptor Signaling. Cancer Research, 2012, 72, 5801-5811.	0.9	84
1810	The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation. Current Medicinal Chemistry, 2012, 19, 3337-3352.	2.4	35
1811	Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S55-S60.	3.4	5
1812	Targeted Therapies for Advanced Non-Small Cell Lung Cancer. Combinatorial Chemistry and High Throughput Screening, 2012, 15, 641-655.	1.1	2
1813	Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Review of Anticancer Therapy, 2012, 12, 1479-1495.	2.4	37
1814	Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer. Onkologie, 2012, 35, 6-6.	0.8	14
1815	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncology, 2012, 8, 451-462.	2.4	48
1816	Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Current Medical Research and Opinion, 2012, 28, 1699-1708.	1.9	10
1817	Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence. Clinical Investigation, 2012, 2, 317-325.	0.0	5
1818	Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases. Journal of Biological Chemistry, 2012, 287, 6113-6127.	3.4	11

#	Article	IF	CITATIONS
1819	Molecular targets in melanoma: time for â€~ethnic personalization'. Expert Review of Anticancer Therapy, 2012, 12, 601-608.	2.4	8
1820	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. OncoTargets and Therapy, 2012, 5, 439.	2.0	35
1821	Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemotherapy Research and Practice, 2012, 2012, 1-10.	1.6	39
1822	Perforating Corneal Ulceration in a Patient with Lung Metastatic Adenocarcinoma Treated with Gefitinib: A Case Report. Case Reports in Ophthalmological Medicine, 2012, 2012, 1-3.	0.5	10
1823	Research progress on criteria for discontinuation of EGFR inhibitor therapy. OncoTargets and Therapy, 2012, 5, 263.	2.0	5
1824	Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC. Japanese Journal of Clinical Oncology, 2012, 42, 528-533.	1.3	28
1825	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. Oncologist, 2012, 17, 555-568.	3.7	44
1826	Molecular Characterization by Immunocytochemistry of Lung Adenocarcinoma on Cytology Specimens. Acta Cytologica, 2012, 56, 603-610.	1.3	25
1827	Detection of EGFR Somatic Mutations in Non-Small Cell Lung Cancer (NSCLC) Using a Novel Mutant-Enriched Liquidchip (MEL) Technology. Current Drug Metabolism, 2012, 13, 1007-1011.	1.2	11
1828	Small Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy. Letters in Drug Design and Discovery, 2012, 9, 84-125.	0.7	4
1829	Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomarkers, 2012, 10, 63-69.	1.7	41
1830	Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anti-Cancer Drugs, 2012, 23, 288-297.	1.4	21
1831	Targeted therapy for lung cancer. Anti-Cancer Drugs, 2012, 23, 1016-1021.	1.4	27
1832	Addition of vandetanib to chemotherapy in advanced solid cancers. Anti-Cancer Drugs, 2012, 23, 731-738.	1.4	8
1834	Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. Oncology Letters, 2012, 3, 1064-1068.	1.8	4
1835	Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2012, 7, 40-48.	1.1	40
1837	Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA. Journal of Thoracic Oncology, 2012, 7, 1369-1381.	1.1	68
1838	EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2012, 7, 1131-1140.	1.1	43

#	Article	IF	CITATIONS
1839	Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR). Journal of Thoracic Oncology, 2012, 7, 1296-1303.	1.1	73
1840	First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study. Journal of Thoracic Oncology, 2012, 7, 1417-1422.	1.1	140
1841	Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer, 2012, 78, 207-211.	2.0	35
1842	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumor Biology, 2012, 33, 2061-2068.	1.8	30
1843	EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment. Lung Cancer, 2012, 77, 2-8.	2.0	62
1844	Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 2069-2077.	2.5	31
1845	Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study. Tumor Biology, 2012, 33, 1341-1348.	1.8	17
1846	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da Associação Médica Brasileira, 2012, 58, 263-268.	0.7	6
1847	The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. Journal of Infection and Public Health, 2012, 5, S50-S60.	4.1	25
1848	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da Associação Médica Brasileira (English Edition), 2012, 58, 263-268.	0.1	0
1849	Targeted therapy of non-small-cell lung carcinoma. Therapeutic Advances in Respiratory Disease, 2012, 6, 41-56.	2.6	4
1850	Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR). Journal of Clinical Oncology, 2012, 30, 1114-1121.	1.6	233
1851	Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respiratory Medicine, 2012, 106, 173-183.	2.9	67
1852	Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells. Life Sciences, 2012, 90, 770-775.	4.3	21
1853	Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treatment Reviews, 2012, 38, 194-202.	7.7	6
1854	Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treatment Reviews, 2012, 38, 505-514.	7.7	53
1855	Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. BMC Cancer, 2012, 12, 185.	2.6	16
1856	Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology, 2012, 9, 208-214.	27.6	46

#	Article	IF	CITATIONS
1857	Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 15-31.	3.4	688
1858	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics: Targets and Therapy, 2012, 6, 337.	3.2	46
1859	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 771-781.	3.4	28
1860	Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomedicine and Pharmacotherapy, 2012, 66, 384-389.	5.6	30
1861	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology, 2012, 83, 407-421.	4.4	151
1862	Cancer chemotherapy: A critical analysis of its 60 years of history. Critical Reviews in Oncology/Hematology, 2012, 84, 181-199.	4.4	87
1863	Ethnic variation in response to EGFR inhibitors. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e61-e66.	0.5	1
1865	Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer, 2012, 75, 82-88.	2.0	94
1866	Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 2012, 76, 177-182.	2.0	119
1867	Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer, 2012, 77, 299-305.	2.0	49
1868	A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer, 2012, 78, 39-44.	2.0	19
1869	Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients. Clinical Chemistry and Laboratory Medicine, 2012, 50, 565-72.	2.3	5
1870	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2012, 12, 1429-1435.	2.4	35
1871	Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Medical Oncology, 2012, 29, 1614-1621.	2.5	18
1872	Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies. BioDrugs, 2012, 26, 83-99.	4.6	33
1873	Molecular Pathology of Lung Cancer. Molecular Pathology Library, 2012, , .	0.1	6
1874	Sex and Gender Differences in Pharmacology. Handbook of Experimental Pharmacology, 2012, , .	1.8	36
1875	Tyrosine Kinase Inhibitors in Lung Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 589-605.	2.2	32

#	Article	IF	CITATIONS
1876	Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells. PLoS ONE, 2012, 7, e41017.	2.5	62
1877	Non-small cell lung cancer: the era of targeted therapy. Lung Cancer: Targets and Therapy, 2012, 3, 31.	2.7	8
1878	Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2012, 2, 35-49.	2.5	6
1879	Gefitinib, but Not Erlotinib, is a Possible Inducer of Fra-1-mediated Interstitial Lung Disease. Keio Journal of Medicine, 2012, 61, 120-127.	1.1	5
1880	The place of TKI in the treatment of EGFR mutation-positive lung cancer. Journal of Solid Tumors, 2012, 2, .	0.1	0
1881	EGFRPolymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated withEGFR-TKI. Yonsei Medical Journal, 2012, 53, 1128.	2.2	23
1882	A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer. Experimental and Therapeutic Medicine, 2012, 3, 53-59.	1.8	1
1883	Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE). Tuberculosis and Respiratory Diseases, 2012, 73, 303.	1.8	6
1884	Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland. Wspolczesna Onkologia, 2012, 2, 170-175.	1.4	6
1885	Targeted therapy for esophagogastric cancers: a review. OncoTargets and Therapy, 2012, 5, 91.	2.0	0
1886	Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemotherapy and Pharmacology, 2012, 69, 1289-1299.	2.3	38
1887	The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer, 2012, 12, 553-563.	28.4	766
1888	Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis. Hematological Oncology, 2012, 30, 89-97.	1.7	31
1889	Mutational analysis of <i>MED12</i> exon 2 in uterine leiomyoma and other common tumors. International Journal of Cancer, 2012, 131, E1044-7.	5.1	128
1890	Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012, 30, 433-446.	1.3	58
1891	A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Investigational New Drugs, 2012, 30, 1684-1689.	2.6	37
1892	Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Medical Oncology, 2012, 29, 957-961.	2.5	9
1893	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemotherapy and Pharmacology, 2012, 69, 891-899.	2.3	77

#	Article	IF	CITATIONS
1894	Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 181-187.	2.6	40
1895	Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2012, 13, 267-279.	2.6	21
1896	Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochemical Pharmacology, 2012, 83, 1340-1348.	4.4	67
1897	Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 267-274.	1.1	3
1898	Phase III, randomized, openâ€label, firstâ€line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonâ€smallâ€cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 232-243.	1.1	42
1899	Molecularly targeted therapies in cervical cancer. A systematic review. Gynecologic Oncology, 2012, 126, 291-303.	1.4	68
1900	Ligandâ€ŧriggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Science, 2012, 103, 1189-1194.	3.9	64
1901	Biomarkers and transcriptome profiling of lung cancer. Respirology, 2012, 17, 620-626.	2.3	20
1902	Translatability scoring in drug development: eight case studies. Journal of Translational Medicine, 2012, 10, 39.	4.4	37
1903	Costâ€effectiveness of epidermal growth factor receptor mutation testing and firstâ€ine treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer, 2012, 118, 1032-1039.	4.1	58
1904	Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response. Skeletal Radiology, 2012, 41, 409-414.	2.0	21
1905	Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology, 2012, 69, 273-280.	2.3	13
1906	A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 131, 899-906.	2.5	23
1907	Frequent <i>EGFR</i> mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. European Respiratory Journal, 2013, 41, 417-424.	6.7	41
1908	Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs. BMC Research Notes, 2013, 6, 139.	1.4	22
1909	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.	11.4	408
1910	The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Quality of Life Research, 2013, 22, 1015-1026.	3.1	13
1911	Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 322-332.	2.6	93

#	Article	IF	CITATIONS
1912	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 991-1003.	2.4	8
1913	Pd(0)-catalyzed benzylic arylation–oxidation of 4-methylquinazolines via sp3 C–H activation under air conditions. Organic and Biomolecular Chemistry, 2013, 11, 6246.	2.8	28
1914	KOtBu-mediated stereoselective addition of quinazolines to alkynes under mild conditions. Organic and Biomolecular Chemistry, 2013, 11, 5908.	2.8	35
1915	Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Molecular Cancer, 2013, 12, 76.	19.2	36
1916	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	1.6	1
1917	Apoptosis Induced by Benzyl Isothiocyanate in Gefitinib-Resistant Lung Cancer Cells is Associated with Akt/MAPK Pathways and Generation of Reactive Oxygen Species. Cell Biochemistry and Biophysics, 2013, 66, 81-92.	1.8	35
1918	EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1327-1335.	2.5	43
1919	Modeling NSCLC Progression: Recent Advances and Opportunities Available. AAPS Journal, 2013, 15, 542-550.	4.4	12
1920	Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 341-348.	2.3	1
1921	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. Cancer Chemotherapy and Pharmacology, 2013, 71, 705-711.	2.3	6
1922	Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. SpringerPlus, 2013, 2, 22.	1.2	7
1923	Response to First-Line Chemotherapy in Patients With Non–Small-Cell Lung Cancer According to Epidermal Growth Factor Receptor and K-RAS Mutation Status. Clinical Lung Cancer, 2013, 14, 680-687.	2.6	19
1924	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treatment Reviews, 2013, 39, 839-850.	7.7	100
1925	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. Expert Opinion on Drug Discovery, 2013, 8, 1381-1397.	5.0	6
1926	Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines. Science Signaling, 2013, 6, ra84.	3.6	90
1927	Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non–Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 2013, 14, 609-626.	2.6	15
1928	Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biology of Sex Differences, 2013, 4, 17.	4.1	29
1929	Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Investigational New Drugs, 2013, 31, 525-534.	2.6	12

ARTICLE IF CITATIONS Treatment Outcomes in Elderly with Advanced-Stage Non-small Cell Lung Cancer. Lung, 2013, 191, 1930 3.3 8 645-654. Scalp Pustules in a Patient Receiving Chemotherapy. JAMA - Journal of the American Medical 7.4 Association, 2013, 310, 1068. Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics, 2013, 35, 1932 2.581 1282-1303. Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 1061-1069. Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. 1934 2.8 87 European Journal of Cancer, 2013, 49, 1216-1225. Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer. Advances in Experimental 1.6 Medicine and Biology, 2013, 779, 145-164. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies 1936 2.0 102 with histological subtypes and graduated smoking dose. Lung Cancer, 2013, 79, 8-13. Epidermal Growth Factor Receptor Exon 20 Mutation Increased inPost-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples. Translational Oncology, 2013, 6, 9 3.7 504-510. The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor 1938 Family Inhibitors in Nonâ€"Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clinical Lung 2.6 11 Cancer, 2013, 14, 311-321. Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity. Clinical Lung Cancer, 2013, 14, 1939 2.6 502-507 Salivary gland cancer stem cells. Oral Oncology, 2013, 49, 845-853. 1940 1.5 50 Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients 1941 2.0 with stage IIIB or IV non-small-cell lung cancer. Lung Cancer, 2013, 80, 319-325. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. 1942 1.4 42 Journal of the Chinese Medical Association, 2013, 76, 249-257. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2013, 69, 708-720. 1943 1.2 94 Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring 1944 2.0 28 EGFR mutations. Lung Cancer, 2013, 81, 435-439. Tumor response and health-related quality of life in clinically selected patients from Asia with 1945 advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the 2.0 44 IPASS study. Lung Cancer, 2013, 81, 280-287. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib. Gene, 1946 2.222 2013, 517, 60-64. 1947 Epidemiology and Outcomes of Regimen-Related Toxicities., 2013, , 3-17.

#	Article	IF	CITATIONS
1948	Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1325-1334.	2.3	24
1949	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2013, 39, 252-260.	7.7	68
1950	Sex Differences in the Drug Therapy for Oncologic Diseases. Handbook of Experimental Pharmacology, 2013, , 411-442.	1.8	70
1953	Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene, 2013, 32, 2346-2355.	5.9	36
1954	Kinase Inhibitors of Marine Origin. Chemical Reviews, 2013, 113, 6761-6815.	47.7	112
1955	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. Cancer Treatment Reviews, 2013, 39, 489-497.	7.7	26
1956	Incorporating Pharmacogenomics in Drug Development. , 2013, , 343-366.		0
1957	EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance. Current Oncology Reports, 2013, 15, 396-404.	4.0	25
1958	Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials. Clinical Lung Cancer, 2013, 14, 14-18.	2.6	30
1959	Prognostic factors for patients with solitary bone metastasis. International Journal of Clinical Oncology, 2013, 18, 164-169.	2.2	9
1960	Gastric Perforation Secondary to Regression of Lung Adenocarcinoma After Gefitinib Treatment. Journal of Clinical Oncology, 2013, 31, e6-e8.	1.6	9
1961	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	1.9	24
1962	Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genetics in Medicine, 2013, 15, 630-638.	2.4	30
1963	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncology, 2013, 9, 327-345.	2.4	8
1964	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. Journal of Carcinogenesis, 2013, 12, 7.	2.5	10
1965	Lung Cancer in Women: Differences in Epidemiology, Biology, Histology, and Treatment Outcomes. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 792-801.	2.1	36
1966	Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR Kinase Using PET with [¹²⁴ 1]-Morpholino-IPQA. BioMed Research International, 2013, 2013, 1-10.	1.9	9
1967	Subtyping Non–Small Cell Lung Cancer. International Journal of Surgical Pathology, 2013, 21, 326-336.	0.8	35

#	Article	IF	CITATIONS
1968	Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian Journal of Cancer, 2013, 50, 87.	0.2	23
1969	Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. Clinical Investigation, 2013, 3, 29-35.	0.0	1
1970	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Therapeutic Drug Monitoring, 2013, 35, 562-587.	2.0	77
1971	Can Serum be Used for Analyzing the EGFR Mutation Status in Patients with Advanced Non-small Cell Lung Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 57-63.	1.3	23
1972	A Comparison of Methods for EGFR Mutation Testing in Non–Small Cell Lung Cancer. Diagnostic Molecular Pathology, 2013, 22, 190-195.	2.1	27
1973	Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer. Anti-Cancer Drugs, 2013, 24, 731-735.	1.4	8
1974	Personalized Treatment of Lung Adenocarcinoma. Clinical Pulmonary Medicine, 2013, 20, 309-314.	0.3	1
1975	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 263-271.	2.0	4
1976	Second-Line Therapy for Advanced NSCLC. Oncologist, 2013, 18, 947-953.	3.7	36
1977	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , .		5
1977 1978	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , . Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326.	1.6	5 327
1977 1978 1979	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , . Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270.	1.6 3.2	5 327 38
1977 1978 1979 1980	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , . Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270. Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. Molecular Cancer Therapeutics, 2013, 12, 925-936.	1.6 3.2 4.1	5 327 38 69
1977 1978 1979 1980 1981	Pathobiology of Cancer Regimen-Related Toxicities., 2013, , . Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270. Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. Molecular Cancer Therapeutics, 2013, 12, 925-936. USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research, 2013, 19, 3894-3904.	1.6 3.2 4.1 7.0	5 327 38 69 112
1977 1978 1979 1980 1981	Pathobiology of Cancer Regimen-Related Toxicities., 2013, . Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270. Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. Molecular Cancer Therapeutics, 2013, 12, 925-936. USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research, 2013, 19, 3894-3904. Stratified medicine: drugs meet genetics. European Respiratory Review, 2013, 22, 53-57.	1.6 3.2 4.1 7.0 7.1	5 327 38 69 112 15
1977 1978 1979 1980 1981 1982	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , . Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270. Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. Molecular Cancer Therapeutics, 2013, 12, 925-936. USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research, 2013, 19, 3894-3904. Stratified medicine: drugs meet genetics. European Respiratory Review, 2013, 22, 53-57. The Effectiveness of Erlotinib Against Brain Metastases in Non-Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 110-115.	1.6 3.2 4.1 7.0 7.1	5 327 38 69 112 15 32
1977 1978 1979 1980 1981 1982 1983	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , . Gefitinib Versus Placebo in Completely Resected Nonâć ⁴⁵ Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. Journal of Clinical Oncology, 2013, 31, 3320-3326. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Therapeutic Advances in Medical Oncology, 2013, 5, 249-270. Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. Molecular Cancer Therapeutics, 2013, 12, 925-936. USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research, 2013, 19, 3894-3904. Stratified medicine: drugs meet genetics. European Respiratory Review, 2013, 22, 53-57. The Effectiveness of Erlotinib Against Brain Metastases in Non-Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 110-115. Nonsmall Cell Lung Cancer Therapy: Insight into Multitargeted Small-Molecule Growth Factor Receptor Inhibitors. BioMed Research International, 2013, 2013, 1-11.	1.6 3.2 4.1 7.0 7.1 1.3 1.9	5 327 38 69 112 15 32 18

#	Article	IF	CITATIONS
1986	SCUBE3 overexpression predicts poor prognosis in non-small cell lung cancer. BioScience Trends, 2013, , .	3.4	9
1987	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptorâ€mutated lung cancer model. Cancer Science, 2013, 104, 1440-1446.	3.9	34
1988	<scp>EGFR</scp> and <scp>KRAS</scp> mutation analyses from specimens obtained by bronchoscopy and <scp>EBUSâ€TBNA</scp> . Thoracic Cancer, 2013, 4, 264-272.	1.9	8
1989	Subtyping of pulmonary adenocarcinoma in cytologic specimens. Cancer Cytopathology, 2013, 121, 601-604.	2.4	5
1991	Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study. Thoracic Cancer, 2013, 4, 109-116.	1.9	7
1992	Classification and regression tree analysis of patients with nonâ€smallâ€cell lung cancer treated with gefitinib after chemotherapy. Thoracic Cancer, 2013, 4, 280-286.	1.9	2
1993	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. Oncology Reports, 2013, 30, 1463-1472.	2.6	6
1994	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 75-85.	1.5	0
1995	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1069-1074.	1.1	110
1996	Gefitinib: re-emerging from the shadows. Lung Cancer Management, 2013, 2, 423-437.	1.5	0
1997	Identification of Stage I Non-small Cell Lung Cancer Patients at High Risk for Local Recurrence Following Sublobar Resection. Chest, 2013, 143, 1365-1377.	0.8	34
1998	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	1.1	113
1999	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 161-169.	4.9	64
2000	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. Journal of Cancer, 2013, 4, 736-754.	2.5	77
2001	The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology. Yonsei Medical Journal, 2013, 54, 1.	2.2	18
2002	The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction. OncoTargets and Therapy, 2013, 6, 603.	2.0	10
2003	A multiple cavity malignancy involving the renal capsule, pleura and meninges: A case report and review of the literature. Oncology Letters, 2013, 6, 709-712.	1.8	2
2004	Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncology Letters, 2013, 5, 435-439.	1.8	11
#	Article	IF	Citations
------	---	-----	-----------
2005	Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e52093.	2.5	108
2006	Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab. PLoS ONE, 2013, 8, e56112.	2.5	32
2007	Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors. PLoS ONE, 2013, 8, e56704.	2.5	10
2008	mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF. PLoS ONE, 2013, 8, e62104.	2.5	32
2009	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS ONE, 2013, 8, e68966.	2.5	31
2010	Quantitative Proteomic Analysis of Human Lung Tumor Xenografts Treated with the Ectopic ATP Synthase Inhibitor Citreoviridin. PLoS ONE, 2013, 8, e70642.	2.5	26
2011	Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer. PLoS ONE, 2013, 8, e59183.	2.5	30
2012	Identification of candidate genes for lung cancer somatic mutation test kits. Genetics and Molecular Biology, 2013, 36, 455-464.	1.3	19
2014	Tyrosine-kinase inhibitors in oncology. , 0, , 872-883.		0
2015	Lung Cancer in Women. Southern Medical Journal, 2013, 106, 582-587.	0.7	6
2016	Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. OncoTargets and Therapy, 2014, 7, 353.	2.0	9
2017	In-Depth Analysis Shows Synergy between Erlotinib and miR-34a. PLoS ONE, 2014, 9, e89105.	2.5	62
2018	Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e103305.	2.5	98
2019	Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. OncoTargets and Therapy, 2014, 7, 841.	2.0	14
2020	Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Design, Development and Therapy, 2014, 8, 1037.	4.3	9
2021	Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. Lung Cancer: Targets and Therapy, 2014, 5, 73.	2.7	3
2022	Phase II Clinical Trial of Gefitinib for the Treatment of ChemonaÃ ⁻ ve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S15172.	1.3	4
2023	Molecular Targeted Therapy in Lung Cancer. Hanyang Medical Reviews, 2014, 34, 37.	0.4	1

#	Article	IF	CITATIONS
2024	The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro. Journal of Molecular Histology, 2014, 45, 641-652.	2.2	8
2025	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer Chemotherapy and Pharmacology, 2014, 74, 939-946.	2.3	10
2026	Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. Langenbeck's Archives of Surgery, 2014, 399, 879-888.	1.9	7
2027	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Translational Respiratory Medicine, 2014, 2, 9.	3.8	12
2028	Afatinib and lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1391-1406.	2.4	13
2029	First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. European Respiratory Review, 2014, 23, 92-105.	7.1	43
2030	Kinase Inhibitors in Cancer. , 2014, , .		4
2031	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British Journal of Cancer, 2014, 110, 55-62.	6.4	351
2032	Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. Acta Pharmacologica Sinica, 2014, 35, 373-380.	6.1	15
2033	Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Current Oncology, 2014, 21, 329-336.	2.2	81
2034	The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials. Indian Journal of Cancer, 2014, 51, 86.	0.2	1
2035	Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement. Oncology Letters, 2014, 8, 2155-2159.	1.8	4
2036	Gefitinib-induced interstitial pneumonia: A case report and review of the literature. Experimental and Therapeutic Medicine, 2014, 7, 855-859.	1.8	8
2037	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology, 2014, 4, 204.	2.8	137
2038	Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies ââ,¬â€œ Past, Present, and Future. Frontiers in Oncology, 2014, 4, 233.	2.8	15
2039	A comparison of consistency of detecting BRAF gene mutations in peripheral blood and tumor tissue of nonsmall-cell lung cancer patients. Journal of Cancer Research and Therapeutics, 2014, 10, 150.	0.9	3
2040	Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Medicine Reports, 2014, 10, 931-938.	2.4	26
2041	The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Science Signaling, 2014, 7, ra78.	3.6	34

#	Article	IF	CITATIONS
2043	Visual DNA microarray for detection of epidermal growth factor receptor (EGFR) gene mutations. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 693-699.	1.2	6
2044	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2693-2708.	1.8	20
2045	Molecular alterations in nonâ€smallâ€cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist. Respirology, 2014, 19, 1117-1125.	2.3	15
2046	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. Advances in Experimental Medicine and Biology, 2014, 799, 85-117.	1.6	98
2047	Factors associated with early progression of nonâ€smallâ€cell lung cancer treated by epidermal growth factor receptor tyrosineâ€kinase inhibitors. Cancer Medicine, 2014, 3, 61-69.	2.8	6
2048	Correlation of Cytomorphology and Molecular Findings in EGFR+, KRAS+, and ALK+ Lung Carcinomas. American Journal of Clinical Pathology, 2014, 141, 420-428.	0.7	21
2049	Antiâ€tumor activity of <scp>WK</scp> 88â€1, a novel geldanamycin derivative, in gefitinibâ€resistant nonâ€small cell lung cancers with Met amplification. Cancer Science, 2014, 105, 1245-1253.	3.9	22
2050	Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. Xenobiotica, 2014, 44, 1083-1098.	1.1	4
2051	Paris saponin l induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. Molecular Medicine Reports, 2014, 9, 2265-2272.	2.4	89
2052	Erlotinib. Recent Results in Cancer Research, 2014, 201, 109-123.	1.8	13
2053	Review of EGFRââ,¬â€°TKIs in Metastatic NSCLC, Including Ongoing Trials. Frontiers in Oncology, 2014, 4, 244.	2.8	55
2054	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. Journal of Hematology and Oncology, 2014, 7, 22.	17.0	29
2055	Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21. Journal of Thoracic Oncology, 2014, 9, 506-511.	1.1	44
2056	Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review. Journal of Thoracic Oncology, 2014, 9, 1180-1186.	1.1	25
2057	Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer, 2014, 83, 316-323.	2.0	40
2058	Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer. Seminars in Oncology, 2014, 41, 101-109.	2.2	19
2059	Extending Survival of Stage IV Non-Small Cell Lung Cancer. Seminars in Oncology, 2014, 41, 69-92.	2.2	34
2060	Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer. Seminars in Oncology, 2014, 41, 57-68.	2.2	18

# 2061	ARTICLE Application of Translational Science to Clinical Development. , 2014, , 1-21.	IF	CITATIONS
2062	Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells. Annals of Surgical Oncology, 2014, 21, 555-563.	1.5	25
2063	Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. Lung Cancer, 2014, 83, 252-258.	2.0	18
2064	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer, 2014, 83, 231-239.	2.0	99
2065	Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer. Medical Oncology, 2014, 31, 893.	2.5	6
2066	Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Supportive Care in Cancer, 2014, 22, 1417-1428.	2.2	33
2067	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 145-153.	2.6	23
2068	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Critical Reviews in Oncology/Hematology, 2014, 89, 300-313.	4.4	68
2069	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. Journal of Pathology, 2014, 232, 274-282.	4.5	48
2070	Targeted therapy-induced diarrhea: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 165-179.	4.4	47
2071	Over-Expression of Egfr is Closely Correlated to Poor Prognosis in Tunisian Patients with Non-Small Cell Lung Adenocarcinoma. Journal of Immunoassay and Immunochemistry, 2014, 35, 256-268.	1.1	11
2073	Carcinome bronchique non à petites cellules : quelle chimiothérapie de rattrapage ?. Revue Des Maladies Respiratoires Actualites, 2014, 6, 442-452.	0.0	0
2074	European perspective for effective cancer drug development. Nature Reviews Clinical Oncology, 2014, 11, 492-498.	27.6	42
2075	In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor. Medicinal Chemistry Research, 2014, 23, 5074-5085.	2.4	49
2076	Update on systemic therapy of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1189-1203.	2.4	31
2077	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1333-1348.	4.1	48
2078	The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Medical Oncology, 2014, 31, 209.	2.5	22
2079	Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Medical Oncology, 2014, 31, 228.	2.5	23

#	Article	IF	CITATIONS
2080	Coadministration of Erlotinib and Curcumin Augmentatively Reduces Cell Viability in Lung Cancer Cells. Phytotherapy Research, 2014, 28, 728-735.	5.8	27
2081	EGFR inhibitors and autophagy in cancer treatment. Tumor Biology, 2014, 35, 11701-11709.	1.8	36
2082	Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1901-1909.	2.5	40
2083	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. Investigational New Drugs, 2014, 32, 946-954.	2.6	10
2084	Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. Pathology Research and Practice, 2014, 210, 155-160.	2.3	4
2085	Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation, 2014, 94, 129-137.	3.7	188
2086	Tilting the Balance of Dose Modification for Oral Anticancer Drugs?. Journal of Clinical Oncology, 2014, 32, 1537-1539.	1.6	10
2087	Ocular adverse events of molecularly targeted agents approved in solid tumours: A systematic review. European Journal of Cancer, 2014, 50, 638-648.	2.8	64
2088	Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respiratory Investigation, 2014, 52, 82-91.	1.8	31
2089	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Reviews, 2014, 40, 990-1004.	7.7	70
2090	Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: Implication of EGFR tyrosine kinase inhibitors. International Journal of Oncology, 2014, 44, 685-692.	3.3	6
2091	Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 576.	2.3	59
2092	Epidermal Growth Factor Receptor Inhibitors: Coming of Age. Cancer Control, 2014, 21, 74-79.	1.8	56
2094	Monitoring of Gefitinib Sensitivity with Radioiodinated PHY Based on EGFR Expression. Biological and Pharmaceutical Bulletin, 2014, 37, 355-360.	1.4	5
2095	SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncology Reports, 2014, 32, 2612-2618.	2.6	10
2096	Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. Oncology Reports, 2014, 32, 1401-1408.	2.6	6
2097	A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy. Oncology Letters, 2014, 8, 1563-1566.	1.8	4
2098	Autophagy induction by low-dose cisplatin: The role of p53 in autophagy. Oncology Reports, 2014, 31, 248-254.	2.6	25

#	Article		CITATIONS
2099	Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR. Oncology Reports, 2014, 31, 2619-2624.		12
2100	Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. Molecular Medicine Reports, 2014, 9, 2417-2422.	2.4	14
2102	Advanced EGFR Mutation-Positive Non–Small-Cell Lung Cancer: Case Report, Literature Review, and Treatment Recommendations. Cancer Control, 2014, 21, 67-73.	1.8	16
2103	AG1478 inhibits the migration and invasion of cisplatin-resistant human lung adenocarcinoma cells via the cell cycle regulation by matrix metalloproteinase-9. Oncology Letters, 2014, 8, 921-927.	1.8	10
2104	Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy. Medicine (United) Tj ETQq0 0 () rg₿ @ /Ov	erlæck 10 Tf 5
2105	MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Molecular Medicine Reports, 2015, 11, 333-340.	2.4	19
2106	Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?. Lung Cancer, 2015, 90, 561-567.	2.0	8
2107	Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer. Medicine (United States), 2015, 94, e775.	1.0	59
2108	Implementation of modern therapy approaches and research for nonâ€small cell lung cancer in <scp>J</scp> apan. Respirology, 2015, 20, 199-208.	2.3	4
2110	Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis. Molecular and Clinical Oncology, 2015, 3, 403-407.	1.0	9
2111	The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. Scientific Reports, 2015, 5, 12675.	3.3	17
2112	Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment. Scientific Reports, 2015, 5, 10648.	3.3	7
2113	Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. Cancer Informatics, 2015, 14, CIN.S22941.	1.9	16
2114	Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncology Letters, 2015, 9, 2419-2421.	1.8	3
2115	Sulforaphane attenuates EGFR signaling in NSCLC cells. Journal of Biomedical Science, 2015, 22, 38.	7.0	31
2116	Multiple primary malignancies involving lung cancer. BMC Cancer, 2015, 15, 696.	2.6	57
2117	Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan. Radiation Oncology, 2015, 10, 127.	2.7	13
2118	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. Cancer Control, 2015, 22, 193-199.	1.8	23

#	Article		CITATIONS
2119	Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 661-671.		14
2120	FDG Uptake in Non–Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation Status. Clinical Nuclear Medicine, 2015, 40, 950-958.	1.3	47
2121	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Molecular Medicine Reports, 2015, 12, 187-191.	2.4	14
2122	Role of network biology and network medicine in early detection of cancer. , 0, , 457-463.		0
2123	Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. OncoTargets and Therapy, 2015, 8, 3665.	2.0	54
2124	Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. Thrombosis and Haemostasis, 2015, 114, 530-536.	3.4	17
2125	Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region. Molecular and Clinical Oncology, 2015, 3, 1371-1374.	1.0	19
2126	Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. Jornal Brasileiro De Pneumologia, 2015, 41, 365-375.	0.7	31
2127	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. OncoTargets and Therapy, 2015, 8, 1603.	2.0	9
2128	Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving <i>EGFR</i> . Oncotarget, 2015, 6, 5465-5474.	1.8	116
2130	Gefitinib and Sonidegib. Hospital Pharmacy, 2015, 50, 868-872.	1.0	0
2131	Squamous Non–small Cell Lung Cancer as a Distinct Clinical Entity. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 220-226.	1.3	25
2132	Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resistance Updates, 2015, 20, 12-28.	14.4	103
2133	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clinical Cancer Research, 2015, 21, 2221-2226.	7.0	72
2134	Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine, 2015, 45, 67-73.	6.4	42
2135	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	2.4	5
2136	Experience with erlotinib in the treatment of non-small cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 146-163.	2.6	25
2137	Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Experimental and Therapeutic Medicine, 2015, 9, 1383-1388.	1.8	78

#	Article		CITATIONS
2138	Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). Journal of Photochemistry and Photobiology B: Biology, 2015, 153, 380-390.		154
2139	Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the †Black Swan' events?. Future Oncology, 2015, 11, 2307-2314.	2.4	2
2140	Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. Oncology Research and Treatment, 2015, 38, 560-569.	1.2	5
2141	Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Targeted Oncology, 2015, 10, 153-170.	3.6	51
2142	Germline oncopharmacogenetics, a promising field in cancer therapy. Cellular Oncology (Dordrecht), 2015, 38, 65-89.	4.4	11
2143	CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab. Molecular Diagnosis and Therapy, 2015, 19, 79-89.	3.8	8
2144	Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights. Skin Appendage Disorders, 2015, 1, 31-37.	1.0	63
2145	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemotherapy and Pharmacology, 2015, 76, 251-256.	2.3	11
2146	Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. Materials, 2015, 8, 519-534.	2.9	6
2147	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review. Current Oncology, 2015, 22, 183-215.	2.2	59
2148	A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. European Journal of Cancer, 2015, 51, 1904-1910.	2.8	14
2149	Emerging treatment for advanced lung cancer with <i>EGFR</i> mutation. Expert Opinion on Emerging Drugs, 2015, 20, 597-612.	2.4	22
2150	CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines. Lung Cancer, 2015, 87, 265-271.	2.0	33
2151	Association Between Parkinson Disease and Risk of Cancer in Taiwan. JAMA Oncology, 2015, 1, 633.	7.1	66
2152	Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer. Medical Principles and Practice, 2015, 24, 486-490.	2.4	1
2153	Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma. Oncology Letters, 2015, 9, 257-261.	1.8	0
2154	Management of egfr tki—Induced Dermatologic Adverse Events. Current Oncology, 2015, 22, 123-132.	2.2	63
2155	Characterization of interaction of calf thymus DNA with gefitinib: Spectroscopic methods and molecular docking. Journal of Photochemistry and Photobiology B: Biology, 2015, 147, 47-55.	3.8	94

#	Article	IF	CITATIONS
2156	Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials. Oncologist, 2015, 20, 400-410.	3.7	123
2157	Boron-Based Drug Design. Chemical Record, 2015, 15, 616-635.	5.8	119
2158	Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecologic Oncology, 2015, 136, 491-497.	1.4	58
2159	Advances in the Chemopreventive Targeting of Oral Carcinogenesis. Current Oral Health Reports, 2015, 2, 63-72.	1.6	6
2160	Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. Oncology, 2015, 89, 175-186.	1.9	21
2161	Monitoring response to gefitinib in nude mouse tumor xenografts by 18 F-FDG microPET-CT: correlation between 18 F-FDG uptake and pathological response. World Journal of Surgical Oncology, 2015, 13, 111.	1.9	4
2162	The epidermal growth factor receptor (EGRF) in lung cancer. Translational Respiratory Medicine, 2015, 3, 1.	3.8	34
2163	Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2015, 72, 656-667.	1.2	39
2164	Histologic Classification and Its Need for Treatment of Lung Cancer. , 2015, , 1-14.		0
2165	Pattern recognition of HER-1 in biological fluids using stochastic sensing. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 283-285.	5.2	9
2166	Racial Differences in Lung Cancer Genetics. Journal of Thoracic Oncology, 2015, 10, 230-231.	1.1	6
2167	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2015, 45, 356-361.	1.3	6
2168	Management of EGFR mutated nonsmall cell lung carcinoma patients. European Respiratory Journal, 2015, 45, 1132-1141.	6.7	36
2169	A Novel and Efficient Synthesis of Anti-Cancer Agent, Mereletinib. Journal of Chemical Research, 2015, 39, 318-320.	1.3	4
2170	Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction. Cancer Chemotherapy and Pharmacology, 2015, 76, 713-721.	2.3	2
2171	Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. Seminars in Oncology, 2015, 42, S19-S28.	2.2	17
2172	Considerations on the management of EGF receptor-TKIs for brain metastases in <i>EGFR</i> -mutant lung carcinoma patients. Lung Cancer Management, 2015, 4, 43-49.	1.5	1
2173	Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung Cancer. Clinical Oncology, 2015, 27, 30-39.	1.4	25

# 2174	ARTICLE Assessment of the change in cetuximabâ€induced antibodyâ€dependent cellular cytotoxicity activity of natural killer cells by steroid. Head and Neck, 2016, 38, 410-416.	IF 2.0	CITATIONS
2175	Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. Chinese Medical Journal, 2016, 129, 332-340.	2.3	18
2176	Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget, 2016, 7, 73618-73637.	1.8	77
2177	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2016, 79, 248.	1.8	41
2178	IN SILICO IDENTIFICATION OF NOVEL EGFR TYROSINE KINASE INHIBITORS ASSOCIATED WITH NON-SMALL CELL LUNG CANCER FROM PHYTOCHEMICAL LIBRARY. International Research Journal of Pharmacy, 2016, 7, 22-25.	0.2	0
2179	A Hybrid Medical Image Compression Techniques for Lung Cancer. Indian Journal of Science and Technology, 2016, 9, .	0.7	4
2180	Virtual screening of natural compounds as inhibitors of EGFR 696-1022 T790M associated with non-small cell lung cancer. Bioinformation, 2016, 12, 311-317.	0.5	11
2181	Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy, 2016, 9, 1291.	2.0	8
2182	Evaluation of Scoring Systems and Prognostic Factors in Patients With Spinal Metastases From Lung Cancer. Spine, 2016, 41, 638-644.	2.0	23
2183	Kinases inhibitors in lung cancer: From benchside to bedside. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 128-140.	7.4	33
2184	Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data. Lung Cancer, 2016, 99, 69-75.	2.0	23
2185	Targeted therapies for treatment of nonâ€small cell lung cancer—Recent advances and future perspectives. International Journal of Cancer, 2016, 138, 2549-2561.	5.1	155
2186	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics, 2016, 38, 1567-1576.	2.5	11
2187	Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with nonâ€smallâ€cell lung cancer. Biomedical Chromatography, 2016, 30, 1150-1154.	1.7	33
2188	HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib. Oncology Letters, 2016, 12, 5363-5369.	1.8	3
2189	Relationship between miR-7 expression and treatment outcomes with gefitinib in non-small cell lung cancer. Oncology Letters, 2016, 12, 4613-4617.	1.8	7
2190	Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function. Oncology Reports, 2016, 36, 3251-3258.	2.6	14
2191	Circulating free DNA in the era of precision oncology: Pre―and postâ€analytical concerns. Chronic Diseases and Translational Medicine, 2016, 2, 223-230.	1.2	30

#	Article		CITATIONS
2192	Rationale of an economically driven PD1 biomarker development in lung cancer—an academic dilemma. Memo - Magazine of European Medical Oncology, 2016, 9, 109-110.		1
2194	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discovery Today, 2016, 21, 962-976.	6.4	46
2195	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Journal of Clinical Oncology, 2016, 34, 3248-3257.	1.6	130
2196	Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. Oncology Letters, 2016, 11, 535-542.	1.8	19
2197	Hepatotoxicity of targeted therapy for cancer. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 789-802.	3.3	16
2198	Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. Future Medicinal Chemistry, 2016, 8, 853-878.	2.3	15
2199	Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000.	2.4	14
2200	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. Clinical Cancer Research, 2016, 22, 2127-2132.	7.0	21
2201	Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage <scp>IIIA</scp> nonâ€small cell lung cancer in a single center. Thoracic Cancer, 2016, 7, 399-405.	1.9	3
2202	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	13.7	132
2203	Resistance to Therapy. Cancer Treatment and Research, 2016, 170, 183-202.	0.5	10
2204	Principles of Chemotherapy. , 2016, , 171-185.e2.		0
2205	Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma. Medical Hypotheses, 2016, 94, 20-22.	1.5	6
2206	Overexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancer. Molecular Medicine Reports, 2016, 14, 3159-3167.	2.4	34
2207	Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro. Journal of Ethnopharmacology, 2016, 194, 1043-1050.	4.1	25
2208	Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study. Oncology Letters, 2016, 11, 2757-2762.	1.8	3
2209	Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry. Molecular Medicine Reports, 2016, 14, 4823-4829.	2.4	4
2210	Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response. Journal of Pharmacy and Pharmacology, 2016, 68, 368-378.	2.4	8

		CITATION REPORT		
#	Article		IF	CITATIONS
2211	Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in pat with non-small cell lung cancer treated with bevacizumab and erlotinib. Lung Cancer, 2016, 9	ents 3, 20-27.	2.0	2
2212	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Fac Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Targeted Oncology, 2 317-327.	cor-Like 016, 11,	3.6	10
2213	Predictive efficacy of ¹¹ Câ€PD153035 <scp>PET</scp> imaging for EGFR–tyre inhibitor sensitivity in nonâ€small cell lung cancer patients. International Journal of Cancer, 20 1003-1012.	osine kinase 116, 138,	5.1	22
2214	A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer. I Journal of Biomedical and Health Informatics, 2016, 20, 424-431.	EEE	6.3	41
2215	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in Single Institution Analysis. Molecular Diagnosis and Therapy, 2016, 20, 55-63.	NSCLC: A	3.8	22
2216	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1307	-1312.	7.0	173
2217	Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefiti patients with epidermal growth factor receptor mutationâ€positive nonâ€small cell lung canc Thoracic Cancer, 2016, 7, 61-65.	nib in er.	1.9	7
2218	Skin problems and EGFR-tyrosine kinase inhibitor. Japanese Journal of Clinical Oncology, 2016 291-298.	, 46,	1.3	82
2219	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Cu Treatment Options in Oncology, 2016, 17, 18.	rrent	3.0	18
2220	Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-Cancer Drugs, 2016, 27, 245-250.		1.4	18
2221	Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as po inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1495-1503.	ent EGFR:	3.0	25
2222	Recent advances in the pathology and molecular genetics of lung cancer: A practical review for cytopathologists. Journal of the American Society of Cytopathology, 2016, 5, 252-265.	r	0.5	Ο
2223	The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small C Cancer. Journal of Genetics and Genomics, 2016, 43, 3-10.	ell Lung	3.9	8
2224	Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thoracic Oncology, 2016, 11, 556-565.	ournal of	1.1	268
2225	Gender, Sex Hormones and Respiratory Disease. Respiratory Medicine, 2016, , .		0.1	5
2226	Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung canc (NSCLC) with gefitinib or carboplatin–paclitaxel. European Journal of Health Economics, 20 855-863.	er 16, 17,	2.8	22
2227	Sex-Specific Differences in Lung Cancer. Respiratory Medicine, 2016, , 147-171.		0.1	2
2228	A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up Humans. AAPS Journal, 2016, 18, 228-238.	to	4.4	38

#	Article	IF	CITATIONS
2229	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell and Developmental Biology, 2016, 50, 164-176.	5.0	31
2230	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics. Journal of Oncology Pharmacy Practice, 2016, 22, 461-476.	0.9	26
2231	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2016, 15, 234-242.	1.9	17
2232	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. British Journal of Cancer, 2017, 116, 568-574.	6.4	155
2233	Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. Molecular Diagnosis and Therapy, 2017, 21, 179-185.	3.8	28
2234	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80
2235	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21.		123
2236	Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 304-313.	1.1	13
2237	Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naÃ ⁻ ve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results. Molecular and Clinical Oncology, 2017, 6, 56-62.	1.0	2
2238	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Molecular Therapy - Nucleic Acids, 2017, 6, 259-268.	5.1	14
2239	An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. MedChemComm, 2017, 8, 871-885.	3.4	128
2240	Leveraging Genomic Factors to Improve Benefit–Risk. Clinical and Translational Science, 2017, 10, 78-83.	3.1	4
2241	Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. Cancer Chemotherapy and Pharmacology, 2017, 79, 1013-1020.	2.3	11
2243	¹⁸ F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non–Small Cell Lung Cancer Patients: A Comparison of Assessment Methods. Journal of Nuclear Medicine, 2017, 58, 1931-1937.	5.0	16
2244	Epidermal Growth Factor Receptor Mutated Advanced Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 83-99.	2.2	10
2245	Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Review of Anticancer Therapy, 2017, 17, 143-155.	2.4	26
2246	Development and Evaluation of 18F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC. Scientific Reports, 2017, 7, 3121.	3.3	22
2247	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. Medical Oncology, 2017, 34, 121.	2.5	12

#	Article	IF	CITATIONS
2248	Drug-biomarker co-development in oncology – 20 years and counting. Drug Resistance Updates, 2017, 30, 48-62.	14.4	48
2249	Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3148-3157.	3.0	29
2250	Dose determination for molecularly targeted therapies: Much Ado About Nothing. Cancer, 2017, 123, 1298-1300.	4.1	1
2251	Prognostic Value of Early Response Assessment Using (18F)Fdg-Pet in Patients with Advanced Non-Small Cell Lung Cancer Treated with Tyrosine-Kinase Inhibitors. Journal of Investigative Medicine, 2017, 65, 935-941.	1.6	5
2252	<i>EGFR</i> Gene Copy Number as a Predictive/Biomarker for Patients with Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-Analysis. Journal of Investigative Medicine, 2017, 65, 72-81.	1.6	18
2253	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value in Health, 2017, 20, 487-495.	0.3	101
2254	Gefitinib: an "orphan―drug for non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2017, 5, 899-906.	0.8	2
2255	Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cellular Oncology (Dordrecht), 2017, 40, 419-441.	4.4	104
2256	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics, 2017, 35, 1195-1209.	3.3	16
2257	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Medical Oncology, 2017, 34, 175.	2.5	5
2258	MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biology, 2017, 39, 101042831770643.	1.8	16
2259	Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas ® EGFR mutation test. Lung Cancer, 2017, 111, 190-194.	2.0	13
2260	Evaluate the relative efficiency of a targeted clinical trial design to an untargeted design under the issue of cost. Communications in Statistics - Theory and Methods, 2017, 46, 12336-12344.	1.0	1
2261	Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors. Oncology Letters, 2017, 14, 7589-7596.	1.8	25
2262	Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with nonâ€'small cell lung cancer: A network metaâ€'analysis. Experimental and Therapeutic Medicine, 2017, 14, 4017-4032.	1.8	18
2263	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 497-505.	2.3	16
2264	Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrology Dialysis Transplantation, 2017, 32, 1089-1097.	0.7	38
2265	Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacologica Sinica, 2017, 38, 100-109.	6.1	14

ARTICLE IF CITATIONS Targeting Oncoproteins for Molecular Cancer Therapy., 2017, , 727-756. 0 2266 Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for 2267 cancer (DRIC). Seminars in Cancer Biology, 2017, 45, 36-49. At the crossroads of cancer stem cells and targeted therapy resistance. Cancer Letters, 2017, 385, 2268 7.2 24 87-96. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer 2269 1.9 with Acquired Resistance. Pathology and Oncology Research, 2017, 23, 307-315. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, 2270 controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup 2.4 24 analysis of the phase 3 RECOURSE trial. Clinical and Translational Oncology, 2017, 19, 227-235. Epidemiology of Lung Cancer., 2017, , 347-366. A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung 2272 1.8 17 adenocarcinoma. Oncology Letters, 2018, 15, 2905-2912. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. 2273 1.1 34 Ecancermedicalscience, 2017, 11, 787. ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 2017, 2275 3.7 25 9, 33. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers in Medicine, 2276 2.6 2017, 4, 39. Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell 2277 2.0 13 carcinoma. OncoTargets and Therapy, 2017, Volume 10, 1527-1533. Concepts, Characteristics, and Clinical Validation of IBM Watson for Oncology. Hanyang Medical 2278 0.4 Reviews, 2017, 37, 49. The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to 2279 2.2 24 Cisplatin In Vitro. Drugs in R and D, 2017, 17, 545-555. Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity. Internal Medicine, 2017, 56, 2895-2898. 2280 0.7 2281 Selective Kinase Inhibitors in Cancer., 2017, , 39-75. 4 The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene 2282 1.8 19 mutation status in non-small cell lung cancer. Oncotarget, 2017, 8, 33736-33744.

CITATION REPORT

A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell 2283

		ORI	
#	Article	IF	CITATIONS
2286	Prognostic factors for post-recurrence survival in patients with completely resected Stage III (N2) non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2018, 54, 554-559.	1.4	7
2287	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. Pharmacoeconomics, 2018, 36, 495-504.	3.3	24
2288	Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine and Growth Factor Reviews, 2018, 41, 18-27.	7.2	22
2289	Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years. Annals of Oncology, 2018, 29, i1-i2.	1.2	10
2290	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 2018, 2018, CD006847.	2.8	44
2291	The biology and management of non-small cell lung cancer. Nature, 2018, 553, 446-454.	27.8	2,877
2292	Have Clinical Trials Properly Assessed c-Met Inhibitors?. Trends in Cancer, 2018, 4, 94-97.	7.4	37
2293	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Lung Cancer, 2018, 126, 217-223.	2.0	89
2294	Personalized Lung Cancer Treatment: A Teamwork. , 2018, , 333-348.		1
2295	Longâ€ŧerm safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). Cancer, 2018, 124, 2407-2414.	4.1	17
2296	Petri Net Siphon Analysis and Graph Theoretic Measures for Identifying Combination Therapies in Cancer. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 231-243.	3.0	9
2297	Gender-Related Differences in Lung Cancer. , 2018, , 30-45.e5.		0
2298	Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5.		0
2299	Genotyping of common EGFR mutations in lung cancer patients by electrochemical biosensor. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 176-182.	2.8	15
2300	Orient Expression: Solving the Mystery of Asian Prostate Cancer?. European Urology, 2018, 73, 340-342.	1.9	3
2301	Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 105-114.	2.6	22
2302	Gefitinib plus Fuzheng Kang'ai Formula (æ‰¶æ£æŠ—ç™Œæ—¹) in Patients with Advanced Non-Small Cell Lu Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial. Chinese Journal of Integrative Medicine, 2018, 24, 734-740.	ng Cance 1.6	r with 23
2303	<i>EGFR</i> Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients. World Journal of Oncology, 2018, 9, 151-155.	1.5	12

#	Article	IF	CITATIONS
2304	Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance. Translational Lung Cancer Research, 2018, 7, S123-S126.	2.8	1
2305	Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors. OncoTargets and Therapy, 2018, Volume 11, 8885-8899.	2.0	3
2306	Role of Cytokines in Combinatorial Immunotherapeutics of Non-Small Cell Lung Cancer Through Systems Perspective. SSRN Electronic Journal, 2018, , .	0.4	0
2307	Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377. Oncology Reports, 2018, 41, 534-542.	2.6	4
2308	Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Analytical Cellular Pathology, 2018, 2018, 1-9.	1.4	35
2309	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Cancers, 2018, 10, 489.	3.7	18
2310	Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. Journal of Medicinal Chemistry, 2018, 61, 11372-11383.	6.4	22
2311	Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer. Cell Death and Disease, 2018, 9, 963.	6.3	25
2312	Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879758.	3.2	41
2313	EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP). Targeted Oncology, 2018, 13, 621-629.	3.6	24
2314	Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors. Computational and Structural Biotechnology Journal, 2018, 16, 462-478.	4.1	8
2316	Molecular Diagnostics in Clinical Oncology. Frontiers in Molecular Biosciences, 2018, 5, 76.	3.5	93
2317	Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells <i>In Vitro</i> . Anticancer Research, 2018, 38, 5165-5176.	1.1	14
2318	Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 665-675.	2.0	10
2319	Translational Sepsis Research. Critical Care Medicine, 2018, 46, 1497-1505.	0.9	8
2320	Identification of circulating tumor cells with EML4‑ALK translocation using fluorescence inÃ ⁻ ¿½situ hybridization in advanced ALK‑positive patients with lung cancer. Oncology Letters, 2018, 15, 8959-8964.	1.8	3
2321	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1601-1611.	2.5	8
2322	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer, 2018, 123, 60-69.	2.0	58

#	Article	IF	CITATIONS
0000	Small Malaculas in Oncology Pasant Pasults in Cancer Pasaarsh 2018	1.0	F
2323	Small Molecules in Oncology. Recent Results in Cancel Research, 2010, , .	1.0	0
2324	Erlotinib. Recent Results in Cancer Research, 2018, 211, 1-17.	1.8	17
2325	Gefitinib. Recent Results in Cancer Research, 2018, 211, 235-246.	1.8	68
2326	Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks. British Journal of Radiology, 2018, 91, 20180334.	2.2	18
2327	Pharmacogenomics and Pharmacoepigenomics: Impact on Therapeutic Strategies. , 2018, , 227-238.		1
2328	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Frontiers in Oncology, 2018, 8, 92.	2.8	506
2329	Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. Oncology Research, 2018, 26, 59-69.	1.5	8
2330	Erlotinib as adjuvant therapy in EGFR-mutant NSCLC. Lancet Respiratory Medicine,the, 2018, 6, 808-810.	10.7	1
2331	Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases. Journal of Cancer, 2018, 9, 1607-1613.	2.5	6
2332	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207.	7.1	56
2333	Clinical Proteomics and Molecular Pathology. , 2018, , 183-203.		0
2334	A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Angewandte Chemie - International Edition, 2019, 58, 3300-3345.	13.8	48
2335	Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. Angewandte Chemie, 2019, 131, 3336-3383.	2.0	5
2336	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
2337	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. Journal of Clinical Medicine, 2019, 8, 998.	2.4	28
2338	Correlation between adverse events after drug treatment and the MDR1 C3435T polymorphism in advanced non-small cell lung cancer patients in an Asian population: a meta-analysis. Journal of International Medical Research, 2019, 47, 3522-3533.	1.0	0
2339	Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization. Molecular Therapy - Nucleic Acids, 2019, 17, 164-174.	5.1	62
2340	EGFR Targeted Therapy. Current Cancer Research, 2019, , 1-30.	0.2	2

#	Article	IF	CITATIONS
2341	A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. Scientific Reports, 2019, 9, 12329.	3.3	26
2342	The Relevance of Gender in Tumor-Influencing Epigenetic Traits. Epigenomes, 2019, 3, 6.	1.8	3
2343	Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo. Toxicology and Applied Pharmacology, 2019, 382, 114734.	2.8	35
2344	Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1978-1984.	1.2	75
2346	Incorporating Pharmacogenomics in Drug Development. , 2019, , 81-101.		1
2347	<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p> . OncoTargets and Therapy, 2019, Volume 12, 635-645.	2.0	124
2348	SGLT1 is required for the survival of tripleâ€negative breast cancer cells via potentiation of EGFR activity. Molecular Oncology, 2019, 13, 1874-1886.	4.6	22
2349	Role of cytokines in combinatorial immunotherapeutics of nonâ€small cell lung cancer through systems perspective. Cancer Medicine, 2019, 8, 1976-1995.	2.8	14
2350	Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics. Cancer Chemotherapy and Pharmacology, 2019, 84, 51-60.	2.3	16
2351	Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. , 2019, , 115-131.		0
2352	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with nonâ€small cell lung cancer harboring an ECFR mutation: A prospective observational study. Thoracic Cancer, 2019, 10, 880-889.	1.9	14
2353	Development and validation of a sensitive LC–MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 364-371.	2.8	20
2354	Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 5.	17.1	231
2355	High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells. Phytomedicine, 2019, 64, 152926.	5.3	10
2356	Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Cells, 2019, 8, 316.	4.1	35
2357	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Seminars in Cancer Biology, 2019, 59, 3-22.	9.6	29
2358	Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. European Radiology, 2019, 29, 4742-4750.	4.5	121
2359	Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S369-S372.	2.8	4

#	Article	IF	CITATIONS
2360	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer Journal (Sudbury, Mass), 2019, 25, 245-253.	2.0	4
2361	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S235-S246.	2.8	8
2362	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S265-S279.	2.8	17
2363	Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer. Journal of Oncology Pharmacy Practice, 2019, 25, 1853-1859.	0.9	3
2364	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. Annual Review of Cancer Biology, 2019, 3, 385-408.	4.5	17
2365	Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 22-26.	2.8	13
2366	Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respiratory Investigation, 2019, 57, 20-26.	1.8	46
2367	Transcriptome-based molecular subtyping of non–small cell lung cancer may predict response to immune checkpoint inhibitors. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 1598-1610.e3.	0.8	23
2368	Non-small Cell Lung Cancer as a Chronic Disease – A Prospective Study from the Czech TULUNG Registry. In Vivo, 2020, 34, 369-379.	1.3	9
2369	Genomics and the History of Precision Oncology. Surgical Oncology Clinics of North America, 2020, 29, 35-49.	1.5	23
2371	Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. PLoS ONE, 2020, 15, e0238120.	2.5	6
2372	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. Tumori, 2020, 107, 030089162096813.	1.1	2
2373	An <scp>EGFR</scp> signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. International Journal of Cancer, 2020, 147, 2621-2633.	5.1	13
2374	Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity. Frontiers in Chemistry, 2020, 8, 210.	3.6	33
2375	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	13.2	23
2376	First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. Investigational New Drugs, 2020, 38, 1826-1835.	2.6	1
2377	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870.	2.4	16
2378	The top 100 cited articles in lung cancer – a bibliometric analysis. Wspolczesna Onkologia, 2020, 24, 17-28.	1.4	7

~		<u> </u>	
(15	ГАТІ	NEDC	DT
	IAL	NLPC	ואר

#	Article	IF	CITATIONS
2379	Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1159-1167.	1.5	5
2380	Applying bioethical principles for directing investment in precision medicine. Clinical Ethics, 2020, 15, 23-28.	0.7	3
2381	First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients. Clinical Lung Cancer, 2020, 21, e572-e582.	2.6	0
2382	Adverse cutaneous reactions to chemotherapeutic drugs. Clinics in Dermatology, 2020, 38, 712-728.	1.6	14
2383	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. Cancer Chemotherapy and Pharmacology, 2020, 85, 605-614.	2.3	3
2384	Epidermal Growth Factor Receptor Mutations. Thoracic Surgery Clinics, 2020, 30, 127-136.	1.0	14
2385	Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Genetics, 2020, 11, 281.	2.3	50
2386	Cutaneous Squamous Cell Carcinoma: From Biology to Therapy. International Journal of Molecular Sciences, 2020, 21, 2956.	4.1	92
2387	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. Journal of Thoracic Disease, 2020, 12, 639-650.	1.4	6
2388	Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer. Journal of Pharmacy Practice, 2021, 34, 11-16.	1.0	2
2389	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. Translational Oncology, 2021, 14, 100951.	3.7	9
2390	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opinion on Therapeutic Patents, 2021, 31, 223-238.	5.0	16
2391	LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis. Cell Cycle, 2021, 20, 179-193.	2.6	9
2392	AIM in Genomic Basis of Medicine: Applications. , 2021, , 1-10.		0
2393	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook. Cureus, 2021, 13, e13470.	0.5	4
2394	High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. Journal of Thoracic Disease, 2021, 13, 1476-1484.	1.4	4
2395	Ocular Toxicity of Targeted Anticancer Agents. Drugs, 2021, 81, 771-823.	10.9	22
2396	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	16.3	79

#	Article	IF	Citations
2397	The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics. Archives of Biochemistry and Biophysics, 2021, 701, 108811.	3.0	30
2398	Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 684073.	2.8	9
2399	Epidermal Growth Factor Receptor Mutation Mechanisms in Nonsmall Cell Lung Cancer by Transcriptome Sequencing. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 560-568.	1.0	3
2400	The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2239-2248.	2.5	1
2401	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells, 2021, 10, 1206.	4.1	17
2402	Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials. Translational Lung Cancer Research, 2021, 10, 2278-2289.	2.8	1
2403	Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma. Frontiers in Endocrinology, 2021, 12, 605797.	3.5	2
2404	Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). Medicni Perspektivi, 2021, 26, 4-11.	0.4	0
2405	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers, 2021, 13, 3164.	3.7	35
2406	Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib. Toxicology Letters, 2021, 343, 1-10.	0.8	14
2407	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. Journal of Molecular Pathology, 2021, 2, 207-222.	1.2	0
2408	The role of EGFR mutation testing in the choice for surgical tactics in NSCLC treatment. Voprosy Onkologii, 2021, 67, 315-322.	0.2	1
2409	Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptorâ€mutant nonâ€small cell lung cancer: A prospective, multicenter, doseâ€modification study. Geriatrics and Gerontology International, 2021, 21, 881-886.	1.5	3
2410	Targeting Akt in cancer for precision therapy. Journal of Hematology and Oncology, 2021, 14, 128.	17.0	94
2411	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	3.9	6
2412	The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. Journal of Pharmaceutical Sciences, 2021, 110, 3507-3519.	3.3	6
2414	Obtacles and opportunities in the clinical development of targeted therapeutics. , 2005, 63, 19-41.		11
2415	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. , 2005, 63, 93-115.		10

		CITATION REPORT		
#	Article		IF	CITATIONS
2416	Targeting Small Molecules in Cancer. Cancer Treatment and Research, 2007, 135, 239	-255.	0.5	2
2417	Update on the Role of EGFR Inhibitors in Cancer Therapeutics. Cancer Treatment and F 135, 257-275.	Research, 2007,	0.5	3
2418	Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inh Lessons Have We Learned?. Advances in Experimental Medicine and Biology, 2008, 61	ibitors: What 0, 128-143.	1.6	4
2419	Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, C	CML, Lung) Tj ETQq1 1 0.78	34314 rgB	T /Overlock
2420	Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) 2008, , 147-160.	Receptors. ,		1
2421	Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients. Advance Experimental Medicine and Biology, 2019, 1168, 79-90.	es in	1.6	3
2422	Identifying Critical Signaling Molecules for the Treatment of Cancer. , 2007, 172, 5-24			3
2423	Erlotinib. Recent Results in Cancer Research, 2010, 184, 21-31.		1.8	3
2424	Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients v solid malignancies. Investigational New Drugs, 2006, 24, 117.	vith advanced	2.6	1
2425	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. , 2008, , 2	1307-1366.		7
2426	DEFINITIVE MANAGEMENT OF INOPERABLE NON–SMALL CELL LUNG CANCER. , 200	8, , 804-821.		1
2427	Growth Factor Signaling Pathways and Receptor Tyrosine Kinase Inhibitors. , 2006, , 15	55-172.		2
2428	Brain tumor treatment: Chemotherapy and other new developments. Seminars in Onc 2004, 20, 260-272.	ology Nursing,	1.5	18
2429	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current statu future perspectives. Revista Da Associação Médica Brasileira, 2012, 58, 263-268.	is and	0.7	4
2430	DNA-binding agents. Cancer Chemotherapy and Biological Response Modifiers, 2003,	21, 171-209.	0.5	5
2431	DNA-binding agents. Cancer Chemotherapy and Biological Response Modifiers, 2005,	, 163-203.	0.5	5
2432	Epidermal growth factor receptor pathway inhibitors. Cancer Chemotherapy and Biolo Modifiers, 2005, 22, 205-223.	gical Response	0.5	14
2434	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advance Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole of Thoracic Oncology, 2006, 1, 52-60.	d Non???Small Story. Journal	1.1	13

#	Article	IF	CITATIONS
2435	Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 417-424.	1.1	17
2436	Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group. Journal of Thoracic Oncology, 2006, 1, 447-453.	1.1	20
2437	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. Journal of Thoracic Oncology, 2006, 1, 545-550.	1.1	6
2438	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 582-587.	1.1	12
2439	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. Journal of Thoracic Oncology, 2006, 1, 965-971.	1.1	33
2440	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. Journal of Thoracic Oncology, 2006, 1, 1002-1009.	1.1	115
2441	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	1.1	134
2442	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Anti-Cancer Drugs, 2007, 18, 949-954.	1.4	12
2443	Oncogenes Come of Age. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 1-9.	1.1	27
2444	EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens. Analytical Cellular Pathology, 2007, 29, 257-264.	1.4	53
2445	The Role of Gefitinib in Lung Cancer Treatment. Clinical Cancer Research, 2004, 10, 4233s-4237s.	7.0	64
2446	Clinical Trial Design Issues in the Era of Targeted Therapies. Clinical Cancer Research, 2004, 10, 4281s-4282s.	7.0	8
2447	Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4210s-4214s.	7.0	50
2448	Bronchioloalveolar Carcinoma. Clinical Cancer Research, 2004, 10, 4205s-4209s.	7.0	47
2449	Personalized therapy for lung cancer: Striking a moving target. JCI Insight, 2018, 3, .	5.0	114
2450	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation, 2006, 116, 2695-2706.	8.2	423
2451	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Journal of Clinical Investigation, 2008, 118, 2609-19.	8.2	443
2452	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Medical Science Monitor, 2016, 22, 276-283.	1.1	17

	CITATION REI	PORT	
#	Article	IF	Citations
2453	Cross-cultural Validation of the Japanese Version of the Lung Cancer Subscale on the Functional Assessment of Cancer Therapy-Lung. Journal of Nippon Medical School, 2007, 74, 402-408.	0.9	12
2454	Customised , Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC) = العلاج Sultan Qaboos University Medical Journal, 2013, 13, 202-217.	ợşù"ùø	±g⁻ùš ù^ ∅
2455	Tobacco Smoking and Lung Cancer : Perception Changing Facts = تØ⁻خين التبغ Ù^ سرØ∙ان Ø Medical Journal, 2013, 13, 345-358.	§ù"رئ 1.0	Ø©:Ø¥Ø⁻Ø 81
2456	Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy. PLoS ONE, 2011, 6, e23756.	2.5	95
2457	LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling. PLoS ONE, 2011, 6, e27720.	2.5	94
2458	An Anilinoquinazoline Derivative Inhibits Tumor Growth through Interaction with hCAP-G2, a Subunit of Condensin II. PLoS ONE, 2012, 7, e44889.	2.5	13
2459	Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review. PLoS ONE, 2013, 8, e59314.	2.5	52
2460	Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e107276.	2.5	20
2461	The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histology and Histopathology, 2005, 20, 1005-15.	0.7	99
2462	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. Journal of Cancer Prevention, 2015, 20, 57-63.	2.0	24
2463	Development of rheumatoid arthritis during the course of gefitinib therapy. Sao Paulo Medical Journal, 2009, 127, 177-178.	0.9	4
2464	Plasticity of lung cancer stem-like cells is regulated by the transcription factor <i>HOXA5</i> that is induced by oxidative stress. Oncotarget, 2016, 7, 50043-50056.	1.8	31
2465	Risk of lung cancer in Parkinson's disease. Oncotarget, 2016, 7, 77319-77325.	1.8	9
2466	Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies. Oncotarget, 2016, 7, 86902-86913.	1.8	11
2467	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	1.8	10
2468	EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR. Oncotarget, 2014, 5, 1265-1278.	1.8	52
2469	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget, 2017, 8, 100801-100818.	1.8	35
2470	Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer. Oncotarget, 2011, 2, 165-177.	1.8	52

#	Article	IF	CITATIONS
2471	Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule. Oncotarget, 2018, 9, 35041-35055.	1.8	5
2472	The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma. Oncotarget, 2019, 10, 1119-1131.	1.8	1
2473	A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget, 2015, 6, 4527-4536.	1.8	85
2474	Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. Oncotarget, 2015, 6, 814-824.	1.8	17
2475	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 30929-30938.	1.8	10
2476	The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget, 2012, 3, 744-758.	1.8	75
2477	<i>KRAS</i> mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget, 2016, 7, 8373-8388.	1.8	73
2478	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 2016, 7, 40781-40791.	1.8	10
2479	The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 326-334.	2.1	2
2480	EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 2018, 8, S23-S47.	1.0	48
2481	Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 241-253.	2.2	43
2482	Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions. Current Pharmaceutical Design, 2005, 11, 265-272.	1.9	24
2483	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	1.6	61
2484	Achievements in Cancer Research and its Therapeutics in Hundred Years. Current Topics in Medicinal Chemistry, 2019, 19, 1545-1562.	2.1	2
2485	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Current Topics in Medicinal Chemistry, 2020, 20, 815-834.	2.1	229
2486	Serum Levels of KL-6, SP-A and SP-D in NSCLC Patients Treated With Gefitinib. Japanese Journal of Lung Cancer, 2005, 45, 823-828.	0.1	2
2487	A Case of Lung Adenocarcinoma with Gefitinib-resistant Carcinomatous Meningitis Exhibiting the Dose-dependent Effects of Erlotinib. Japanese Journal of Lung Cancer, 2014, 54, 806-811.	0.1	1
2488	Two Cases of Stage IV Lung Adenocarcinoma That Achieved a Long-term Survival on Gefitinib. Japanese Journal of Lung Cancer, 2015, 55, 1029-1036.	0.1	2

#	Article	IF	CITATIONS
2489	High Sensitivity Detection of Tumor Gene Mutations. , 2015, 1, 1-6.		5
2491	Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-134.	2.8	20
2493	Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 1382.	3.3	29
2494	Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressaâ,,¢) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. World Journal of Gastroenterology, 2006, 12, 5140.	3.3	25
2496	A Comparison of Patient Acceptance and Preferences Between CT Colonography and Conventional Colonoscopy in Colorectal Cancer Screening. Korean Journal of Internal Medicine, 2009, 24, 43.	1.7	41
2497	EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. Korean Journal of Internal Medicine, 2009, 24, 48.	1.7	60
2498	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. Journal of Thoracic Disease, 2010, 2, 144-53.	1.4	10
2499	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). Journal of Thoracic Disease, 2011, 3, 57-64.	1.4	16
2500	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S579-92.	1.4	37
2501	Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. Journal of Gastrointestinal Oncology, 2014, 5, 57-66.	1.4	5
2502	Gefitinib in non-small-cell lung cancer-an old lesson new re-visited. Translational Lung Cancer Research, 2013, 2, 435-8.	2.8	2
2503	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Translational Lung Cancer Research, 2015, 4, 36-54.	2.8	499
2504	The Efficacy of ZD1839 (Iressaâ,,¢) in Patients with Advanced Non-small Cell Lung Cancer which has Progressed After Previous Chemotherapy. Tuberculosis and Respiratory Diseases, 2004, 57, 160.	1.8	2
2505	A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia. Indian Journal of Cancer, 2017, 54, 104.	0.2	3
2506	The role of Gefitinib in patients with non-small-cell lung cancer in India. Indian Journal of Palliative Care, 2013, 19, 48.	1.0	6
2507	Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. Journal of Natural Science, Biology and Medicine, 2016, 7, 119.	1.0	31
2508	Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study. Biomedical Journal, 2015, 38, 221.	3.1	7
2509	Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the glioblastoma multiforme patients in the backdrop of mutational status of epidermal growth factor receptor and PTEN Genes. Journal of Innovative Optical Health Sciences. 2018, 13, 46.	1.0	8

#	Article	IF	CITATIONS
2510	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. Cancer Research Statistics and Treatment, 2019, 2, 36.	0.6	23
2511	The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy. Cancer Research and Treatment, 2005, 37, 339.	3.0	5
2512	Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2012, 44, 74-84.	3.0	10
2513	How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. Cancer Research and Treatment, 2013, 45, 178-185.	3.0	11
2514	Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non–Small Cell Lung Cancer. , 2012, 02, .		1
2515	Two-stage design for phase II oncology trials with relaxed futility stopping. Statistics and Its Interface, 2016, 9, 93-98.	0.3	3
2516	Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharmacy Practice, 2006, 4, 168-78.	1.5	9
2517	Lung Cancer. Annals of Saudi Medicine, 2005, 25, 1-12.	1.1	28
2518	Pharmacology of epidermal growth factor inhibitors. International Journal of Biological Markers, 2007, 22, 24-39.	1.8	19
2519	Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. International Journal of Biological Markers, 2007, 22, 10-23.	1.8	5
2520	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World Journal of Clinical Oncology, 2011, 2, 367.	2.3	39
2521	Advances in adjuvant systemic therapy for non-small-cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 633.	2.3	19
2522	Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. World Journal of Clinical Oncology, 2014, 5, 858.	2.3	12
2523	ls there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?. World Journal of Clinical Oncology, 2015, 6, 45.	2.3	4
2524	Tissue proteomics for cancer biomarker development - Laser microdissection and 2D-DIGE BMB Reports, 2008, 41, 626-634.	2.4	25
2525	Non-small cell lung cancer - genetic predictors. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2013, 157, 125-136.	0.6	34
2526	EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis. Chinese Journal of Cancer, 2011, 30, 701-711.	4.9	12
2527	The evolution of phase I trials in cancer medicine: a critical review of the last decade. Chinese Journal of Cancer, 2011, 30, 815-820.	4.9	4

#	Article	IF	CITATIONS
2528	Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer. Chinese Journal of Cancer, 2012, 31, 491-499.	4.9	13
2529	Is the Epidermal Growth Factor Receptor Status in Lung Cancers Reflected in Clinicopathologic Features?. Archives of Pathology and Laboratory Medicine, 2010, 134, 66-72.	2.5	86
2530	Molecular Diagnostics of Lung Carcinomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 622-629.	2.5	30
2531	Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 655-664.	2.5	30
2532	Tyrosine kinase – Role and significance in Cancer. International Journal of Medical Sciences, 2004, 1, 101-115.	2.5	419
2533	Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7071-7076.	1.2	8
2534	Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area. Asian Pacific Journal of Cancer Prevention, 2016, 17, 785-789.	1.2	8
2535	Treatment of non-small cell lung cancer. , 2001, , 69-134.		0
2536	Interstitial Lung Disease Induced by Gefitinib-The Final Report of a Specialist Committee. Japanese Journal of Lung Cancer, 2003, 43, 927-932.	0.1	4
2537	委員会å±å'Šã€Œã,²ãƒ•ã,£ãƒãƒ‹ãƒ−ã€ã«é−¢ã™ã,‹å£°æ~Ž. Japanese Journal of Lung Cancer, 2003, 43, 780-78⁄	40.1	0
2538	Target-based anti-cancer drugs. Drug Delivery System, 2004, 19, 103-109.	0.0	0
2539	Acneiform Follicular Eruption in Patients Treated with Gefitinib: Report of Six Cases. Nishinihon Journal of Dermatology, 2004, 66, 599-601.	0.0	Ο
2540	Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines. The Showa University Journal of Medical Sciences, 2004, 16, 147-159.	0.1	0
2542	Immunohistochemical Study of Phosphatase and Tensin Homolog Deleted on Chromosome Ten in Gefitinib Treated Nonsmall Cell Lung Cancer Patients. Tuberculosis and Respiratory Diseases, 2005, 58, 473.	1.8	0
2543	Three Cases of Primary Non-Small Cell Lung Carcinoma with Mutation of the Epidermal Growth Factor Receptor Gene that Responded to Gefitinib. Kitakanto Medical Journal, 2005, 55, 169-176.	0.0	0
2544	New Chemotherapeutic Agents. Japanese Journal of Lung Cancer, 2005, 45, 793-799.	0.1	Ο
2545	Lung cancer. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 413-442.	0.5	2
2546	Treatment Strategy for N2 Non-Small-Cell Lung Cancer:. Japanese Journal of Lung Cancer, 2005, 45, 295-299.	0.1	0

#	Article	IF	CITATIONS
2547	ZD1839 (Gefinitib, Iressa) In Patients With Non Small Cell Lung Cancer: A Real Promise?. Internet Journal of Oncology, 2005, 2, .	0.1	0
2548	Treatment of non-small cell lung cancer. , 2005, , 65-125.		0
2549	Abordaje terapéutico del carcinoma de pulmón no microcÃŧico avanzado: ¿estamos "avanzando"?. Oncologia, 2005, 28, .	0.0	1
2551	Pitfalls in the Design, Conduct and Analysis of Randomized Clinical Trials. , 2005, , 567-579.		0
2553	Prediction of Sensitivity of Non-small Cell Lung Cancers to Gefitinib by Gene Expression Profiling. Japanese Journal of Lung Cancer, 2006, 46, 245-251.	0.1	0
2554	Nichtkleinzelliges Lungenkarzinom. , 2006, , 3467-3584.		0
2555	BronchioloalveolÃæs Karzinom und weitere seltene Lungentumoren. , 2006, , 3626-3640.		0
2556	A Case of Adenocarcinoma of the Lung with a Favorable Response to Retreatment with Gefitinib. Japanese Journal of Lung Cancer, 2006, 46, 357-362.	0.1	3
2557	Update Chemotherapy for Lung Cancer. Juntendoì,, Igaku, 2006, 52, 536-545.	0.1	0
2558	Gefitinib: impact on survival benefit. Drug Delivery System, 2006, 21, 58-63.	0.0	0
2559	Effect of Gefitinib on Quality of Life in Patients with Advanced Non-small-cell Lung Cancer in General Practice. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2006, 32, 1033-1037.	0.1	1
2560	Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®). Japanese Journal of Lung Cancer, 2006, 46, 345-352.	0.1	0
2561	Retrospective Study of Alternate-day Administration of Gefitinib. Japanese Journal of Lung Cancer, 2007, 47, 9-12.	0.1	1
2562	Re-treatment with Gefitinib for Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2007, 47, 689-694.	0.1	2
2563	Malignome des Respirationstrakts. , 2007, , 511-548.		0
2564	Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. Yearbook of Pulmonary Disease, 2007, 2007, 144-146.	0.4	1
2565	High Density Tissue Microarray for Establishing Lung Cancer Expression Profiling Database and Its Clinical Application. Japanese Journal of Lung Cancer, 2007, 47, 915-919.	0.1	0
2566	Epidermal Growth Factor Receptor Inhibition in Non–Small Cell Lung Cancer. Translational Medicine Series, 2007, , 81-96.	0.0	0

#	Article	IF	CITATIONS
2567	Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response. Translational Medicine Series, 2007, , 97-122.	0.0	0
2568	Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. , 2007, , 19-44.		2
2569	Therapeutic Targeting of Apoptosis in Cancer. , 2008, , 263-278.		1
2571	Monoclonaux contre inhibiteurs de tyrosine kinase. , 2008, , 81-97.		0
2572	Cell Adhesion Molecules. Molecular Pathology Library, 2008, , 22-39.	0.1	0
2573	Response to Conventional Therapy and Targeted Molecular Therapy. Molecular Pathology Library, 2008, , 226-232.	0.1	Ο
2574	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
2575	Phase 1 Trials Today. , 2008, , 553-570.		Ο
2576	A Case of Adenocarcinoma of the Lung with Malignant Pleural Effusion and Elevated Serum IL-6 Levels Successfully Treated with Gefitinib. Japanese Journal of Lung Cancer, 2008, 48, 273-278.	0.1	0
2577	Fundamentals of Cancer Cell Biology and Molecular Targeting. , 2008, , 1933-1945.		0
2578	EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. , 2008, , 281-324.		0
2579	Targeting Signaling Pathways in Cancer Therapy. , 2009, , 309-326.		0
2580	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415.	0.1	0
2581	Difference of EGFR-Binding Proteins between Wild Type and Mutant EGFR. , 2009, , 132-138.		0
2582	Targeted Approaches to Drug Development. , 2009, , 57-98.		3
2583	CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS. , 2009, , 83-90.		0
2584	The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy. Medical Radiology, 2009, , 191-219.	0.1	0
2585	Terminating Chemotherapy and Transition to Palliative Care for Patients with Recurrent Non-small Cell Lung Cancer in the Terminal Stage. Japanese Journal of Lung Cancer, 2009, 49, 836-843.	0.1	0

#	Article	IF	CITATIONS
2586	Selective Use of Gefitinib and Erlotinib on Non-small Cell Lung Cancer Patients. Japanese Journal of Lung Cancer, 2009, 49, 950-956.	0.1	0
2587	Retrospective Analysis of Acquired Resistance During the Treatment with Gefitinib in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations. Japanese Journal of Lung Cancer, 2009, 49, 257-261.	0.1	0
2588	Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients. Korean Journal of Pathology, 2009, 43, 509.	1.3	0
2590	Clinical Analysis of 24 Cases Treated Twice or More with Gefitinib for Recurrent Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2009, 49, 831-835.	0.1	0
2591	Individualization of treatment in non-small cell lung cancer. F1000 Medicine Reports, 2009, 1, .	2.9	1
2592	Targeted therapy in nonsmall cell lung cancer. , 2009, , 284-198.		0
2593	A resected case of lung metastasis after treatment with gefitinib. The Journal of the Japanese Association for Chest Surgery, 2010, 24, 166-169.	0.0	0
2594	Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer. , 2010, , 195-204.		0
2595	A Patient with Advanced Lung Adenocarcinoma Effectively Treated with Gemcitabine Plus Vinorelbine After Failure with Gefitinib. Japanese Journal of Lung Cancer, 2010, 50, 297-302.	0.1	1
2596	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. , 2010, , 205-226.		2
2597	Effects of Antacids on Clinical Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2010, 36, 832-839.	0.1	3
2598	Quality of Life for Patients Receiving Cancer Chemotherapy: The Japanese Perspective. , 2010, , 2923-2933.		0
2599	Targeted Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer—Patient Selection Changes the Fate of Gefitinib. Clinical Medicine Reviews in Oncology, 0, 2, 231-244.	0.0	0
2600	Pharmacodiagnostic Testing. , 2010, , 87-117.		0
2601	Epidermal Growth Factor Receptor-Targeted Therapies. , 2011, , 305-333.		0
2602	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
2603	Translational Research in Lung Cancer. Medical Radiology, 2011, , 793-808.	0.1	0
2604	Lung Adenocarcinoma. , 2011, , 177-183.		0

Сп	ON	REPORT
<u> </u>		

#	Article	IF	CITATIONS
2605	Pulmonary Endothelial Impairment During Gefitinib Therapy: A Preliminary Assessment with Iodine-123-Metaiodobenzylguanidine (123IMIBG) Scintigraphy. The Open Lung Cancer Journal, 2011, 4, 1-3.	0.1	0
2606	Epidermal Growth Factor Receptor Inhibition as a Therapeutic Strategy for Glioblastoma Multiforme. , 2011, , 321-336.		0
2609	Preclinical and Clinical Developments in Molecular Targeting Therapeutic Strategies for Breast Cancer. , 0, , .		0
2610	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
2611	Pharmacogenomics in Developing Asian Countries. Advances in Microbial Ecology, 2012, , 183-214.	0.1	0
2612	Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma Who Had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report. Journal of Clinical Medicine Research, 2012, 4, 216-20.	1.2	6
2613	Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials. Journal of Cancer Therapy, 2012, 03, 467-476.	0.4	0
2614	A case of primary lung cancer with EGFR mutation which needed to be distinguished from lung metastasis of breast cancer. The Journal of the Japanese Society of Clinical Cytology, 2012, 51, 120-124.	0.0	0
2615	Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. Journal of Neurology Research, 2012, 2, 1-9.	0.5	7
2616	Treatment of non-small cell lung cancer in the era of targeted therapy. Advances in Lung Cancer (Irvine), 2012, 01, 1-4.	0.2	0
2617	Molecular Targeted Therapy of Lung Cancer. Molecular Pathology Library, 2012, , 99-107.	0.1	0
2618	Principles of Chemotherapy. , 2012, , 165-179.		0
2619	Clinical Analysis of 17 Cases Beginning Treatment with Erlotinib the Day After Terminating Gefitinib for Advanced Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2012, 52, 871-877.	0.1	0
2620	Malignome des Respirationstrakts. , 2012, , 495-532.		0
2621	HGFK1 is Associated with a Better Prognostis and Reverses Inhibition by Gefitinib in NSCLC Cases. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1457-1461.	1.2	0
2622	Bridging Diversity. Chapman & Hall/CRC Biostatistics Series, 2012, , 1-16.	0.0	0
2623	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
2624	Potential of Tocotrienols in Lung Cancer. , 2012, , 151-162.		0

		CITATION RE	PORT	
#	Article		IF	CITATIONS
2625	Six Cases of Lung Adenocarcinoma Successfully Treated Using Alternate Day Administra Gefitinib. Japanese Journal of Lung Cancer, 2013, 53, 25-28.	tion of	0.1	1
2626	Lung cancer and molecular targeted drugs. Okayama Igakkai Zasshi, 2013, 125, 57-66.		0.0	1
2627	TYPES OF DNA DAMAGE. , 2013, , 115-118.			0
2629	Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer. Tang [humanitas Medic 10.1-10.8.	ne], 2013, 3,	0.2	0
2631	Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. , 2014, , 75-118	}.		0
2632	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.			0
2633	Longcarcinoom. , 2014, , 117-124.			0
2635	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. , 2014, , 31-66.			0
2636	Tyrosine Kinase Inhibitors for EGFR Gene Mutation-Positive Non-SmallCell Lung Cancers: Recent Advances in Therapeutics. Journal of Pharmacovigilance, 2015, 03, .	An Update for	0.2	1
2637	Phase I Trials Today. , 2015, , 661-676.e2.			0
2638	The EGFR/ERBB Receptor Family. , 2015, , 107-164.			3
2639	Inhibition of nucleoside transporters by tyrosine kinase inhibitors and its effects on chen efficacy. Cancer Cell & Microenvironment, 0, , .	notherapy	0.8	0
2640	Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Ad- Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. Journal of Cancer Thera 1214-1222.	/anced py, 2015, 06,	0.4	0
2641	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.			0
2642	Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. Journal of Cancer Prevention, 2015, 16, 5521-5524.	Asian Pacific	1.2	6
2643	Current surgery for patients with lung cancer. Journal of Microwave Surgery, 2016, 34, 4	7-51.	0.3	0
2644	Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer. Advances Medicine, 2016, 06, 17-22.	in Clinical	0.0	0
2645	Progress in the Research of Multi-Target Tyrosine Kinase Inhibitors. Hans Journal of Medi Chemistry, 2016, 04, 42-54.	cinal	0.1	0

#	Article	IF	CITATIONS
2646	Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2016, 26, 1-2.	0.1	0
2647	Oncogenes and the Initiation and Maintenance of Tumorigenesis. , 2017, , 143-157.		1
2648	Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. , 2017, , 709-726.		0
2649	Companion Diagnostics. , 2017, , 117-136.		0
2650	Design and Data Analysis of Multiregional Clinical Trials (MRCTs)—Theory and Practice. ICSA Book Series in Statistics, 2018, , 269-286.	0.2	0
2651	Enzymatic Research Having Pharmaceutical Significance. Advances in Medical Technologies and Clinical Practice Book Series, 2018, , 141-158.	0.3	0
2652	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.2	0
2653	Diagnosis and Treatment of Non-Squamous Lung Cancer Based on Molecular Tumor Testing. Korean Journal of Medicine, 2018, 93, 266-270.	0.3	0
2654	Non small cell lung cancer with targetable driver alterations: Imaging perspective. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	0
2655	Cytology microarray on cell block preparation: A novel diagnostic approach in fluid cytology. Journal of Cytology, 2019, 36, 79.	0.6	5
2657	Successful Dose-reduction Therapy for Osimertinib-induced Neutropenia in EGFR-mutant Lung Adenocarcinoma: a Report of Two Cases. Japanese Journal of Lung Cancer, 2019, 59, 46-52.	0.1	0
2658	Pharmacodiagnostic Testing — Immunohistology. , 2019, , 87-118.		0
2659	Progress in individualized treatment for <i>EGFR</i> -mutated advanced non-small cell lung cancer. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2020, 96, 266-272.	3.8	4
2660	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
2661	Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. Acta Pharmacologica Sinica, 2022, 43, 1857-1864.	6.1	1
2662	Pitfalls in the Design, Conduct and Analysis of Randomised Clinical Trials. , 2005, , 495-503.		0
2671	Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. , 2008, , 291-306.		0
2672	Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316.		1

#	Article	IF	CITATIONS
2673	Achievements in targeted therapies. , 0, , 215-233.		0
2675	Tyrosine Kinase Inhibitors. , 2007, , 477-508.		0
2677	Untargeted Use of Targeted Therapy. , 2008, , 227-240.		0
2678	How to Define Treatment Success or Failure if Tumors Do Not Shrink. , 2008, , 657-674.		0
2682	Rational Development of Targeted Cancer Therapies Using Biomarkers. Laboratory Medicine, 2008, 37, 482-489.	1.2	0
2683	Management of transitional cell carcinoma by targeting the epidermal growth factor receptor. Therapy: Open Access in Clinical Medicine, 2006, 3, 407-416.	0.2	0
2684	Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer. , 2006, , 643-670.		0
2685	Possibilities of supportive therapy in patients with blood system tumors and malignant neoplasms. Oncogematologiya, 2020, 15, 107-127.	0.3	0
2687	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
2689	Biological response modifiers in cancer. MedGenMed: Medscape General Medicine, 2006, 8, 33.	0.2	5
2690	Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. Ulster Medical Journal, 2008, 77, 31-5.	0.2	8
2691	Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics: Targets and Therapy, 2007, 1, 335-46.	3.2	24
2692	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. Biologics: Targets and Therapy, 2007, 1, 185-94.	3.2	4
2693	Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma. Biologics: Targets and Therapy, 2007, 1, 321-4.	3.2	3
2694	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics: Targets and Therapy, 2009, 3, 215-24.	3.2	25
2695	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P and T, 2009, 34, 554-64.	0.9	17
2696	The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist. P and T, 2010, 35, 219-29.	0.9	1
2697	Lung cancer. Clinical Evidence, 2009, 2009, .	0.2	1
#	Article	IF	CITATIONS
------	--	-----	-----------
2698	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology, 2010, 36, 19-27.	3.9	4
2699	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Annals of Thoracic and Cardiovascular Surgery, 2009, 15, 213-20.	0.8	9
2700	Lung cancer. Clinical Evidence, 2010, 2010, .	0.2	0
2701	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 2010, 10, 1-48.	1.8	23
2703	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. American Journal of Translational Research (discontinued), 2013, 5, 481-96.	0.0	13
2704	EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. International Journal of Clinical and Experimental Pathology, 2013, 6, 2800-12.	0.5	26
2705	Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 293-302.	1.0	1
2707	Does the order of factors affect the product? Lessons learned from the TORCH trial. Translational Lung Cancer Research, 2013, 2, 50-4.	2.8	0
2708	Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients. International Journal of Clinical and Experimental Medicine, 2015, 8, 16064-70.	1.3	2
2709	Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya Journal of Medical Science, 2012, 74, 133-40.	0.3	34
2710	Role of epidermal growth factor receptor in lung cancer and targeted therapies. American Journal of Cancer Research, 2017, 7, 187-202.	1.4	43
2711	Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Research, 2013, 33, 4695-700.	1.1	26
2712	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. Asian Pacific Journal of Cancer Prevention, 2017, 18, 107-114.	1.2	9
2722	Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. American Journal of Cancer Research, 2018, 8, 2575-2589.	1.4	0
2723	Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 63S-65S.	0.6	0
2724	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight, 2022, 7, .	5.0	20
2725	Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. Translational Oncology, 2022, 16, 101309.	3.7	5
2726	ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. , 2004, 6, 12-21.		2

		CITATION REPORT		
#	Article		IF	CITATIONS
2727	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules, 202	2, 27, 819.	3.8	32
2728	Influence Factors of Gefitinib Concentration in Patients with Non-Small Cell Lung Canc Treatment. Advances in Clinical Medicine, 2022, 12, 196-205.	er in Clinical	0.0	1
2729	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100)015.		8
2730	Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduction and Tar 2021, 6, 425.	geted Therapy,	17.1	302
2733	AIM in Genomic Basis of Medicine: Applications. , 2022, , 1087-1096.			0
2734	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: Study in Chinese Patients. Cancer Management and Research, 2022, Volume 14, 863-6	A Real-World 873.	1.9	4
2735	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Sn Cancer. Frontiers in Oncology, 2022, 12, 869672.	nall Cell Lung	2.8	30
2736	EGFR Signaling in Lung Fibrosis. Cells, 2022, 11, 986.		4.1	18
2737	Amivantamab for the treatment of <i>EGFR</i> exon 20 insertion mutant non-small cell Expert Review of Anticancer Therapy, 2022, 22, 3-16.	lung cancer.	2.4	9
2738	C1632 suppresses the migration and proliferation of nonâ€smallâ€cell lung cancer cel and FGFR1 pathway. Journal of Cellular and Molecular Medicine, 2022, 26, 422-435.	ls involving LIN28	3.6	8
2739	EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Bi 253-275.	ology, 2022, 85,	9.6	61
2740	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Stat Metabolic Activity in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 780	us and 18F-FDG 0186.	2.8	8
2741	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug di 499-517.	scovery. , 0, ,		0
2745	Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368.			0
2746	Treatment of Bronchioloalveolar Carcinoma. , 0, , 144-152.			0
2748	Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Fac Clinical Cancer Research, 2005, 11, 397-405.	tor Receptor.	7.0	168
2761	The changing world of oncology drug development-A global pharmaceutical company' Chinese Clinical Oncology, 2014, 3, 20.	s perspective.	1.2	6
2762	Translating basic research in cancer patient care. Annali Dell'Istituto Superiore Di Sanit 64-71.	a, 2011, 47,	0.4	4

ARTICLE

IF CITATIONS

2763 DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resistance (Alhambra,) Tj ETQq0 0.0 rgBT /Qverlock 10

2764	Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration. Signal Transduction and Targeted Therapy, 2022, 7, 157.	17.1	23
2765	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nature Reviews Clinical Oncology, 2022, 19, 499-514.	27.6	140
2766	Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 124-141.	1.7	1
2767	Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer. Cancer Research, 2005, 65, 226-235.	0.9	357
2768	Gefitinib reverses breast cancer resistance protein–mediated drug resistance. Molecular Cancer Therapeutics, 2004, 3, 1119-1125.	4.1	153
2769	Identified Gefitinib Metabolism-Related IncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	2.8	9
2770	Disease monitoring of epidermal growth factor receptor (EGFR)â€mutated nonâ€smallâ€cell lung cancer patients treated with tyrosine kinase inhibitors via <scp>EGFR</scp> status in circulating tumor <scp>DNA</scp> . Thoracic Cancer, 2022, 13, 2201-2209.	1.9	4
2771	Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1. Biomedicine and Pharmacotherapy, 2022, 153, 113373.	5.6	8
2772	Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Molecular Cancer Therapeutics, 2004, 3, 465-472.	4.1	262
2773	The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers. Clinical Cancer Research, 2005, 11, 1167-1173.	7.0	396
2775	Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Molecular Cancer Therapeutics, 2004, 3, 977-983.	4.1	36
2776	Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice. Pneumonologia I Alergologia Polska, 2008, 76, 451-455.	0.6	0
2777	Lung Cancer Targeted Chemoradiotherapy via Dual-Stimuli Responsive Biodegradable Core-Shell Nanoparticles. Pharmaceutics, 2022, 14, 1525.	4.5	7
2778	The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer. Clinical Cancer Research, 2005, 11, 795-805.	7.0	206
2779	Panel Sequencing for Targeted Therapy Selection in Solid Tumors. Clinics in Laboratory Medicine, 2022, 42, 309-323.	1.4	1
2780	Translational Research in Lung Cancer. Medical Radiology, 2022, , .	0.1	0
2781	Targeted Therapies in Non-small Cell Lung Cancer. Medical Radiology, 2022, , .	0.1	1

#	Article	IF	CITATIONS
2782	SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14.	1.9	2
2783	Targeting the epidermal growth factor receptor (EGFR) - a new therapeutic option in oncology?. Swiss Medical Weekly, 0, , .	1.6	6
2784	Changes in survival of patients with non–small cell lung cancer in Japan: An interrupted time series study. Cancer Science, 2023, 114, 1154-1164.	3.9	3
2785	KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner. Drug Resistance Updates, 2023, 66, 100908.	14.4	13
2786	Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). Methods in Enzymology, 2022, , .	1.0	0
2787	Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC Pulmonary Medicine, 2022, 22, .	2.0	2
2788	The Simon's two-stage design accounting for genetic heterogeneity. Communications in Statistics - Theory and Methods, 2024, 53, 2661-2669.	1.0	1
2789	The Therapeutic Application of RBAC in Cancer. , 2023, , 67-79.		0
2790	CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarHâ€ʻlike homeobox 2 axis. Anti-Cancer Drugs, 2023, 34, 640-651.	1.4	1
2792	Historical development of EGFR-targeted therapy. , 2023, , 1-11.		0
2793	Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Current Cardiology Reports, 2023, 25, 269-280.	2.9	6
2794	The development and implementation of EGFR inhibitors in advanced NSCLC. , 2023, , 13-36.		0
2795	Dopamine agonists and risk of lung cancer in patients with restless legs syndrome. Pharmacoepidemiology and Drug Safety, 2023, 32, 726-734.	1.9	0
2796	Flashback Foreword: Gefitinib in Non–Small-Cell Lung Cancer: The IDEAL 1 Trial. Journal of Clinical Oncology, 2023, 41, 1159-1160.	1.6	0
2797	Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer. Oncogene, 2023, 42, 1233-1246.	5.9	7
2798	A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma. SAGE Open Medical Case Reports, 2023, 11, 2050313X2311595.	0.3	0
2799	Precision medicine-based cancer care. , 2024, , 272-283.		0
2800	Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions. Clinical Breast Cancer, 2023, 23, 784-799.	2.4	4

#	Article	IF	CITATIONS
2801	Is EGFR gene mutation testing necessary in smokers with non-small cell lung cancer?. , 2017, 3, 156-159.		0
2802	Synthesis, antiproliferative and 4D-QSAR studies of thiadiazole derivatives bearing acrylamide moiety as EGFR inhibitors. SAR and QSAR in Environmental Research, 2023, 34, 341-359.	2.2	Ο
2803	è,ºãŒã,"蔺ç™,ã«ãŠãʿã,‹Advanced Care Planning. Japanese Journal of Lung Cancer, 2023, 63, 147-152.	0.1	0
2804	Role of EGFR and FASN in breast cancer progression. Journal of Cell Communication and Signaling, 2023, 17, 1249-1282.	3.4	3
2805	The efficacy and safety of immune checkpoint inhibitors for patients with <scp>EGFR</scp> â€mutated nonâ€small cell lung cancer who progressed on <scp>EGFR</scp> tyrosineâ€kinase inhibitor therapy: A systematic review and network metaâ€analysis. Cancer Medicine, 2023, 12, 18516-18530.	2.8	1
2806	Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?. Lancet Oncology, The, 2023, 24, e385-e394.	10.7	2
2808	Inherent efficacies of pyrazole-based derivatives for cancer therapy: the interface between experiment and <i>in silico</i> . Future Medicinal Chemistry, 2023, 15, 1719-1738.	2.3	0
2809	Safety of Re-administration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-mutated NSCLC: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2023, , .	2.6	0
2810	The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders. Expert Opinion on Therapeutic Patents, 2023, 33, 477-492.	5.0	0
2811	Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer. Journal of Translational Medicine, 2023, 21, .	4.4	Ο
2812	Molecular pathology of nonâ€small cell carcinoma. Histopathology, 2024, 84, 50-66.	2.9	2
2813	Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for <i>EGFR</i> mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Japanese Journal of Clinical Oncology, 0, , .	1.3	Ο
2814	To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors. Current Topics in Medicinal Chemistry, 2023, 23, 2877-2972.	2.1	2
2815	CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS. Pharmaceuticals, 2024, 17, 9.	3.8	Ο
2816	Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards. Surgical Oncology Clinics of North America, 2024, 33, 197-216.	1.5	0
2817	Ocular Surface Side Effects of Novel Anticancer Drugs. Cancers, 2024, 16, 344.	3.7	0
2818	Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles. Bioactive Materials, 2024, 34, 422-435.	15.6	0
2819	Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6844 patients. Chinese Medical Journal, 2013, 126, 3348-3355.	2.3	0

CITATION REPORT

#ARTICLEIFCITATIONS2820Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after
failure of chemotherapy. Chinese Medical Journal, 2014, 127, 266-271.2.322821Making a case for cancer research in India. Cancer Research Statistics and Treatment, 2018, 1,71.0.602822High-efficiency <i>EGFR</i> genotyping using cell-free DNA in bronchial washing fluid. Japanese1.30

CITATION REPORT